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Salmonella enterica subsp. enterica is one of the leading causes of foodborne illness 
worldwide. Recently, genomic characterizations of S. Typhi, the causative agent of typhoid 
fever, identified a novel hybrid toxin which combines the active subunits of both the pertussis 
toxin and the cytolethal distending toxin, into one holotoxin which was called the ‘typhoid 
toxin’, for its hypothesized role in typhoid fever. However, the ‘typhoid toxin’ was later found to 
be encoded by several nontyphoidal serotypes as well, and therefore will be referred to as S-CDT 
(for Salmonella Cytolethal Distending Toxin). The overall goal of the work presented here was 
to characterize the ‘typhoid toxin’ encoded by nontyphoidal serotypes, including i) the 
distribution and conservation of S-CDT genes in common nontyphoidal serotypes, (ii) 
characterization of the activity and function of the toxin at the cellular level, and (iii) asserting 
which genes are essential for toxin activity in vitro.  
 Among the nontyphoidal serotypes causing roughly 75% of human cases of salmonellosis 
in the US, genes encoding S-CDT were conserved in (50 out of 50 isolates screened) serotypes 
Javiana, Montevideo, and Oranienburg, while for serotype Mississippi, S-CDT genes were clade-
associated. Alignment of amino acid sequences of S-CDT subunits demonstrated that these 4 
nontyphoidal serotypes encoded an S-CDT with high similarity to the typhoid toxin encoded by 
serotype Typhi. Infection of eukaryotic cells with S-CDT-positive serotypes, but not S-CDT-
 negative serotypes resulted in activation of the DNA damage response, and a G2/M cell cycle 
arrest, both of which support that these serotypes produce an active toxin. This activity was 
dependent on CdtB, the active subunit of S-CDT which acts as a nuclease in vitro, as deletion of 
cdtB abolished the ability of the S-CDT positive serotypes to activate the DNA damage response.  
 Similar to Typhi, deletion of toxin subunit genes cdtB and pltA abolished activity in vitro. 
In contrast, deletion of pltB, encoding the binding subunit, did not affect S-CDT intoxication, 
suggesting that either the trafficking or activity of S-CDT differs between nontyphoidal and 
typhoidal serotypes, or that the toxin uses an alternative binding subunit. Genetic screening 
showed that S. Javiana (a nontyphoidal serotype) encoded a gene, artB, with homology to pltB. 
Deletion of artB decreased, but did not eliminate, S-CDT activity in vitro, but deletion of both 
artB and pltB abolished S-CDT-induced activity, suggesting that at least one subunit is required 
for S-CDT activity in vitro. Strains harboring deletions in either ttsA or STY1887 did not have a 
significant effect on S-CDT-mediated intoxication, suggesting that they are not essential for 
activity in vitro.  
 Importantly, this work provides experimental evidence that nontyphoidal serotypes not 
only encode a ‘typhoid toxin’ that is nearly identical at the amino acid level to the one encoded 
by S. Typhi, but that it is also functional in these serotypes. Furthermore, we provide evidence 
that S-CDT positive nontyphoidal serotypes significantly impact the outcome of infection at the 
cellular level. Taken together, these results suggest that S-CDT plays an important role in 
nontyphoidal salmonellosis, and provides one such ‘factor’ that may aide in current efforts to 
target specific serotypes for reducing the incidence of human cases of salmonellosis in the US.
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CHAPTER 1 
INTRODUCTION 
Foodborne illness sickens an estimated 1 in 6 people in the US each year, accounting for 
an estimated 48 million illnesses (90% credible interval: 28.7 - 71.1 million) and 3,037 deaths 
(90% credible interval: 1,492 – 4,983) per year (1). Economically, this equates to over $14.0 
billion (90% credible interval: $4.4 - $33.0 billion USD) accrued from the cost of illness (2). The 
foodborne pathogen Salmonella enterica subspecies enterica is the leading cause of foodborne 
illness resulting from a bacterial agent, in the US (3), and is the second leading agent worldwide 
(4). As such, an improved understanding of the virulence mechanisms employed by S. enterica 
represents a key component in understanding the nature of salmonellosis, in order to reduce 
morbidity and mortality associated with this foodborne pathogen. The overall goal of this 
dissertation was to assess the importance of the cytolethal distending toxin (CDT), a toxin which 
has been previously associated with DNA damage resulting from infection with other bacterial 
pathogens (5-7), in the context of foodborne salmonellosis.  
Significance of foodborne nontyphoidal salmonellosis. In the US foodborne infections with 
nontyphoidal Salmonella (NTS; i.e., all serotypes except for Typhi) account for an estimated 
1.03 million illnesses, 19,336 hospitalizations, and 378 deaths annually (3), the most of any 
foodborne pathogen in the US. Globally, the impact of nontyphoidal salmonellosis is much 
greater, causing an estimated 93.8 million cases, and 155,000 deaths (8).  
Salmonella is a Gram-negative foodborne pathogen. The genus Salmonella includes 2 species, 
enterica and bongori (9). Within the species enterica, there are 6 subspecies; enterica, salamae, 
arizonae, diarizonae, houtenae, and indica. The majority of Salmonella infecting warm-blooded 
hosts belong to subspecies enterica. Characterization of the O (somatic) and H (flagellar) 
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antigens using anti-sera (called serotyping) was adopted as a classification scheme among 
Salmonella subspecies. Currently, there are over 2,600 serotypes (10), but in the U.S., the top 20 
most commonly isolated serotypes among subspecies enterica account for >85% of all NTS 
infections (CDC, 2011). 
 Infection with typhoidal and paratyphoidal serotypes (i.e. S. enterica subsp. enterica 
serotypes Typhi, Paratyphi A, Paratyphi B, and Paratyphi C) typically results in a more severe, 
prolonged illness characterized by a high fever (>39°C), malaise, vomiting, headache, and an 
elevated pulse rate (11). Serotype Typhi is a host-restricted serotype, and is transmitted from 
human to human, primarily through contamination of drinking water or improper food handling 
(12). Infections with nontyphoidal serotypes (NTS; i.e. all serotypes not Typhi, Paratyphi A, 
Paratyphi B, or Paratyphi C) typically result in a self-limiting gastroenteritis that is short-lived 
(13). However, NTS vary greatly with respect to the severity of the illness, with certain serotypes 
being significantly more likely to result in invasive disease, hospitalization, and death (14). 
Genomic and phenotypic profiling of NTS have expanded our understanding of Salmonella 
virulence, but these efforts have failed to definitively account for differences in disease severity 
(13, 15, 16). Nontyphoidal salmonellosis has been linked to several long term sequelae including 
reactive arthritis and post-infectious irritable bowel syndrome (17), although the exact 
mechanisms behind the development of these long-term sequelae remain unknown. Therefore, 
characterizations of novel virulence factors produced by NTS are of critical importance in 
understanding why certain nontyphoidal salmonellosis cases differ in severity, and are more 
likely to result in long term sequelae.  
The cytolethal distending toxin is an A-B type toxin associated with eukaryotic cell DNA 
damage. The cytolethal distending toxin (CDT) was first reported by Johnson and Lior, who 
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observed that the addition of supernatants of Escherichia coli to CHO cell monolayers resulted in 
a distended cell morphology, G2/M cell cycle arrest, and eventually, cell death (18). The number 
of species encoding a CDT has expanded to 8 bacterial genera including, Campylobacter spp. 
(19-22) Haemophilus spp. (23-25), Aggregatibacter actinomycetemcomitans (A. 
actinomycetemcomitans) (26, 27), Helicobacter spp. (28-30), Shigella spp. (31), Yersinia spp. 
(32), Providencia alcalifaciens (33), and Salmonella  (34, 35). Interestingly, the CDT produced 
by all genera, except for Salmonella, exists as a tripartite toxin consisting of equimolar ratios of 
binding and trafficking components CdtA and CdtC, and the active component CdtB (5, 6, 36). 
CdtB was originally characterized as a nuclease, owing to its structural homology to Dnase I, and 
its activity as a nuclease in a super-coiled plasmid assay (36). The CDT produced by A. 
actinomycetemcomitans also has phosphatidylinositol-3,4,5-triphosphate phosphatase activity 
(37), which could interfere with host signaling pathways (38).  
Importance of characterizing S-CDT as a novel virulence factor in nontyphoidal 
salmonellosis. The CDT encoded by Salmonella (called S-CDT) was first characterized in S. 
Typhi, and was thought to be unique to this serotype (34, 35, 39). S-CDT is distinct from CDTs 
produced by other Gram-negative pathogens, as it substitutes the binding subunits CdtA and 
CdtC, for the active and binding subunits of the pertussis toxin (5, 32, 34, 40). Genomic 
characterizations of NTS have since established that this novel virulence factor is present in at 
least 40 NTS as well (15, 40). Importantly, administration of purified S-CDT was shown to 
recapitulate symptoms of typhoid fever, lending to its classification as the “typhoid toxin” (41). 
The DNA damaging activity of S-CDT, the hallmark of the CDT family of toxins (5, 32), has 
been established both in vitro and in vivo for S. Typhi (41, 42). Furthermore, recent research 
established a role for S-CDT in prolonged infections with S. Typhi, demonstrating the 
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importance of the toxin in immune evasion (42). It was recently established that S-CDT plays an 
important role in infections with NTS serotypes as well, significantly altering the outcome of 
infection at the cellular level (43).  
Significance of bacterial genotoxins in development of cancer. CDTs have been associated 
with an increased risk of genomic instability (44). Causal links between bacterial genotoxins and 
cancer have been established for E. coli (45, 46), and Helicobacter pylori (47). Furthermore, 
chronic infection with S. Typhi is associated with an increased risk of gallbladder cancer (48-51). 
Although the potential role of S-CDT in the development of gallbladder cancer, has not been 
established, chronic exposure to CDT has been shown to cause genomic instability leading to 
anchorage-independent growth [i.e. malignant transformation (44)]. Little is known about the 
activity of S-CDT in vitro, with regards to the type of DNA damage induced, how the DNA 
damage is repaired, or the ultimate outcome of S-CDT-mediated DNA damage. Detailed 
characterizations of the DNA damage invoked by exposure to S-CDT produced by NTS, along 
with the ultimate fate of S-CDT intoxicated cells is critical to assessing the potential 
contributions of S-CDT to carcinogenesis.  
 Overall, our knowledge of the contributions of S-CDT to acute and chronic sequelae 
resulting from nontyphoidal salmonellosis, is very limited. The ultimate goal of this dissertation 
was to understand the distribution, regulation, and contributions of S-CDT to salmonellosis. The 
following chapters address key knowledge gaps in our understanding of S-CDT. Namely, this 
dissertation (i) provides a review of the literature characterizing S-CDT from both typhoidal and 
nontyphoidal serotypes, (ii) describes the distribution and activity of S-CDT encoded by 
nontyphoidal serotypes associated with foodborne salmonellosis in the US, and (iii) expands our 
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understanding of the genetic requirements for S-CDT-mediated intoxication of normal human 
intestinal epithelial cells.  
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CHAPTER 2 
DYNAMIC DUO- THE SALMONELLA CYTOLETHAL DISTENDING TOXIN 
COMBINES ADP-RIBOSYLTRANSFERASE AND NUCLEASE ACTIVITIES IN A 
NOVEL FORM OF THE CYTOLETHAL DISTENDING TOXIN* 
 
 
 
 
 
 
 
 
 
 
 
 
 
*R.A. Miller, and M. Wiedmann 
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ABSTRACT 
The cytolethal distending toxin (CDT) is a well characterized bacterial genotoxin encoded 
by several Gram-negative bacteria, including Salmonella enterica (S. enterica). The CDT 
produced by Salmonella (S-CDT) differs from the CDT produced by other bacteria, as it utilizes 
subunits with homology to the pertussis and subtilase toxins, in place of the traditional CdtA 
and CdtC subunits. Previously, S-CDT was thought to be a unique virulence factor of S. 
enterica subspecies enterica serotype Typhi, lending to its classification as the “typhoid toxin.” 
Recently, this important virulence factor has been identified and characterized in multiple 
nontyphoidal Salmonella (NTS) serotypes as well. The significance of S-CDT in salmonellosis 
with regards to the: (i) distribution of S-CDT encoding genes among NTS serotypes, (ii) 
contributions to pathogenicity, (iii) regulation of S-CDT expression, and (iv) the public health 
implication of S-CDT as it relates to disease severity, are reviewed here (Figure 2.1). 
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FIGURE  2.1 Overview of the structure and function of the salmonella cytolethal 
distending toxin (S-CDT). S-CDT combines the active subunit, CdtB, from the traditional 
cytolethal distending toxin, with the pertussis toxin subunits, to form a novel toxin which induces 
DNA damage resulting in activation of the DNA damage response, and subsequent G2/M cell 
cycle arrest. 
 
INTRODUCTION 
Salmonella enterica (S. enterica) is a Gram-negative bacterium that causes gastrointestinal 
illness in humans and animals. The genus Salmonella includes two species, enterica and 
bongori. Within the species S. enterica, there are six subspecies: enterica (subspecies I), 
salamae (subspecies II), arizonae (subspecies IIIa), diarizonae (subspecies IIIb), houtenae 
(subspecies IV), and indica (subspecies VI) [1]. Subspecies enterica is further categorized into 
1586 serotypes (e.g., Typhimurium, Typhi, Newport, and Enteritidis), representing unique 
antigenic formulae of the O and H antigens [2]. For simplicity, S. enterica serotypes may be 
further categorized as “typhoidal” (i.e., S. enterica serotype Typhi [S. Typhi]), “paratyphoidal” 
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(i.e., S. enterica serotypes Paratyphi A, B, or C) or nontyphoidal (i.e., S. enterica serotypes 
except Typhi, and Paratyphi A, B, or C) [3]. 
Salmonellosis, the disease resulting from a Salmonella infection, is primarily acquired 
through the consumption of contaminated food or water. In the US, foodborne salmonellosis 
accounts for an estimated 1.03 million cases of foodborne illness per year [4]. Internationally, 
nontyphoidal salmonellosis is responsible for an estimated 80.3 million illnesses and 150,000 
deaths per year [5]. Importantly, some serotypes (e.g., Typhimurium, Newport, and Enteritidis) 
are capable of causing disease in a wide range of hosts, including humans and other mammals, 
birds, and reptiles, while others are host-restricted (e.g., S. Typhi in humans) [6,7]. 
Although not fully understood, S. enterica serotypes differ in virulence, with some serotypes 
being more commonly associated with invasive disease, and others causing a self-limiting 
gastroenteritis [6]. S. Typhi, the causative agent of typhoid fever, causes a severe, sometimes 
life-threatening illness. Serotypes Paratyphi A, B, and C cause a similar illness known as 
paratyphoid fever [3]. Whole genome sequence comparisons of serotype Typhi and 
nontyphoidal serotypes have failed to definitively account for differences in virulence [8,9]. 
Recently, S. Typhi was found to encode a variant of the cytolethal distending toxin (CDT), an 
important virulence factor for several other Gram-negative bacteria [10]. This novel form of 
CDT (hereafter referred to as “S-CDT” for Salmonella CDT) was believed to be unique to S. 
Typhi, leading to its classification as the “typhoid toxin” [8,11,12]. However, S-CDT has since 
been identified in at least 40 NTS serotypes [13]. Our current understanding of S-CDT with 
regards to its regulation, structure, function, and mechanism of action has primarily been 
informed by characterization of S-CDT produced by S. Typhi. The established genetic and 
pathogenic differences among S. enterica serotypes, particularly Typhi and nontyphoidal 
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serotypes, warrant further characterization of S-CDT among different NTS serotypes. This 
review will: (i) summarize the current understanding of the distribution, production, structure 
and function, and cytotoxic effects of S-CDT produced by S. enterica serotypes; and (ii) 
compare the unique features of S-CDT to the CDTs produced by other Gram-negative bacteria. 
SALMONELLA ENCODES A NOVEL FORM OF CDT 
CDT was first characterized in Escherichia coli (E. coli) in the late 1980s by Johnson and 
Lior, who noted that eukaryotic cells which were co-incubated with filtrates of overnight cultures 
of E. coli appeared distended, and arrested in the G2/M phase [14]. Subsequent analyses also 
identified CDT production by other Gram-negative pathogens, including Campylobacter spp. 
[15–18], Haemophilus spp. [19,20], Aggregatibacter actinomycetemcomitans (A. 
actinomycetemcomitans) [21], Helicobacter spp. [22–26], Shigella spp. [27], Yersinia spp. [10], 
Providencia alcalifaciens [28], and S. Typhi [12,29]. The CDT encoded by all of these 
pathogens, with the exception of S. Typhi, exists as a tripartite AB2 toxin encoded by the genes 
cdtA, cdtB, and cdtC, with the CdtB subunit serving as the active component of the toxin, and 
subunits CdtA and CdtC implicated in binding to host cells and subsequent intracellular 
trafficking [10]. S-CDT represents an important exception, as Salmonella strains producing S-
CDT encode cdtB, but not cdtA or cdtC [11,12,29]. In contrast to the AB2 configuration of CDTs 
encoded by other Gram-negative bacteria, S-CDT is an A2B5 toxin, comprised of toxin subunits: 
(i) CdtB (encoded by cdtB, cytolethal distending toxin subunit B), a nuclease subunit; (ii) PltA 
(encoded by pltA, pertussis like toxin subunit A), an ADP-ribosylating toxin subunit; and (iii) 
PltB (encoded by pltB, pertussis like toxin subunit B), serving as a pentameric ring constituting 
the binding subunit [11]. Subunits PltA and PltB share homology with the Ptx S1 (active) and 
Ptx S2 (binding) subunit, respectively, of the pertussis toxin, which ADP-ribosylates host G 
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proteins [11,30]. Similarly, the 3D configuration of the PltB subunit also aligns well with the 
binding subunit (SubB) of the E. coli subtilase toxin, which is a serine protease [8,31]. Recent 
studies have identified genes encoding S-CDT in a number of NTS serotypes as well [9,13,32–
34]. To date, genes encoding S-CDT (i.e., genes pltA, pltB, and cdtB) have been characterized in 
at least 40 NTS serotypes (see Table 2.1) [9,13,32]. Amino acid alignments of CdtB, PltA, and 
PltB from both NTS serotypes and serotype Typhi suggest that these proteins are highly 
conserved among S. enterica serotypes [34]. Genomic analyses have also detected orthologs of 
genes encoding S-CDT in S. bongori and S. enterica subsp. arizonae, although the functionality 
of these gene products has not been assessed [34,35]. Further DNA-based analyses will aid in the 
characterization and detection of genes encoding S-CDT in other NTS serotypes, and will likely 
expand the list of NTS serotypes known to encode S-CDT. 
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TABLE 2.1 Salmonella cytolethal distending toxin (S-CDT) status of select Salmonella enterica subspecies 
enterica serotypes. 
Serotype S-CDT Status 1 References 
9,12:I,v:- − [9] 
Agbeni + [13] 
Agona − [13] 
Anatum − [13] 
Arechavaleta + [13] 
Bareilly − [13] 
Barranquilla + [13] 
Berta − [13] 
Braenderup − [13] 
Brandenburg + [13] 
Bredeney + [9] 
Choleraesuis − [9,13] 
Corvallis + [13] 
Cotham + [13] 
Cubana + [13] 
Dublin − [9,13] 
Enteritidis − [9,13] 
Freetown + [13] 
Gaminara + [13] 
Georgia + [13] 
Give + [13] 
Glostrup + [13] 
Hadar − [9,13] 
Hartford − [13] 
Heidelberg − [9,13] 
4,[5],12:i:- − [13] 
Indiana + [13] 
Infantis − [13] 
Inverness + [13] 
Javiana + [13,32] 
Johannesburg + [13] 
Kiambu + [13] 
Kintambo + [13] 
Kisarawe + [13] 
Luciana + [13] 
Miami + [13] 
Minnesota + [13] 
Mississippi ± [13] 
Montevideo + [9,13,36] 
Muenchen − [13] 
Muenster + [13] 
Newport − [9,13] 
Oranienburg + [13] 
Overschie + [13] 
Panama + [13] 
Paratyphi A + [13] 
Pomona + [13] 
Poona + [13] 
Reading + [13] 
Rubislaw + [13] 
Sandiego + [13] 
Schwarzengrund + [9,13] 
Telelkebir + [13] 
Thompson − [13] 
Typhi + [12,29] 
Typhimurium − [9,13] 
Urbana + [13] 
Virchow − [9,13] 
Wandsworth + [13] 
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1
 Status based on the presence of all S-CDT encoding genes (pltA, pltB, and cdtB) as determined by PCR-
based amplification; ‘‘+’’ denotes all genes are present; ‘‘−’’ denotes one or more genes were not 
detected; ‘‘±’’ denotes some isolates within the serotype are positive, but others are negative (unpublished 
data). 
 
REGULATION OF S-CDT EXPRESSION 
Several reports have confirmed that S-CDT expression is restricted to intracellular S. Typhi 
residing within the salmonella containing vacuole (SCV) [11,12]. Importantly, this is in contrast 
to CDT production by other Gram-negative bacteria, for which the toxin is routinely detected in 
cell-free supernatants of CDT positive strains cultivated in standard laboratory media 
[14,19,37,38]. The intracellular requirement for S-CDT production has not yet been confirmed 
for NTS expressing CDT. 
The requirement of bacterial internalization for S-CDT expression by S. Typhi has been 
confirmed at both the transcriptional and translational levels. Haghjoo and Galán used a 
luciferase reporter strain to establish that cdtB is not expressed by S. Typhi grown in lysogeny 
broth (LB), and that transcription was only activated when S. Typhi was allowed to infect 
eukaryotic cells [12]. Furthermore, epithelial cells infected with an invasion-deficient mutant of 
S. Typhi did not have the characteristic distended phenotype, nor did they arrest in the G2/M 
phase, suggesting that invasion, and not just adhesion, is required for S-CDT production by S. 
Typhi [12]. However, transcription of pltA and pltB can be detected when S. Typhi is grown in 
standard LB media, although at very low quantities [11]. This is likely due to the organization of 
the CdtB-islet into two distinct operons encoding the toxin subunits [11]. Taken together, the fact 
that pltA and pltB are located in an operon separate from cdtB, and that transcription of pltA and 
pltB, but not cdtB, may occur in standard culturing medium, suggests that pltA and pltB may be 
regulated separately of cdtB. 
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A transposon  mutagenesis screen identified IgeR, a transcriptional regulator belonging to 
the DeoR family of transcriptional regulators, as a repressor of cdtB transcription in S. Typhi 
[39]. In vitro analyses determined that IgeR is able to bind to the cdtB promoter, and effectively 
suppress cdtB expression [39]. Likewise, deletion of igeR was sufficient to de-repress cdtB 
expression in LB media, a normally non-permissive environment for cdtB expression by S. Typhi 
[39]. IgeR also plays a role in the regulation of other genes involved in virulence, including SPI-
1 encoded type three secretion system (TTSS) components, flagellar proteins, and SPI-1 TTSS 
effector proteins, as deletion of igeR resulted in decreased expression of these genes [39]. IgeR is 
conserved among S. enterica subsp. enterica serotypes, and hence could also control 
transcription for S-CDT production in NTS [39]. In addition, cdtB transcription was found to be 
activated concurrently with parE and mntR, but repressed with transcription of potG and tldD, 
although the exact mechanisms regarding their regulation are currently unknown [39]. In support 
of IgeR-mediated repression of cdtB transcription, plasmid-based expression of cdtB under 
control of its native promoter, in a heterologous bacterial host (i.e., S. Typhimurium), was found 
to be sufficient for constitutive expression of the CdtB-islet under conditions that are normally 
non-permissive for wild type strains of S. Typhi [39,40]. Another study suggested that the two 
component PhoQ-PhoP regulatory system may also play a role in cdtB expression in S. Typhi, as 
increased levels of cdtB mRNA transcripts and CdtB were detected when Salmonella cells were 
subjected to PhoP-inducing conditions [41]. As the CdtB-islet constitutes two operons, and 
expression of the pltAB operon may be detected when S-CDT positive strains are cultured under 
conditions that are normally non-permissive for expression of the operon containing cdtB, it is 
unclear whether IgeR also regulates transcription of the pltAB operon. Taken together, these 
results suggest that regulation of S-CDT expression in S. Typhi at the transcriptional level 
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involves multiple regulatory components, which are likely also involved in the regulation of 
invasion-associated genes. 
Two additional genes, sty1887 and sty1889 within the CdtB-islet, are implicated in S-CDT 
gene regulation as well (see Fig 2.2) [42]. Deletion of sty1889 (renamed ttsA), but not sty1887, 
abrogated secretion of S-CDT in a S. Typhi strain, and prevented subsequent intoxication of 
epithelial cells [42]. In silico analysis implicates that ttsA encodes a N-acetyl-β-D-muramidase, 
with homology to a bacteriophage muramidase [42]. Similar to CdtB, TtsA is not detected in 
standard LB culturing medium, and is only detected when S. Typhi infects a host cell [42]. 
Further analyses determined that the TtsA peptidoglycan binding domain is required for S-CDT 
secretion [42]. Currently, all S-CDT regulatory analyses have been performed in serotype Typhi. 
Due to the marked differences between Typhi and NTS serotypes, it will be important to 
characterize the regulation and expression of S-CDT in NTS. 
 
 
 
FIGURE 2.2 Comparison of the CdtB-islet encoded by Salmonella enterica serotypes and all other 
Gram-negative species producing a cytolethal distending toxin (CDT). (a) The Salmonella CDT (S-CDT) 
is comprised of subunits PltA, PltB, and CdtB encoded by pltA, pltB, and cdtB, respectively. The CdtB-
islet in Salmonella also encodes two genes (sty1887 and ttsA) which are implicated in toxin secretion but 
are not subunits of S-CDT [39,42]. (b) Genes cdtA, cdtB, and cdtC encode the CDT for Aggregatibacter 
actinomycetemcomitans, Campylobacter spp., Escherichia coli, Haemophilus spp., Helicobacter spp., 
Providencia alcalifaciens, Shigella spp., and Yersinia spp. Genes colored red compose the CDT and S-
CDT; genes shown in gray are present in the CdtB-islet of Salmonella, but do not encode subunits of the 
S-CDT. 
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ARTA AND ARTB AND THEIR RELATIONSHIP TO S-CDT 
Homologs to genes encoding the PltA and PltB subunits of S-CDT have also been detected 
in a number of NTS serotypes [13]. First identified in S. enterica serotype Typhimurium strain 
DT104, genes encoding an ADP-ribosyl transferase toxin homolog (artA and artB) have been 
characterized on a putative prophage in serotype Typhimurium, as well as in other NTS 
serotypes [13,43]. The protein encoded by artA is homologous to both the pertussis-like toxin 
subunit in S. Typhi (encoded by pltA) and the S1 subunit of the pertussis toxin (encoded by 
ptxA), with the predicted amino acid products sharing 59% and 33% amino acid identity, 
respectively [43]. A second subunit, ArtB, has homology to the amino acid product encoded by 
pltB (30% amino acid identity), as well as the S2 and S3 subunits (30.7% amino acid identity) of 
the Ptx binding component of the pertussis toxin [43]. Genome alignments have detected artA 
and artB in the majority of NTS serotypes encoding the CdtB-islet [13]. For these serotypes, the 
location of artA and artB was inconsistent, providing support for the genes being encoded on a 
prophage [13]. Despite the seemingly widespread distribution of artA and artB, the function and 
potential contributions of artA and artB gene products to virulence remain unknown. Likewise, it 
is unclear if artA and artB are expressed concurrently with genes in the CdtB-islet. While all 
three subunits of S-CDT are required for full activity, some studies have shown that deletion 
mutants of pltB retain some residual cytotoxic activity [32]. Therefore, it would be interesting to 
examine whether ArtA or ArtB, or both, can potentially substitute for PltA or PltB. A recent 
study analyzing the 3D crystal structure of S-CDT from S. Typhi predicted that three cysteine 
residues in the PltA subunit serve as the physical link between CdtB and PltA [8]. In contrast, the 
ArtA subunit only contains two such cysteine residues that could interact with CdtB, and 
therefore CdtB is predicted to be preferentially bound by PltA rather than ArtA [8]. ArtA and 
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ArtB appear to be more widespread among NTS, as they are also present in strains that do not 
encode S-CDT [43]. However, the activity and effects on host cellular processes resulting from 
the “ArtAB toxin” remain uncharacterized. 
STRUCTURE AND FUNCTION OF S-CDT 
S-CDT is arranged in an A2B5 configuration (see Fig 2.3) [8]. In its final quaternary form the 
toxin exists as a pyramid-shaped structure that is ~90 Å tall with a maximum width of ~60 Å (at 
the base) [8]. Five PltB subunits (encoded by a single copy of pltB) form a pentameric ring at the 
base of the toxin [8]. The pentameric ring is covalently linked to PltA at its carboxy terminus, 
which inserts into the hydrophobic alpha-helical ring of the PltB pentamer [8]. A disulfide 
linkage between PltA Cys214 and CdtB Cys269 anchors CdtB at the most distal location from S-
CDT’s pentameric base (Fig 2.3) [8]. Therefore, CdtB does not physically interact with the PltB 
subunits [8]. Structurally, the disulfide bonds and catalytic residues of both the pertussis toxin S1 
(Glu129) and the PltA subunit of S-CDT (Glu 133) overlap in the 3D configuration, suggesting 
that reduction of the disulfide bonds would be necessary for activation of the ADP-ribosylating 
function of PltA, as is the case for the pertussis toxin [8]. Alignment of the 3D protein structures 
of the S-CDT subunits PltA, PltB, and CdtB with their respective homologous protein subunits 
(i.e., Ptx S1 with PltA, Ptx S2 or SubB with PltB, and CdtB from S. Typhi with CdtB from 
Haemophilus ducreyi (H. ducreyi) yielded low root-mean-square-deviations [8]. This further 
supports the hypothesis that the subunits PltA and PltB share homology to subunits of the 
pertussis and subtilase toxins, respectively, and also share a common structure and function (Fig 2.3) 
[8]. 
The translated product of pltB, encoding the pentameric B-subunit of S-CDT, is 137 amino 
acids in length, composed of a 23 aa secretion signal peptide and a 114 aa chain [44]. 
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Interestingly, the amino acid sequence of PltB, as well as the 3D configuration, aligns well with 
the SubB subunit of the subtilase toxin encoded by E. coli [8,31]. Analogous to SubB, PltB is 
implicated in binding to host cells [8,31]. Chromatography-based interaction studies have 
identified several possible host cell receptors for the PltB subunit of S-CDT, namely 
podocalyxin-like protein 1 (PODXL), but also a variety of sugar moieties on glycoproteins and 
glycoplipids, including sialylated glycans [8]. Given S-CDT’s ability to intoxicate a wide variety 
of cell types, it is likely that PltB is able to bind to a variety of host cell structures, namely 
glycans [8]. Similarly, the SubB subunit of the subtilase toxin preferentially recognizes and binds 
to sialylated glycoproteins [31]. There are conflicting reports regarding the requirement of PltB 
for cytotoxicity [11,32]. A ΔpltB mutant of S. Typhi failed to induce a G2/M cell cycle arrest in a 
cell culture model, suggesting that PltB plays a critical role in toxin trafficking [8,12]. However, 
HeLa cells infected with a ΔpltB mutant of S. enterica serotype Javiana (S. Javiana) showed 
evidence of a G2/M phase arrest, consistent with S-CDT [32]. Purified PltB has been shown to 
up-regulate chemokine and cytokine production in a cell culture model as well, suggesting that 
its role in virulence may not be limited to just ensuring delivery of CdtB to host cells [45]. 
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FIGURE 2.3 Space-fill models of the 3D structure of the: (a) pertussis toxin; (b) cytolethal distending 
toxin (CDT) from Salmonella enterica serotype Typhi; and (c) CDT from Haemophilus ducreyi. The 
unique A2B5 structure of the Salmonella cytolethal distending toxin (S-CDT) combines active subunits 
CdtB from the CDT produced by other Gram-negative species, and the ADP-ribosyltransferase toxin 
subunit of the pertussis toxin. The binding subunit of S-CDT is arranged as a pentameric ring, similar to 
the binding portion of the pertussis toxin. Protein databank accession numbers: Pertussis toxin (1PRT) 
[46], S-CDT (4K6L) [8], and CDT (1SR4) [47]. 
 
PltA, one of S-CDT’s two active subunits, is a functional ADP-ribosylating subunit with 
homology to the active subunit of the pertussis toxin [8,11,13]. The 27.1 kDa PltA subunit 
consists of 242 aa, comprising both a signal sequence peptide of 18 aa residues and a 224 aa 
chain [48]. The functionality of PltA as an ADP-ribosyltransferase has been confirmed in S. 
Typhi, however the host protein target(s) remain(s) unknown [11]. In Bordetella pertussis, the 
causative agent of whooping cough, the pertussis toxin plays a critical role in modulating the 
host immune response by ADP-ribosylating host G proteins, and subsequently disrupting G 
protein signaling pathways [30,49,50]. Importantly, eukaryotic cells infected with S. Typhi ΔpltA 
mutants do not have the characteristic distended phenotype [11,32]. However, substitution of 
PltA with a catalytically inactive variant PltA
E133A
, restored S-CDT-induced cytotoxicity, 
suggesting that despite PltA’s functioning as an active ADP-ribosylating toxin, its role in S-
CDT-mediated cytotoxicity is most likely related to entry and trafficking of S-CDT in 
intoxicated eukaryotic cells, as the subunits CdtB and PltB do not physically interact [8,11]. 
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Further elucidation of the molecular targets of PltA-mediated ribosylation will be necessary to 
fully understand its role as a virulence factor, and furthermore, its role in S-CDT-mediated 
cytotoxicity. While PltA does not appear to play an important role in the DNA damaging activity 
of the CdtB subunit, it will be important to identify the molecular targets of the ADP-ribosyl 
transferase in order to elucidate its potential contributions to the outcome of an infection with a 
S-CDT positive strain. 
The cytotoxic effects associated with S-CDT intoxication are primarily attributable to the 
CdtB subunit. The CdtB subunit has limited amino acid sequence homology to mammalian 
DNase I, and is thought to cleave host DNA, thereby triggering activation of the host cell’s DNA 
damage response (DDR), resulting in the distended morphology and G2/M cell cycle arrest 
[10,51]. The CdtB subunit may also act as a phosphatase, as the CDT produced by A. 
actinomycetemcomitans has demonstrated PI-3,4,5-triphosphate phosphatase activity, although 
phosphatase activity has yet to be confirmed for S-CDT [52]. The CdtB subunit is highly 
conserved among CDT positive Salmonella [34]. The CdtB subunit has a mass of 29.6 kDa, and 
is 269 aa in length, comprising a 22 aa signal peptide and 247 aa chain [48]. In agreement with 
characterization of the CDT produced by other Gram-negative bacteria, CdtB is necessary for the 
distended phenotype of infected cells, as deletion of cdtB in S. Typhi and NTS strains results in a 
loss of the ability to elicit a G2/M phase arrest in eukaryotic cells [11,12,32,34,51]. Transfection 
of a Cos-2 cell line with plasmid-encoded S. Typhi cdtB was sufficient for cytotoxicity, further 
supporting CdtB as the active component of S-CDT [12]. Despite CdtB’s confirmed activity, it is 
still unclear if CdtB preferentially targets certain DNA motifs, and how many single strand 
breaks (SSB) and/or double strand breaks (DSB) it may introduce into any given strand of DNA. 
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MECHANISM OF ACTION 
The delivery and trafficking of S-CDT differs from that of the CDT produced by other 
Gram-negative bacteria. The key differences distinguishing S-CDT trafficking and activation 
from CDTs produced by other Gram-negative bacteria include: (i) S-CDT is only produced when 
Salmonella cells are residing within a host eukaryotic cell; (ii) S-CDT must be exported out of 
the SCV and subsequently out of the host cell, after which the exported S-CDT may either re-
enter the cell or intoxicate a nearby cell; (iii) S-CDT’s unique A2B5 structure (compared to the 
AB2 configuration of other CDTs) requires a reducing atmosphere to dissociate the PltA and 
CdtB subunits; and (iv) the host cell receptors for S-CDT differ as a reflection of its use of PltB 
rather than CdtA and CdtC subunits for binding to host cells. 
S-CDT Uses Multiple Host Cell Receptors Enabling it to Intoxicate a Wide Variety of Cell 
Types. Collectively, S-CDT and other CDTs are able to intoxicate a wide variety of host cells 
[8,51]. Despite this, several reports suggest that CDT binding and intracellular trafficking within 
host cells is species specific, with different receptors and intracellular trafficking mechanisms 
being utilized depending on the bacterial species producing the CDT [51,53–56]. A recent study 
suggested that S-CDT binds to a variety of host receptors, including PODXL, and CD45 on B 
and T cells [8].  
Song et al. noted that sugar moieties of primarily glycoproteins, but also glycolipids, are the 
primary target for S-CDT binding [8]. S-CDT preferentially binds α(2-3)-linked N-
acetylneuraminic acid [8]. In comparison, the B subunit of the subtilase toxin (which has 
homology to the B subunit of S-CDT) binds preferentially to α(2-3)-linked N-glycolylneuraminic 
acid terminating glycans, but also α(2-3)-linked N-acetylneuraminic acid glycans [31]. Similar to 
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the pertussis toxin S2 binding subunit, S-CDT also demonstrates some affinity for terminal sialic 
acid moieties [8,30]. 
The CDTs produced by other Gram-negative bacteria may also use N-linked carbohydrate 
structures as receptors. Initially, E. coli CDT was characterized as binding to N-linked 
carbohydrate moieties of glycoproteins, while the CDT produced by A. actinomycetemcomitans 
preferentially uses the ganglioside GM3 as the cell receptor [57,58]. Eshraghi et al. noted that the 
CDTs produced by E. coli, H. ducreyi, Campylobacter jejuni, and A. actinomycetemcomitans 
were affected differently by host cell N-linked glycosylation, cholesterol levels, and deficiencies 
in sialic acid, galactose and glycolipids, therefore suggesting that the CDT mode of entry is 
dependent on the bacterial species producing the CDT [55]. In summary, like other CDTs, it 
appears that S-CDT does not utilize a single receptor. Rather, S-CDT can utilize multiple 
different receptors, perhaps explaining why S-CDT is capable of intoxicating a number of 
different cell types [8,34,40]. It has been suggested that the variability in host cell receptors 
utilized by CDTs from different bacterial species, may partially explain why certain CDT-
producing pathogens preferentially inhabit and colonize particular regions of the host 
[10,51,55,59]. 
Entry and Trafficking of S-CDT. Intracellular trafficking and subsequent targeting of CdtB to 
the nucleus occurs via different mechanisms, depending on the bacterial species producing the 
CDT [10,56]. In the case of S-CDT, following its production by Salmonella residing within the 
SCV, it appears that S-CDT must first be exported out of the infected host cell, before being 
endocytosed by either the eukaryotic host cell from which it was produced, or by another cell 
[11]. The most convincing evidence for this hypothesis was generated by Spanò et al., who 
showed that addition of a toxin-neutralizing antibody prevented intoxication of epithelial cells 
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that were infected with S. Typhi cells actively producing S-CDT [11]. The secretion of S-CDT 
out of the SCV, and subsequently out of the host cell, requires the production of outer membrane 
vesicles (OMV), which “bud” off of the SCV, and are trafficked by host kinesin along 
microtubules to the plasma membrane [40]. 
Re-entry of S-CDT into a eukaryotic cell infected with Salmonella (autocrine pathway), or 
entry into an uninfected cell (paracrine pathway), occurs via endocytosis (See Fig 2.4). Similarly, 
the pertussis toxin, subtilase toxin, and CDTs produced by other Gram-negative bacteria, also 
utilize endocytosis for toxin entry [30,31,51]. While the requirement of clathrin in the 
endocytosis of S-CDT is currently unknown, endocytosis of other CDTs may occur via clathrin-
dependent or clathrin-independent mechanisms, while endocytosis of the subtilase toxin is 
clathrin-dependent [31,51,53,60]. Following endocytosis, S-CDT is predicted to follow 
retrograde trafficking through the Golgi complex and endoplasmic reticulum [40]. For H. 
ducreyi, endosomal trafficking transports the CdtB and CdtC subunits retrograde to the trans-
Golgi network, and then subsequently through the Golgi complex via COPI vesicles, as 
evidenced by sulfation (a Golgi-specific activity) of CdtB, and the absence of a distended 
phenotype when intoxicated cells were treated with Brefeldin A, which inhibits the formation of 
COPI vesicles [59,61]. Subsequent transportation of S-CDT across the nuclear membrane, and 
into the nucleus of the host cell where it elicits SSB and/or DSB, is currently uncharacterized. It 
is still unclear how CdtB dissociates from the other components of S-CDT, and at which stage 
this occurs [8]. Presumably, the disulfide bond between PltA Cys214 and CdtB Cys269, is 
reduced by host cell reductases [8]. By comparison, the pertussis toxin active component is 
dissociated, and therefore activated, in the ER prior to being released into the cytosol where it 
ADP-ribosylates G proteins [30]. It is possible that S-CDT components PltA and CdtB separate 
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in the ER as well. Following exit of the ER, the CdtB subunit must cross the nuclear membrane, 
and enter the host cell nucleus in order to induce DNA damage. 
The current understanding of the intracellular trafficking of S-CDT is largely based on the 
intracellular trafficking of related toxins, namely the CDTs produced by other Gram-negative 
bacteria, and the pertussis and subtilase toxins. However, some studies have demonstrated that 
CDTs may utilize different intracellular trafficking mechanisms, requiring different components 
of the host cell for trafficking to the nucleus [56,62]. For example, treatment of HeLa cells with 
chemical agents blocking endosomal acidification (e.g., bafilomycin A1 or ammonium chloride) 
prevented H. ducreyi CdtB transportation to the nucleus, but not E. coli CdtB trafficking to the 
nucleus [56]. These results suggest that E.coli and H. ducreyi CDTs utilize different intracellular 
trafficking mechanisms to elicit their cytotoxic effects [56]. 
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FIGURE 2.4 Proposed model for the entry and intracellular trafficking of Salmonella cytolethal 
distending toxin (S-CDT). (1) The PltB subunits of S-CDT bind to sugar moieties on glycoproteins and 
glycolipids on the host cell surface [8]. (2) S-CDT is internalized by endocytosis and is (3) trafficked in 
endosomes, which deliver the S-CDT to the Golgi complex [11]. Subsequently, S-CDT is (4) transported 
retrograde through the Golgi complex, likely mediated by COPI vesicles, and then (5) through the 
endoplasmic reticulum [53]. (6) It is hypothesized that in the ER, host reductases reduce the disulfide 
bonds covalently linking the PltA and CdtB subunits, releasing CdtB from the holotoxin [8]. (7) The 
CdtB subunit is imported into the nucleus, likely by passing through the nuclear pore complex, as is done 
for other CDTs [53]. Once in the nucleus, CdtB acts as a nuclease and cleaves host DNA to activate the 
host cell’s DNA damage response [40]. Protein databank entry for S-CDT (4K6L) [8]. Cell adapted from 
[63]. 
 
Importantly, S-CDT has multiple structural differences in comparison to the CDTs produced 
by other Gram-negative bacteria, namely, the absence of CdtA and CdtC subunits, and the 
presence of subunits PltA and PltB subunits. Therefore, further research will be necessary to 
confirm the exact trafficking mechanisms of S-CDT produced by Typhi and nontyphoidal 
serotypes. 
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S-CDT’S ROLE IN VIRULENCE 
Characterizations of the deleterious effects associated with S-CDT intoxication at both the 
cellular and organismal levels have provided key insights into the contributions of S-CDT to 
disease. 
DNA Damage and Induction of the DNA Damage Response. The hallmark of CDT-
intoxication is the production of SSB and/or DSB, resulting in activation of the intoxicated host 
cell’s DDR, and subsequent G2/M phase arrest and cellular distention (see Table 2.2) 
[10,51,64,65]. This is also true of S-CDT, and has been confirmed for S-CDT produced by both 
Typhi and NTS serotypes [8,11,12,32–34,42]. Interestingly, CDT-mediated DNA damage 
preferentially results in G2/M phase arrest [10,16,17,19,21–26,38,51,65]. However, it should be 
noted that cells arrested in the G2/M phase may have sustained damage prior to entering the G2 
phase [51,64,66]. The majority of studies reporting G2/M phase arrest in CDT-intoxicated cell 
populations used DNA content to attribute cells to a defined growth phase [10,12,51,59]. 
However, the quantification of DNA within a given cell would not distinguish damage that 
occurred and was detected prior to G2 phase, versus damage occurring in G2 [51,66]. In support 
of this, Fedor et al. determined that for HeLa cells intoxicated with low doses of E. coli CDT, 
SSB were converted to DSB in the S-phase [64]. Therefore, it is likely that CDT and S-CDT 
DNase activity induces DNA damage regardless of the eukaryotic cell cycle phase, but the actual 
cell arrest is evident in the G2/M phase transition. 
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TABLE 2.2. Pathogenic outcomes attributed to intoxication with Salmonella cytolethal 
distending toxin and other Gram-negative bacteria producing cytolethal distending toxins. 
Pathogenic Outcome of 
CDT-Mediated 
Intoxication 
Bacterial Species 
1
 References 
Cellular Outcomes   
G2/M Phase arrest A. actinomycetemcomitans [12,14,15,17,19,22,
24,27,28,34,67]  C. jejuni 
E. coli 
Haemophilus spp. 
Helicobacter spp. 
P. alcalifaciens 
Shigella spp. 
Salmonella (Typhi and NTS) 
Activation of host cell DNA 
damage response 
A. actinomycetemcomitans [26,28,40,64,68–71] 
C. jejuni 
E. coli 
Haemophilus spp. 
H. ducreyi 
H. hepaticus 
P. alcalifaciens 
S. Typhi 
Induction of autophagy NTS [33] 
Induction of apoptosis A. actinomycetemcomitans [33,72–78] 
C. jejuni 
E. coli 
H. ducreyi 
Helicobacter spp. 
P. alcalifaciens 
NTS 
Host Outcomes   
Tumorigenesis and 
neoplastic lesions 
H. cinaedi [79–82] 
H. hepaticus 
H. ducreyi 
Typhoid-like illness S. Typhi [8] 
Chronic infection H. hepaticus [83] 
1
 Pathogenic outcome reported for CDT produced by given bacterial species. NTS refers to “nontyphoidal 
Salmonella”. 
 
Following detection of DNA damage, the host cell’s DDR is activated. While the activation 
of DDR proteins has not been reported for S-CDT, studies of CDT-mediated intoxication for 
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other Gram-negative bacteria have confirmed the activation of the MRN complex (a complex of 
Mre11, Rad50 and Nbs1) in the ataxia telangiectasia mutated (ATM) dependent DNA damage 
signaling pathway, as well as phosphorylation of the C-terminal serine 139 of histone H2AX 
(called γH2AX), which is commonly associated with DSBs [40,64,67,69,77,84,85]. In addition, 
single cell electrophoresis of CDT-intoxicated cells (also referred to as the “comet assay”) has 
demonstrated DNA fragmentation, indicating that CdtB is capable of inducing multiple lesions in 
the host DNA [64,85,86]. However, Fahrer et al. also suggested that CDT is capable of 
activating the ataxia telangiectasia and Rad3 related (ATR) mediated DDR signaling pathway, 
but at a delayed rate compared to the ATM-dependent signaling pathway [85]. Finally, the DNA 
damage induced by S-CDT and the CDTs of other Gram-negative bacteria causes nuclear 
enlargement and a distended morphology among intoxicated cells [10–12,14,51]. 
Apoptosis of Immune Cells and Host Immune Suppression. Apoptosis resulting from CDT-
intoxication has been demonstrated for a wide range of host cell types, including immune and 
non-immune cell types [33,73,87–90]. Williams et al. demonstrated that  
S-CDT produced by S. Javiana induced apoptosis in J774A.1 macrophage cells, which also had a 
significant increase in expression of the pro-apoptotic Bax gene compared to J774.A1 cells 
infected with a S. Javiana ΔcdtB isogenic mutant [33]. Currently, it appears that CDT-mediated 
induction of apoptosis occurs primarily via the intrinsic pathway, through increased expression 
of Bax and activation of caspase 9 and subsequently caspase 3 [51,77]. 
Tumorigenesis and Carcinogenic Potential. Chronic exposure to CDT has been investigated for 
several Gram-negative bacterial species. Despite similar hepatic colonization levels, mice 
infected with CDT positive Helicobacter hepaticus (H. hepaticus) developed hepatic dysplasic 
nodules, while mice infected with a CDT-null mutant did not [82]. Similarly, chronic 
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intoxication with purified H. hepaticus or H. ducrecyi CDT was associated with malignant 
transformations in a cell culture model [79]. Chronic inflammation is an important predisposition 
for cancer development [80,91–93]. In multiple cell culture models, administration of purified 
PltB (called ArtB in the study) of S. Typhi elicited expression of pro-inflammatory cytokines, 
possibly suggesting a role for S-CDT in the induction of inflammation [45]. Chronic infection 
with S. Typhi is significantly associated with gall bladder cancer, although the contribution to, or 
requirement for, S-CDT production has not yet been established [94–96]. Together, these studies 
implicate a potential role for CDT and S-CDT in tumorigenesis and carcinogenesis. 
One of the major limitations of studying the outcomes of chronic infection with S. Typhi, 
and therefore the potential of S-CDT in tumorigenesis or carcinogenesis, has been the lack of a 
suitable animal model. Recently, a humanized mouse model for S. Typhi infection was 
developed [97]. Investigations into the cellular and organismal outcomes of infection with 
chronic exposure to S-CDT will provide important information regarding the potential for 
tumorigenesis or carcinogenesis associated with salmonellosis involving S-CDT positive 
serotypes. 
Administration of S-CDT May Recapitulate Symptoms of Typhoid Fever. Injection of purified 
S-CDT recapitulated symptoms associated with the acute phase of typhoid fever, for a mouse 
model of infection [8]. Following systemic administration, mice injected with active S-CDT lost 
significantly more weight compared to control mice [8]. Furthermore, mice intoxicated with the 
wild type S-CDT showed a marked decrease in neutrophil counts, which is characteristic of 
typhoid fever in humans [8]. However, infection with NTS serotypes encoding S-CDT does not 
result in a typhoid-like illness [6,98–100]. While S-CDT may indeed contribute to typhoid fever, 
the widespread distribution of S-CDT among NTS, along with the marked difference in virulence 
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between NTS serotypes and S. Typhi, suggest that the typhoid toxin may not solely responsible 
for, but may contribute to, typhoid fever. Alternatively, the discrepancy in disease severity 
between infections with S. Typhi and NTS serotypes producing an S-CDT, could reflect 
differences in expression of S-CDT, as alignments of toxin-encoding gene components from 
NTS and S. Typhi suggest that cdtB, pltA, and pltB are highly conserved [34]. Use of the recently 
developed humanized mouse model may provide an opportunity to further define the 
contribution(s) of S-CDT to human typhoid fever [97]. More specifically, it would be interesting 
to establish if S-CDT contributes to immune cell depletion, and if S-CDT enhances the ability of 
S. Typhi to establish a chronic infection, as has been proposed by other groups studying 
colonization and persistence of other CDT-producing pathogens [83]. 
Persistence and Chronic Infection. Approximately 2–5% of S. Typhi infections result in chronic 
infection [101,102]. For H. hepaticus, CDT is required for colonization in a host model of 
infection [83]. It is possible that the cell cycle arrest and immune suppression associated with S-
CDT intoxication may play an important role in the colonization and development of a chronic 
infection with S. Typhi as well. 
DISCUSSION AND FUTURE DIRECTIONS 
Overall, CDT has been implicated as an important virulence factor among Gram-negative 
bacteria, having been associated with the bacteria’s ability to colonize, survive, and persist 
within the host. Still, few studies have examined these effects in regards to the S-CDT produced 
by select Salmonella serotypes. Further characterization of S-CDT regulation, production, and 
mechanism of action will provide important information regarding the production of the toxin 
during different intra- and extracellular stages of infection. Furthermore, the true benefits of S-
CDT to Salmonella during the course of an infection remain unclear. There is a clear difference 
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in the severity of salmonellosis among NTS serotypes, with some serotypes being more 
frequently associated with invasive disease resulting in infections requiring hospitalization [6]. 
Could S-CDT play an important role in disease outcome? The long-term sequelae associated 
with salmonellosis are well established, yet the mechanisms by which these sequelae arise are 
poorly understood. For example, the well-established association between gall bladder cancer 
and chronic infection with S. Typhi may be attributable to chronic exposure to S-CDT [94–96]. 
Chronic infection with NTS is less studied, although some reports suggest that NTS may induce 
chronic infections in humans and in animals [103,104]. Genotoxin production by other pathogens 
has also been implicated in carcinogenesis in the host [73,105,106]. Further elucidation of the 
true long-term sequelae associated with S-CDT-mediated intoxication will provide valuable 
information, which may partially explain the observed differences in virulence among the NTS 
serotypes. 
Select pathogens are differentiated based on their possessing certain virulence factors. Shiga 
toxin producing E. coli (STEC) are characterized based on the presence of stx1 and stx2 genes 
encoding shiga toxins 1 and 2, respectively [107]. In STEC infections, appropriate treatment is 
guided by rapid detection of the stx genes, as antibiotic treatment is associated with a 
significantly higher incidence of hemolytic uremic syndrome, and is therefore discouraged [108]. 
S-CDT status could influence treatment regimens, and could also serve as an epidemiological 
tool for comparing similar strains implicated with a common food vehicle, as is done with the stx 
genes in E. coli [107]. 
Further characterization of S-CDT has the potential to identify novel rapid detection 
methods for S-CDT-producing Salmonella in clinical settings. Characterization of this bacterial 
toxin may also inform the development of novel diagnostic, treatment, and prevention strategies 
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for salmonellosis, as demonstrated previously for a variety of diseases including botulism, 
Clostridium difficile infection, and HUS resulting from infection with shiga toxin producing E. 
coli [109–111]. 
CONCLUSIONS 
Overall, the implications of S-CDT in the context of salmonellosis present a unique and 
intriguing challenge. Multiple CDT-producing pathogens have been linked to an increased 
incidence of cancer among chronically infected individuals [80,95,96]. The public health 
implications of S-CDT production by NTS should be considered, as the recent discovery of the 
widespread nature of the toxin among NTS suggests that, at least in the US, many individuals 
may be exposed to S-CDT. Future investigations relating S-CDT’s role in pathogenesis, as well 
as implications for the long-term sequelae attributable to S-CDT-mediated intoxication will be 
beneficial in assessing the contributions of S-CDT to salmonellosis in both humans and animals. 
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CHAPTER 3 
THE CYTOLETHAL DISTENDING TOXIN PRODUCED BY NONTYPHOIDAL 
SALMONELLA SEROTYPES JAVIANA, MONTEVIDEO, ORANIENBURG, AND 
MISSISSIPPI, INDUCES DNA DAMAGE IN A MANNER SIMILAR TO SEROTYPE 
TYPHI* 
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ABSTRACT 
Select nontyphoidal Salmonella (NTS) serotypes were recently found to encode the 
Salmonella cytolethal distending toxin (S-CDT), an important virulence factor for serotype 
Typhi, the causative agent of typhoid fever. Using a PCR-based assay we determined that among 
21 NTS serotypes causing the majority of foodborne salmonellosis cases in the US, genes 
encoding S-CDT are conserved in isolates representing serotypes Javiana, Montevideo, and 
Oranienburg, while for serotype Mississippi isolates the presence of S-CDT-encoding genes is 
clade-associated. HeLa cells infected with representative strains of these S-CDT-positive 
serotypes had a significantly higher proportion of cells arrested in the G2/M phase compared to 
HeLa cells infected with representative strains of S-CDT-negative serotypes Typhimurium, 
Newport, and Enteritidis. The G2/M cell cycle arrest was dependent on CdtB, the active subunit 
of S-CDT, as infection with isogenic ΔcdtB mutants abolished their ability to induce a G2/M cell 
cycle arrest. Infection with S-CDT-encoding serotypes was significantly associated with 
activation of the host cell’s DNA damage response (DDR), a signaling cascade that is important 
for detecting and repairing damaged DNA. HeLa cell populations infected with S-CDT-positive 
serotypes had a significantly higher proportion of cells with DDR proteins 53BP1 and γH2AX 
foci, compared to cells infected with either S-CDT-negative serotypes or isogenic ΔcdtB strains. 
Intoxication with S-CDT occurred via autocrine and paracrine pathways, as uninfected HeLa 
cells among populations of infected cells also had an activated DDR. Overall, we show that S-
CDT plays a significant role in the cellular outcome of infection with NTS serotypes. 
IMPORTANCE 
The recent discovery that multiple serotypes encode S-CDT, which was previously 
established as an important virulence factor for serotype Typhi, suggested that this toxin may 
also contribute to the outcome of infection with nontyphoidal serotypes. In this study, we 
demonstrate that at a cellular level, S-CDT significantly alters the outcome of infection by 
inducing DNA damage which is associated with a cell cycle arrest and activation of the host 
cell’s DDR. Importantly, these results contribute valuable information for assessing the public 
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health implications of S-CDT in infections with NTS serotypes. Our data suggest that infection 
with Salmonella strains that encode S-CDT has the potential to result in DNA damage, which 
may contribute to long-term sequelae. 
INTRODUCTION 
Cytolethal distending toxins (CDT) are important virulence factors produced by Gram-
negative bacteria, including those causing predominantly extracellular infections 
(Aggregatibacter actinomycetemcomitans, Haemophilus spp., Providencia alcalifaciens) and 
those able to cause intracellular infections (Campylobacter spp., Escherichia coli, Helicobacter 
spp.,  Salmonella enterica, Shigella spp., and Yersinia spp.) (1, 2). In vitro, CDTs act as 
genotoxins, inducing single strand or double strand breaks, resulting in activation of the 
eukaryotic cell DDR (3-5). DDR protein 53 binding protein 1 (53BP1), and phosphorylation of 
histone 2AX (producing γH2AX), have been shown previously to localize at DNA double strand 
breaks, recruiting DNA repair machinery to the DNA damage (6, 7). In vivo, CDT-induced 
damage has been associated with enhanced colonization of the host by CDT-producing 
pathogens, tumorigenesis and neoplastic lesions, as well as contributing to the establishment of 
chronic infections (8-10).  
 The CDTs encoded by most Gram-negative pathogens exist as an AB2 toxin composed of 
2 binding subunits, CdtA and CdtC, and an active subunit CdtB (3). In vitro analyses have 
demonstrated  nuclease activity of the CdtB subunit using plasmid relaxation assays (11). 
However, the CDT encoded by select S. enterica serotypes (referred to as S-CDT for Salmonella 
cytolethal distending toxin) represents a unique form of CDT with an A2B5 configuration with 2 
active subunits (CdtB and PltA), and 5 binding subunits (PltB) arranged as a pentameric ring (2, 
12). The PltA subunit shares structural and functional homology with the S1 subunit of the 
pertussis toxin, which acts as an ADP-ribosyl transferase (2, 13). The PltB subunit has been 
suggested to play a role in binding of S-CDT to host cell receptors, as it shares homology to the 
binding subunits of both the pertussis toxin (subunits S2 and S3) and the subtilase cytotoxin 
(SubB) produced by E. coli (12-14).  
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 S-CDT was originally characterized as a unique virulence factor of S. enterica subspecies 
enterica serotype Typhi (2, 15, 16). In vitro studies demonstrated that, similar to CDTs produced 
by other Gram-negative pathogens, the S-CDT produced by S. Typhi induced DNA damage 
leading to a G2/M arrest among infected cell culture populations (2, 12, 16). Recent studies 
suggest that the S-CDT produced by S. Typhi is capable of recapitulating symptoms of typhoid 
fever, modulating the immune system, and enabling S. Typhi to persist in vivo (8, 12).  
Each year, NTS infections account for approximately 1.03 million cases of foodborne 
illness in the US, and an estimated 80.3 million cases internationally (17, 18). There are marked 
differences in the disease severity resulting from infections with different Salmonella serotypes 
(19), yet genetic analyses have failed to definitively account for differences in virulence among 
nontyphoidal Salmonella (NTS) serotypes (20, 21). Recent studies have identified genes 
encoding S-CDT in > 40 NTS serotypes (20, 22). However little is known regarding the 
distribution and conservation of S-CDT-encoding genes among NTS serotypes, and the 
contributions of S-CDT in the course of infection with NTS serotypes (23-25).  
In this study, we examined differences in the cellular outcome of infection between S-
CDT-positive and negative NTS serotypes. Using a PCR-based screen, we characterized the 
distribution and sequence conservation of S-CDT-encoding genes among 21 of the NTS 
serotypes most frequently isolated from clinical cases of salmonellosis in the US. Next, we 
examined the cellular response to infection with the 4 S-CDT-positive serotypes identified 
through our PCR-screen, and compared this to infection with 3 S-CDT-negative serotypes in 
order to determine what role S-CDT may play in a cell model of infection. Overall, we show that 
genes encoding S-CDT are highly conserved among isolates representing NTS serotypes Javiana, 
Montevideo, Oranienburg, as well as 1 clade of serotype Mississippi. Importantly, infection with 
NTS serotypes encoding S-CDT significantly alters the outcome of infection in a HeLa cell 
model. These data suggest that S-CDT is an important virulence factor in NTS, which may 
contribute to differences in disease severity observed among different NTS serotypes. With the 
recognized potential of CDTs to serve as genotoxins, our data also suggest that infection with 
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some Salmonella strains (i.e., those that carry S-CDT) has the potential to cause DNA damage in 
host cells, which may predispose case patients to long-term sequelae that remain to be defined.  
 
MATERIALS AND METHODS 
Bacterial strains, human cell lines, and culturing conditions. A total of 864 wild-type 
Salmonella isolates obtained from foods (e.g., raw oysters, shrimp, jalapeño peppers, spices, and 
others), environmental samples (e.g., ground water, soil, drag swabs from produce fields, dairy 
and avian farm environments), animals (e.g., bovines, avians, reptiles), and humans with clinical 
symptoms in the US were selected from an existing strain collection for inclusion in this study 
(see Table 3.1 and Table 3.2 for complete list).  
 
TABLE 3.1 Salmonella strains used for in vitro analyses 
Strain  Serotype Genotype Source Date Isolated
a
 
FSL S5-0415 Enteritidis Wild-type Human April 2004 
FSL S5-0536 Typhimurium Wild-type Human November 2004 
FSL S5-0639 Newport Wild-type Human December 2004 
FSL S5-0395 Javiana Wild-type Human March 2004 
FSL R8-2779 Mississippi Wild-type Human November 2008 
FSL R8-4841 Montevideo Wild-type Human April 2010 
FSL S5-0642 Oranienburg Wild-type Human December 2004 
FSL B2-0360 Javiana FSL S5-0395 ΔcdtB  Lab Strain NAb 
FSL B2-0364 Montevideo FSL R8-4841 ΔcdtB Lab Strain NAb 
aNA= not applicable 
bthese mutants and their construction were previously described (25) 
 
Isolates were selected to belong to 21 NTS serotypes most frequently isolated from human 
clinical cases of salmonellosis in the US in 2011, as reported by the 2011 CDC National 
Salmonella Surveillance report. Approximately 50 isolates were selected for each serotype 
except for 7 serotypes (see Table 2.2) where only a smaller number of isolates could be obtained 
from the Cornell Food Safety Laboratory’s Salmonella collection. In addition, the isogenic 
ΔcdtB mutants FSL B2-0360 and FSL B2-0364 and the corresponding parent strains FSL S5-
0395 (serotype Javiana) and FSL R8-4181 (serotype Montevideo) were used (Table 2.1); these 
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strains including the ΔcdtB mutants had previously been described (25). As previously detailed, 
ΔcdtB mutants were constructed by deleting the entire cdtB ORF using the λ-Red recombinase 
method  (26). All strains were maintained in 15% v/v glycerol stored at -80°C. Salmonella were 
grown on brain heart infusion (BHI; Becton Dickinson, Sparks, MD) agar plates, which were 
incubated at 37°C. For infections, Salmonella strains were cultured in Lysogeny Broth (LB; pH 
8, 0.3 M NaCl) under static conditions at 37°C to increase invasion efficiency (27-29). 
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TABLE 2.3 All Salmonella isolates screened for pltA, pltB, and cdtB 
Isolate ID Serotype Source 16s (Y/N) pltA (Y/N) cdtB (Y/N) pltB (Y/N) 
FSL A4-0021 Agona animal Y N N N 
FSL A4-0656 Agona human Y N N N 
FSL A4-0792 Agona animal Y N N N 
FSL M5-0005 Agona animal Y N N N 
FSL M8-0482 Agona environmental swab Y N N N 
FSL M8-0483 Agona environmental swab Y N N N 
FSL M8-0484 Agona environmental swab Y N N N 
FSL M8-0485 Agona nutmeg, ground Y N N N 
FSL M8-0486 Agona hard cheese Y N N N 
FSL M8-0487 Agona raw peeled shrimp Y N N N 
FSL M8-0488 Agona basil, fresh Y N N N 
FSL M8-0490 Agona Sewage Effluent Y N N N 
FSL R6-0774 Agona environment, farm Y N N N 
FSL R8-0774 Agona human, clinical Y N N N 
FSL R8-0779 Agona human, clinical Y N N N 
FSL R8-1193 Agona human, clinical Y N N N 
FSL R8-1194 Agona human, clinical Y N N N 
FSL R8-1195 Agona human, clinical Y N N N 
FSL R8-1196 Agona human, clinical Y N N N 
FSL R8-1197 Agona human, clinical Y N N N 
FSL R8-2497 Agona human, clinical Y N N N 
FSL R8-2519 Agona human, clinical Y N N N 
FSL R8-2527 Agona human, clinical Y N N N 
FSL R8-2566 Agona human, clinical Y N N N 
FSL R8-2961 Agona human, clinical Y N N N 
FSL R8-3244 agona animal, clinical Y N N N 
FSL R8-3344 agona animal, clinical Y N N N 
FSL R8-3712 Agona human, clinical Y N N N 
FSL R8-3810 Agona animal, clinical Y N N N 
FSL R8-3811 Agona animal, clinical Y N N N 
FSL R8-3819 Agona animal, clinical Y N N N 
FSL R8-3820 Agona animal, clinical Y N N N 
FSL R8-3821 Agona animal, clinical Y N N N 
FSL R8-3822 Agona animal, clinical Y N N N 
FSL R8-3823 Agona animal, clinical Y N N N 
FSL R8-3825 Agona animal, clinical Y N N N 
FSL R8-4666 Agona human, clinical Y N N N 
FSL R8-5059 Agona human, clinical Y N N N 
FSL R8-5377 Agona human, clinical Y N N N 
FSL R8-7953 Agona human, clinical Y N N N 
FSL R8-8141 Agona human, clinical Y N N N 
FSL R8-9536 Agona human, clinical Y N N N 
FSL R9-0830 Agona human, clinical Y N N N 
FSL S10-1750 Agona environment, farm Y N N N 
FSL S10-1759 Agona environment, farm Y N N N 
FSL S10-1760 Agona environment, farm Y N N N 
FSL S10-1761 Agona environment, farm Y N N N 
FSL S5-0437 Agona animal Y N N N 
FSL S5-0547 Agona animal Y N N N 
FSL S9-0322 Agona food Y N N N 
FSL A4-0009 Anatum animal Y N N N 
FSL A4-0525 Anatum animal Y N N N 
FSL A4-0550 Anatum animal Y N N N 
FSL A4-0576 Anatum human Y N N N 
FSL A4-0635 Anatum human Y N N N 
FSL A4-0660 Anatum human Y N N N 
FSL R6-0513 Anatum human, clinical Y N N N 
FSL R6-0788 Anatum environment, farm Y N N N 
FSL R6-0927 Anatum environment, farm Y N N N 
FSL R6-0928 Anatum environment, farm Y N N N 
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FSL R8-0187 Anatum environment, farm Y N N N 
FSL R8-0188 Anatum environment, farm Y N N N 
FSL R8-0349 Anatum environment, farm Y N N N 
FSL R8-0350 Anatum environment, farm Y N N N 
FSL R8-0351 Anatum environment, farm Y N N N 
FSL R8-0353 Anatum environment, farm Y N N N 
FSL R8-0354 Anatum environment, farm Y N N N 
FSL R8-0905 Anatum environment, farm Y N N N 
FSL R8-0906 Anatum environment, farm Y N N N 
FSL R8-0907 Anatum environment, farm Y N N N 
FSL R8-0908 Anatum environment, farm Y N N N 
FSL R8-1260 anatum animal, clinical Y N N N 
FSL R8-1305 Anatum human, clinical Y N N N 
FSL R8-1400 Anatum environment, farm Y N N N 
FSL R8-1401 Anatum environment, farm Y N N N 
FSL R8-1402 Anatum environment, farm Y N N N 
FSL R8-1404 Anatum environment, farm Y N N N 
FSL R8-1625 Anatum environment, farm Y N N N 
FSL R8-1819 anatum animal, clinical Y N N N 
FSL R8-1820 anatum animal, clinical Y N N N 
FSL R8-1853 anatum animal, clinical Y N N N 
FSL R8-1854 anatum animal, clinical Y N N N 
FSL R8-1855 anatum animal, clinical Y N N N 
FSL R8-1879 anatum animal, clinical Y N N N 
FSL R8-2108 Anatum human, clinical Y N N N 
FSL R8-3652 Anatum environment, farm Y N N N 
FSL R8-3653 Anatum environment, farm Y N N N 
FSL R8-4506 Anatum human, clinical Y N N N 
FSL R8-5396 Anatum human, clinical Y N N N 
FSL S5-0529 Anatum human Y N N N 
FSL S5-0530 Anatum human Y N N N 
FSL S5-0540 Anatum human Y N N N 
FSL R6-0929 Anatum var. 15+ environment, farm Y N N N 
FSL R6-0930 Anatum var. 15+ environment, farm Y N N N 
FSL R8-0347 Anatum var. 15+ environment, farm Y N N N 
FSL R8-0348 Anatum var. 15+ environment, farm Y N N N 
FSL R8-0851 Anatum var. 15+ animal, non-clinical Y N N N 
FSL R8-0852 Anatum var. 15+ animal, non-clinical Y N N N 
FSL R8-0853 Anatum var. 15+ animal, non-clinical Y N N N 
FSL R8-0854 Anatum var. 15+ animal, non-clinical Y N N N 
FSL A4-0677 Bareilly human Y N N N 
FSL R8-2449 Bareilly human, clinical Y N N N 
FSL R8-2587 Bareilly human, clinical Y N N N 
FSL R8-3741 Bareilly human, clinical Y N N N 
FSL R8-3886 Bareilly human, clinical Y N N N 
FSL R8-5210 Bareilly human, clinical Y N N N 
FSL R8-8142 Bareilly human, clinical Y N N N 
FSL R8-9535 Bareilly human, clinical Y N N N 
FSL R9-0050 Bareilly human, clinical Y N N N 
FSL R9-0059 Bareilly human, clinical Y N N N 
FSL R9-0061 Bareilly human, clinical Y N N N 
FSL R9-0099 Bareilly human, clinical Y N N N 
FSL R9-0144 Bareilly human, clinical Y N N N 
FSL R9-0146 Bareilly human, clinical Y N N N 
FSL R9-1723 Bareilly human, clinical Y N N N 
FSL M8-0474 Bareilly poultry feather meal Y N N N 
FSL M8-0475 Bareilly feather meal Y N N N 
FSL M8-0476 Bareilly irrigation water Y N N N 
FSL M8-0477 Bareilly nonfat dry milk Y N N N 
FSL M8-0478 Bareilly whisker fish Y N N N 
FSL M8-0479 Bareilly fennel seeds Y N N N 
FSL M8-0481 Bareilly pepper, ground red Y N N N 
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FSL A4-0622 Berta human Y N N N 
FSL A4-0805 Berta human Y N N N 
FSL R8-1568 Berta human, clinical Y N N N 
FSL R8-1606 Berta human, clinical Y N N N 
FSL R8-2917 Berta human, clinical Y N N N 
FSL R8-3761 Berta human, clinical Y N N N 
FSL R8-4514 Berta human, clinical Y N N N 
FSL R8-4531 Berta human, clinical Y N N N 
FSL R8-4681 Berta human, clinical Y N N N 
FSL R8-5033 Berta human, clinical Y N N N 
FSL R8-5395 Berta human, clinical Y N N N 
FSL R8-6083 Berta human, clinical Y N N N 
FSL R8-8681 Berta human Y N N N 
FSL R8-9524 Berta human, clinical Y N N N 
FSL R8-9525 Berta human, clinical Y N N N 
FSL R8-9532 Berta human, clinical Y N N N 
FSL R9-0297 Berta human, clinical Y N N N 
FSL R9-1179 Berta human, clinical Y N N N 
FSL S5-0502 Berta human Y N N N 
FSL S5-0637 Berta human Y N N N 
FSL A4-0555 Braenderup human Y N N N 
FSL A4-0616 Braenderup human Y N N N 
FSL A4-0694 Braenderup human Y N N N 
FSL A4-0825 Braenderup human Y N N N 
FSL A4-0841 Braenderup human Y N N N 
FSL M8-0493 Braenderup shrimp, frozen Y N N N 
FSL R6-0213 Braenderup human, clinical Y N N N 
FSL R8-0286 Braenderup human, clinical Y N N N 
FSL R8-0461 Braenderup human, clinical Y N N N 
FSL R8-1284 Braenderup human, clinical Y N N N 
FSL R8-1293 Braenderup human, clinical Y N N N 
FSL R8-1533 Braenderup human, clinical Y N N N 
FSL R8-1567 Braenderup human, clinical Y N N N 
FSL R8-1576 Braenderup human, clinical Y N N N 
FSL R8-2517 Braenderup human, clinical Y N N N 
FSL R8-2544 Braenderup human, clinical Y N N N 
FSL R8-2922 Braenderup human, clinical Y N N N 
FSL R8-2944 Braenderup human, clinical Y N N N 
FSL R8-2950 Braenderup human, clinical Y N N N 
FSL R8-3373 Braenderup human, clinical Y N N N 
FSL R8-3503 Braenderup human, clinical Y N N N 
FSL R8-3549 Braenderup human, clinical Y N N N 
FSL R8-3676 Braenderup human, clinical Y N N N 
FSL R8-3678 Braenderup human, clinical Y N N N 
FSL R8-3733 Braenderup human, clinical Y N N N 
FSL R8-3883 Braenderup human, clinical Y N N N 
FSL R8-4415 Braenderup human, clinical Y N N N 
FSL R8-4460 Braenderup human, clinical Y N N N 
FSL R8-4547 Braenderup human, clinical Y N N N 
FSL R8-4658 Braenderup human, clinical Y N N N 
FSL R8-4849 Braenderup animal, clinical Y N N N 
FSL R8-4978 Braenderup human, clinical Y N N N 
FSL R8-5017 Braenderup human, clinical Y N N N 
FSL R8-5387 Braenderup human, clinical Y N N N 
FSL R8-6090 Braenderup human, clinical Y N N N 
FSL R8-6532 Braenderup animal, clinical Y N N N 
FSL R8-7966 Braenderup human, clinical Y N N N 
FSL R8-8054 Braenderup human, clinical Y N N N 
FSL R8-8058 Braenderup human, clinical Y N N N 
FSL R8-8062 Braenderup human, clinical Y N N N 
FSL R8-9595 Braenderup animal, clinical Y N N N 
FSL R8-9602 Braenderup animal, clinical Y N N N 
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FSL R8-9668 Braenderup human, clinical Y N N N 
FSL R8-9677 Braenderup human, clinical Y N N N 
FSL R9-0052 Braenderup human, clinical Y N N N 
FSL R9-0097 Braenderup human, clinical Y N N N 
FSL R9-0151 Braenderup human, clinical Y N N N 
FSL S10-0939 Braenderup environment, farm Y N N N 
FSL S10-0947 Braenderup environment, farm Y N N N 
FSL S5-0373 Braenderup human Y N N N 
FSL F6-0967 Enteritidis human, clinical Y N N N 
FSL R6-0876 Enteritidis human, clinical Y N N N 
FSL R6-0880 Enteritidis human, clinical Y N N N 
FSL R8-0096 Enteritidis human, clinical Y N N N 
FSL R8-0099 Enteritidis human, clinical Y N N N 
FSL R8-0100 Enteritidis human, clinical Y N N N 
FSL R8-0102 Enteritidis human, clinical Y N N N 
FSL R8-0120 Enteritidis human, clinical Y N N N 
FSL R8-0121 Enteritidis human, clinical Y N N N 
FSL R8-0803 Enteritidis human, clinical Y N N N 
FSL R8-0804 Enteritidis human, clinical Y N N N 
FSL R8-0808 Enteritidis human, clinical Y N N N 
FSL R8-1577 Enteritidis human, clinical Y N N N 
FSL R8-1580 Enteritidis human, clinical Y N N N 
FSL R8-1581 Enteritidis human, clinical Y N N N 
FSL R8-1582 Enteritidis human, clinical Y N N N 
FSL R8-1587 Enteritidis human, clinical Y N N N 
FSL R8-1589 Enteritidis human, clinical Y N N N 
FSL R8-1601 Enteritidis human, clinical Y N N N 
FSL R8-1608 Enteritidis human, clinical Y N N N 
FSL R8-1609 Enteritidis human, clinical Y N N N 
FSL R8-3498 Enteritidis human, clinical Y N N N 
FSL R8-3500 Enteritidis human, clinical Y N N N 
FSL R8-3505 Enteritidis human, clinical Y N N N 
FSL R8-3532 Enteritidis human, clinical Y N N N 
FSL R8-3533 Enteritidis human, clinical Y N N N 
FSL R8-3534 Enteritidis human, clinical Y N N N 
FSL R8-3538 Enteritidis human, clinical Y N N N 
FSL R8-3539 Enteritidis human, clinical Y N N N 
FSL R8-3542 Enteritidis human, clinical Y N N N 
FSL R8-3543 Enteritidis human, clinical Y N N N 
FSL R8-3544 Enteritidis human, clinical Y N N N 
FSL R8-3548 Enteritidis human, clinical Y N N N 
FSL R8-3552 Enteritidis human, clinical Y N N N 
FSL R8-3553 Enteritidis human, clinical Y N N N 
FSL R8-3556 Enteritidis human, clinical Y N N N 
FSL R8-4074 Enteritidis environment, farm Y N N N 
FSL R8-4075 Enteritidis animal, clinical Y N N N 
FSL R8-4086 Enteritidis environment, farm Y N N N 
FSL S10-1621 Enteritidis environment, farm Y N N N 
FSL S10-1623 Enteritidis environment, farm Y N N N 
FSL S10-1644 Enteritidis environment, farm Y N N N 
FSL S10-1646 Enteritidis environment, farm Y N N N 
FSL S5-0271 Enteritidis animal Y N N N 
FSL S5-0279 Enteritidis animal Y N N N 
FSL S5-0280 Enteritidis animal Y N N N 
FSL S5-0281 Enteritidis animal Y N N N 
FSL S5-0282 Enteritidis animal Y N N N 
FSL S5-0283 Enteritidis animal Y N N N 
FSL S5-0284 Enteritidis animal Y N N N 
FSL R8-5224 I 13,23:b:- type strain Y N N N 
FSL A4-0563 Hadar human Y N N N 
FSL A4-0588 Hadar human Y N N N 
FSL A4-0621 Hadar human Y N N N 
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FSL A4-0681 Hadar human Y N N N 
FSL A4-0698 Hadar human Y N N N 
FSL A4-0836 Hadar human Y N N N 
FSL M8-0508 Hadar Turkey, raw Y N N N 
FSL M8-0520 Hadar Turkey carcass swab Y N N N 
FSL M8-0521 Hadar Young chicken rinse Y N N N 
FSL M8-0522 Hadar Ground beef Y N N N 
FSL M8-0523 Hadar Ground turkey Y N N N 
FSL R6-0306 Hadar human, clinical Y N N N 
FSL R6-0394 Hadar animal, clinical Y N N N 
FSL R6-0515 Hadar animal, clinical Y N N N 
FSL R8-0117 Hadar human, clinical Y N N N 
FSL R8-1289 Hadar human, clinical Y N N N 
FSL R8-1610 Hadar human, clinical Y N N N 
FSL R8-2109 Hadar human, clinical Y N N N 
FSL R8-2529 Hadar human, clinical Y N N N 
FSL R8-2538 Hadar human, clinical Y N N N 
FSL R8-2558 Hadar human, clinical Y N N N 
FSL R8-2603 Hadar human, clinical Y N N N 
FSL R8-2609 Hadar human, clinical Y N N N 
FSL R8-2614 Hadar human, clinical Y N N N 
FSL R8-2780 Hadar human, clinical Y N N N 
FSL R8-2782 Hadar human, clinical Y N N N 
FSL R8-2783 Hadar human, clinical Y N N N 
FSL R8-2784 Hadar human, clinical Y N N N 
FSL R8-2920 Hadar human, clinical Y N N N 
FSL R8-2990 Hadar human, clinical Y N N N 
FSL R8-2991 Hadar human, clinical Y N N N 
FSL R8-3392 Hadar human, clinical Y N N N 
FSL R8-3509 Hadar human, clinical Y N N N 
FSL R8-3566 Hadar human, clinical Y N N N 
FSL R8-3644 Hadar human, clinical Y N N N 
FSL R8-3708 Hadar human, clinical Y N N N 
FSL R8-4060 Hadar human, clinical Y N N N 
FSL R8-4436 Hadar human, clinical Y N N N 
FSL R8-4466 Hadar human, clinical Y N N N 
FSL R8-4557 Hadar human, clinical Y N N N 
FSL R8-5219 Hadar human, clinical Y N N N 
FSL R8-5933 Hadar animal, clinical Y N N N 
FSL R8-5935 Hadar animal, clinical Y N N N 
FSL R8-6091 Hadar human, clinical Y N N N 
FSL R9-1719 Hadar human, clinical Y N N N 
FSL S5-0399 Hadar human Y N N N 
FSL S5-0543 Hadar human Y N N N 
FSL A4-0591 Hartford human Y N Ya N 
FSL A4-0600 Hartford human Y N N N 
FSL A4-0617 Hartford human Y N N N 
FSL M8-0492 Hartford raw oysters Y N N N 
FSL M8-0518 Hartford human, clinical Y N N N 
FSL R6-0220 Hartford human, clinical Y N N N 
FSL R6-0371 Hartford animal, clinical Y N N N 
FSL R6-0620 Hartford animal, clinical Y N Ya N 
FSL R8-2102 Hartford human, clinical Y N N N 
FSL R8-2478 Hartford human, clinical Y N N N 
FSL R8-2493 Hartford human, clinical Y N N N 
FSL R8-4058 Hartford human, clinical Y N N N 
FSL R8-4430 Hartford human, clinical Y N N N 
FSL R8-4521 Hartford human, clinical Y N N N 
FSL R8-8628 Hartford animal, clinical Y N N N 
FSL R8-9607 Hartford animal, clinical Y N N N 
FSL R9-0034 Hartford human, clinical Y N N N 
FSL S5-0510 Hartford human Y N Ya N 
55 
 
FSL R9-0453 Heidelberg human, clinical Y N N N 
FSL R6-0205 Heidelberg human, clinical Y N N N 
FSL R6-0210 Heidelberg human, clinical Y N N N 
FSL R6-0314 Heidelberg human, clinical Y N N N 
FSL R6-0529 Heidelberg human Y N N N 
FSL R6-0537 Heidelberg human Y N N N 
FSL R6-0886 Heidelberg human, clinical Y N N N 
FSL R6-0988 Heidelberg human, clinical Y N N N 
FSL R6-0991 Heidelberg human, clinical Y N N N 
FSL R8-0106 Heidelberg human, clinical Y N N N 
FSL R8-0109 Heidelberg human, clinical Y N N N 
FSL R8-0145 Heidelberg human, clinical Y N N N 
FSL R8-0284 Heidelberg human, clinical Y N N N 
FSL R8-0463 Heidelberg human, clinical Y N N N 
FSL R8-2241 Heidelberg environment, farm Y N N N 
FSL R8-3508 Heidelberg human, clinical Y N N N 
FSL R8-3547 Heidelberg human, clinical Y N N N 
FSL R8-3571 Heidelberg human, clinical Y N N N 
FSL R8-3573 Heidelberg human, clinical Y N N N 
FSL R8-3705 Heidelberg human, clinical Y N N N 
FSL R8-3852 Heidelberg animal, clinical Y N N N 
FSL R8-4446 Heidelberg human, clinical Y N N N 
FSL R8-8014 Heidelberg animal, clinical Y N N N 
FSL R8-8015 Heidelberg animal, clinical Y N N N 
FSL R8-8016 Heidelberg animal, clinical Y N N N 
FSL R8-8018 Heidelberg animal, clinical Y N N N 
FSL R8-8022 Heidelberg animal, clinical Y N N N 
FSL R8-8023 Heidelberg animal, clinical Y N N N 
FSL R8-8392 Heidelberg animal, clinical Y N N N 
FSL R8-9089 Heidelberg animal, clinical Y N N N 
FSL R8-9129 Heidelberg animal, clinical Y N N N 
FSL R8-9800 Heidelberg animal, clinical Y N N N 
FSL R9-0300 Heidelberg human, clinical Y N N N 
FSL R9-0451 Heidelberg human, clinical Y N N N 
FSL R9-0983 Heidelberg human, clinical Y N N N 
FSL R9-1082 Heidelberg animal, clinical Y N N N 
FSL R9-1263 Heidelberg animal, clinical Y N N N 
FSL R9-1393 Heidelberg human, clinical Y N N N 
FSL S3-0901 Heidelberg animal Y N N N 
FSL S3-0902 Heidelberg animal Y N N N 
FSL S3-0919 Heidelberg animal Y N N N 
FSL S3-0920 Heidelberg animal Y N N N 
FSL S3-0921 Heidelberg animal Y N N N 
FSL S5-0448 Heidelberg human Y N N N 
FSL S5-0455 Heidelberg human Y N N N 
FSL S5-0475 Heidelberg human Y N N N 
FSL S5-0480 Heidelberg human Y N N N 
FSL S5-0491 Heidelberg human Y N N N 
FSL S5-0495 Heidelberg human Y N N N 
FSL S5-0655 Heidelberg human Y N N N 
FSL R8-2121 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-2602 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-9523 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-9533 I 4, 5,12:i:- human, clinical Y N N N 
FSL R9-0090 I 4, 5,12:i:- human, clinical Y N N N 
FSL R9-0150 I 4, 5,12:i:- human, clinical Y N N N 
FSL R9-0298 I 4, 5,12:i:- human, clinical Y N N N 
FSL R9-0301 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-3683 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-3502 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-3369 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-3672 I 4, 5,12:i:- human, clinical Y N N N 
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FSL R8-4066 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-3504 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-1299 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-1300 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-1310 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-1584 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-1586 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-1604 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-1620 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-2104 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-2532 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-2930 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-3399 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-3523 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-3546 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-3707 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-4391 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-4442 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-4504 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-4508 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-4536 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-4549 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-4972 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-6088 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-6459 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-8056 I 4, 5,12:i:- human, clinical Y N N N 
FSL R8-8074 I 4, 5,12:i:- human, clinical Y N N N 
FSL R9-0464 I 4, 5,12:i:- human, clinical Y N N N 
FSL R9-0835 I 4, 5,12:i:- human, clinical Y N N N 
FSL R9-0840 I 4, 5,12:i:- human, clinical Y N N N 
FSL R9-1180 I 4, 5,12:i:- human, clinical Y N N N 
FSL R9-1259 I 4, 5,12:i:- animal, clinical Y N N N 
FSL R9-1273 I 4, 5,12:i:- animal, clinical Y N N N 
FSL R9-1447 I 4, 5,12:i:- human, clinical Y N N N 
FSL R9-1727 I 4, 5,12:i:- human, clinical Y N N N 
FSL R9-1728 I 4, 5,12:i:- human, clinical Y N N N 
FSL S10-1237 I 4, 5,12:i:- environment, farm Y N N N 
FSL S10-1241 I 4, 5,12:i:- environment, farm Y N N N 
FSL A4-0546 Infantis animal Y N N N 
FSL R6-0206 Infantis human, clinical Y N N N 
FSL R6-0789 Infantis environment, farm Y N N N 
FSL R6-0790 Infantis environment, farm Y N N N 
FSL R6-0791 Infantis environment, farm Y N N N 
FSL R6-0931 Infantis environment, farm Y N N N 
FSL R6-0932 Infantis environment, farm Y N N N 
FSL R8-0452 Infantis human, clinical Y N N N 
FSL R8-0770 Infantis human, clinical Y N N N 
FSL R8-0801 Infantis human, clinical Y N N N 
FSL R8-1392 Infantis environment, farm Y N N N 
FSL R8-1569 Infantis human, clinical Y N N N 
FSL R8-2479 Infantis human, clinical Y N N N 
FSL R8-2525 Infantis human, clinical Y N N N 
FSL R8-2598 Infantis human, clinical Y N N N 
FSL R8-2601 Infantis human, clinical Y N N N 
FSL R8-2811 Infantis environment, farm Y N N N 
FSL R8-2973 Infantis human, clinical Y N N N 
FSL R8-3391 Infantis human, clinical Y N N N 
FSL R8-8053 Infantis human, clinical Y N N N 
FSL R8-8080 Infantis human, clinical Y N N N 
FSL R8-8691 Infantis human, clinical Y N N N 
FSL R8-9662 Infantis human, clinical Y N N N 
FSL R8-9667 Infantis human, clinical Y N N N 
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FSL R9-0149 Infantis human, clinical Y N N N 
FSL R9-0987 Infantis human, clinical Y N N N 
FSL R9-1070 Infantis environment, farm Y N N N 
FSL S10-1647 Infantis environment, farm Y N N N 
FSL S10-1665 Infantis environment, farm Y N N N 
FSL S10-1666 Infantis environment, farm Y N N N 
FSL S10-1669 Infantis environment, farm Y N N N 
FSL S10-1670 Infantis environment, farm Y N N N 
FSL S5-0506 Infantis human Y N N N 
FSL S5-0553 Infantis animal Y N N N 
FSL S5-0560 Infantis animal Y N N N 
FSL S5-0566 Infantis animal Y N N N 
FSL S5-0571 Infantis animal Y N N N 
FSL S5-0572 Infantis animal Y N N N 
FSL S5-0573 Infantis animal Y N N N 
FSL S5-0574 Infantis animal Y N N N 
FSL S5-0575 Infantis animal Y N N N 
FSL S5-0576 Infantis animal Y N N N 
FSL S5-0582 Infantis animal Y N N N 
FSL S5-0584 Infantis animal Y N N N 
FSL S5-0593 Infantis animal Y N N N 
FSL S5-0617 Infantis animal Y N N N 
FSL S5-0725 Infantis animal Y N N N 
FSL S5-0734 Infantis animal Y N N N 
FSL S5-0743 Infantis animal Y N N N 
FSL S5-0750 Infantis animal Y N N N 
FSL A4-0574 Javiana human Y Y Y Y 
FSL A4-0602 Javiana human Y Y Y Y 
FSL A4-0613 Javiana human Y Y Y Y 
FSL A4-0679 Javiana human Y Y Y Y 
FSL A4-0690 Javiana human Y Y Y Y 
FSL A4-0696 Javiana human Y Y Y Y 
FSL M8-0480 Javiana creek sediment Y Y Y Y 
FSL M8-0489 Javiana creek sediment Y Y Y Y 
FSL M8-0491 Javiana creek water Y Y Y Y 
FSL M8-0494 Javiana canal water Y Y Y Y 
FSL M8-0495 Javiana stream water Y Y Y Y 
FSL M8-0496 Javiana Basil Y Y Y Y 
FSL M8-0497 Javiana Frog Legs Y Y Y Y 
FSL M8-0498 Javiana Cantaloupe Y Y Y Y 
FSL M8-0510 Javiana Cheese Y Y Y Y 
FSL R6-0243 Javiana human Y Y Y Y 
FSL R6-0248 Javiana human Y Y Y Y 
FSL R6-0253 Javiana human Y Y Y Y 
FSL R6-0312 Javiana human, clinical Y Y Y Y 
FSL R6-0533 Javiana human Y Y Y Y 
FSL R6-0985 Javiana human, clinical Y Y Y Y 
FSL R8-0293 Javiana human, clinical Y Y Y Y 
FSL R8-0301 Javiana human, clinical Y Y Y Y 
FSL R8-2462 Javiana human, clinical Y Y Y Y 
FSL R8-2516 Javiana human, clinical Y Y Y Y 
FSL R8-2919 Javiana human, clinical Y Y Y Y 
FSL R8-2936 Javiana human, clinical Y Y Y Y 
FSL R8-2972 Javiana human, clinical Y Y Y Y 
FSL R8-3888 Javiana human, clinical Y Y Y Y 
FSL R8-4395 Javiana human, clinical Y Y Y Y 
FSL R8-4530 Javiana human, clinical Y Y Y Y 
FSL R8-4534 Javiana human, clinical Y Y Y Y 
FSL R8-4543 Javiana human, clinical Y Y Y Y 
FSL R8-4562 Javiana human, clinical Y Y Y Y 
FSL R8-4655 Javiana human, clinical Y Y Y Y 
FSL R8-4958 Javiana human, clinical Y Y Y Y 
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FSL R8-5214 Javiana human, clinical Y Y Y Y 
FSL R8-6103 Javiana human, clinical Y Y Y Y 
FSL R9-2204 Javiana animal, clinical Y Y Y Y 
FSL S5-0290 Javiana animal Y Y Y Y 
FSL S5-0359 Javiana human Y Y Y Y 
FSL S5-0360 Javiana human Y Y Y Y 
FSL S5-0361 Javiana human Y Y Y Y 
FSL S5-0362 Javiana human Y Y Y Y 
FSL S5-0363 Javiana human Y Y Y Y 
FSL S5-0395 Javiana human Y Y Y Y 
FSL S5-0406 Javiana human Y Y Y Y 
FSL S5-0652 Javiana human Y Y Y Y 
FSL S5-0665 Javiana human Y Y Y Y 
FSL S5-0675 Javiana human Y Y Y Y 
FSL A4-0633 Mississippi human Y N N N 
FSL M8-0515 Mississippi Food Y N N N 
FSL M8-0516 Mississippi Food Y N N N 
FSL R8-1549 Mississippi human, clinical Y Y Y Y 
FSL R8-2455 Mississippi human, clinical Y Y Y Y 
FSL R8-2593 Mississippi human, clinical Y N N N 
FSL R8-2779 Mississippi human, clinical Y Y Y Y 
FSL R8-7996 Mississippi human, clinical Y Y Y Y 
FSL A4-0562 Montevideo human Y Y Y Y 
FSL R6-0873 Montevideo human, clinical Y Y Y Y 
FSL R6-0884 Montevideo human, clinical Y Y Y Y 
FSL R8-0129 Montevideo human, clinical Y Y Y Y 
FSL R8-0147 Montevideo human, clinical Y Y Y Y 
FSL R8-1540 Montevideo human, clinical Y Y Y Y 
FSL R8-1552 Montevideo human, clinical Y Y Y Y 
FSL R8-1602 Montevideo human, clinical Y Y Y Y 
FSL R8-1613 Montevideo human, clinical Y Y Y Y 
FSL R8-2004 Montevideo environment, farm Y Y Y Y 
FSL R8-2005 Montevideo environment, farm Y Y Y Y 
FSL R8-2106 Montevideo human, clinical Y Y Y Y 
FSL R8-2165 Montevideo animal, clinical Y Y Y Y 
FSL R8-2533 Montevideo human, clinical Y Y Y Y 
FSL R8-2589 Montevideo human, clinical Y Y Y Y 
FSL R8-2607 Montevideo human, clinical Y Y Y Y 
FSL R8-2812 Montevideo environment, farm Y Y Y Y 
FSL R8-2849 Montevideo environment, farm Y Y Y Y 
FSL R8-2868 Montevideo animal, non-clinical Y Y Y Y 
FSL R8-2923 Montevideo human, clinical Y Y Y Y 
FSL R8-3400 Montevideo human, clinical Y Y Y Y 
FSL R8-3417 Montevideo environment, farm Y Y Y Y 
FSL R8-3559 Montevideo human, clinical Y Y Y Y 
FSL R8-3658 Montevideo environment, farm Y Y Y Y 
FSL R8-3659 Montevideo environment, farm Y Y Y Y 
FSL R8-3854 Montevideo animal, clinical Y Y Y Y 
FSL R8-4841 Montevideo human, clinical Y Y Y Y 
FSL R8-4917 Montevideo animal, clinical Y Y Y Y 
FSL R8-4918 Montevideo human, clinical Y Y Y Y 
FSL R8-4919 Montevideo human, clinical Y Y Y Y 
FSL R8-4920 Montevideo human, clinical Y Y Y Y 
FSL R8-4921 Montevideo human, clinical Y Y Y Y 
FSL R8-4922 Montevideo human, clinical Y Y Y Y 
FSL R8-4923 Montevideo human, clinical Y Y Y Y 
FSL R8-7305 Montevideo animal, clinical Y Y Y Y 
FSL R9-1588 Montevideo environment, farm Y Y Y Y 
FSL S5-0264 Montevideo animal Y Y Y Y 
FSL S5-0265 Montevideo animal Y Y Y Y 
FSL S5-0266 Montevideo animal Y Y Y Y 
FSL S5-0382 Montevideo human Y Y Y Y 
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FSL S5-0457 Montevideo human Y Y Y Y 
FSL S5-0463 Montevideo human Y Y Y Y 
FSL S5-0470 Montevideo human Y Y Y Y 
FSL S5-0474 Montevideo human Y Y Y Y 
FSL S5-0478 Montevideo human Y Y Y Y 
FSL S5-0559 Montevideo animal Y Y Y Y 
FSL S5-0630 Montevideo animal Y Y Y Y 
FSL S5-0757 Montevideo animal Y Y Y Y 
FSL A4-0649 Muenchen human Y N N N 
FSL M8-0509 Muenchen Frog Legs Y N N N 
FSL M8-0511 Muenchen Orange Juice Y N N N 
FSL M8-0512 Muenchen Sea Water Y N N N 
FSL M8-0513 Muenchen Nonfat Dry Milk Y N N N 
FSL M8-0514 Muenchen Dairy Environment Y N N N 
FSL M8-0517 Muenchen Raw Oysters Y N N N 
FSL R6-0093 Muenchen animal Y N N N 
FSL R6-0309 Muenchen human, clinical Y N N N 
FSL R6-0881 Muenchen human, clinical Y N N N 
FSL R8-0149 Muenchen human, clinical Y N N N 
FSL R8-0777 Muenchen human, clinical Y N N N 
FSL R8-1592 Muenchen human, clinical Y N N N 
FSL R8-1596 Muenchen human, clinical Y N N N 
FSL R8-1845 muenchen animal, clinical Y N N N 
FSL R8-3288 muenchen animal, clinical Y N N N 
FSL R8-3506 Muenchen human, clinical Y N N N 
FSL R8-3550 Muenchen human, clinical Y N N N 
FSL R8-4059 Muenchen human, clinical Y N N N 
FSL R8-4399 Muenchen human, clinical Y N N N 
FSL R8-4400 Muenchen human, clinical Y N N N 
FSL R8-4401 Muenchen human, clinical Y N N N 
FSL R8-4407 Muenchen human, clinical Y N N N 
FSL R8-4440 Muenchen human, clinical Y N N N 
FSL R8-4463 Muenchen human, clinical Y N N N 
FSL R8-4833 Muenchen animal, clinical Y N N N 
FSL R8-4850 Muenchen animal, clinical Y N N N 
FSL R8-4858 Muenchen animal, clinical Y N N N 
FSL R8-6093 Muenchen human, clinical Y N N N 
FSL R8-8211 Muenchen animal, clinical Y N N N 
FSL R8-8227 Muenchen animal, clinical Y N N N 
FSL R8-8228 Muenchen animal, clinical Y N N N 
FSL R8-8229 Muenchen animal, clinical Y N N N 
FSL R8-8235 Muenchen animal, clinical Y N N N 
FSL R8-8236 Muenchen animal, clinical Y N N N 
FSL R8-8239 Muenchen animal, clinical Y N N N 
FSL R8-8240 Muenchen animal, clinical Y N N N 
FSL R8-8375 Muenchen animal, clinical Y N N N 
FSL R8-8689 Muenchen human, clinical Y N N N 
FSL R8-9195 Muenchen human, clinical Y N N N 
FSL R8-9624 Muenchen animal, clinical Y N N N 
FSL R8-9634 Muenchen animal, clinical Y N N N 
FSL R8-9844 Muenchen animal, clinical Y N N N 
FSL R9-0041 Muenchen human, clinical Y N N N 
FSL R9-1108 Muenchen animal, clinical Y N N N 
FSL S5-0479 Muenchen human Y N N N 
FSL S5-0504 Muenchen human Y N N N 
FSL S5-0636 Muenchen human Y N N N 
FSL R6-0001 Newport animal Y N N N 
FSL R6-0004 Newport animal Y N N N 
FSL R6-0005 Newport animal Y N N N 
FSL R6-0007 Newport animal Y N N N 
FSL R6-0010 Newport animal Y N N N 
FSL R6-0011 Newport animal Y N N N 
60 
 
FSL R6-0204 Newport human, clinical Y N N N 
FSL R6-0218 Newport human, clinical Y N N N 
FSL R8-0341 Newport environment, farm Y N N N 
FSL R8-0342 Newport environment, farm Y N N N 
FSL R8-1117 Newport human, clinical Y N N N 
FSL R8-1118 Newport human, clinical Y N N N 
FSL R8-1119 Newport human, clinical Y N N N 
FSL R8-1120 Newport human, clinical Y N N N 
FSL R8-1121 Newport human, clinical Y N N N 
FSL R8-1637 Newport environment, farm Y N N N 
FSL R8-1638 Newport environment, farm Y N N N 
FSL R8-1639 Newport environment, farm Y N N N 
FSL R8-2248 Newport environment, farm Y N N N 
FSL R8-2350 newport animal, clinical Y N N N 
FSL R8-2351 newport animal, clinical Y N N N 
FSL R8-2353 newport animal, clinical Y N N N 
FSL R8-2490 Newport human, clinical Y N N N 
FSL R8-2512 Newport human, clinical Y N N N 
FSL R8-3908 Newport animal, clinical Y N N N 
FSL R8-4085 Newport environment, farm Y N N N 
FSL R8-4159 Newport animal, clinical Y N N N 
FSL R8-4315 Newport animal, clinical Y N N N 
FSL R8-7260 Newport animal, clinical Y N N N 
FSL R8-8684 Newport human, clinical Y N N N 
FSL R8-8686 Newport human, clinical Y N N N 
FSL R8-9176 Newport human, clinical Y N N N 
FSL R8-9190 Newport human, clinical Y N N N 
FSL R8-9198 Newport human, clinical Y N N N 
FSL S10-1020 Newport environment, farm Y N N N 
FSL S10-1570 Newport environment, farm Y N N N 
FSL S10-1630 Newport environment, farm Y N N N 
FSL S10-1632 Newport environment, farm Y N N N 
FSL S10-1634 Newport environment, farm Y N N N 
FSL S10-1638 Newport environment, farm Y N N N 
FSL S10-1640 Newport environment, farm Y N N N 
FSL S10-1642 Newport environment, farm Y N N N 
FSL S10-1743 Newport environment, farm Y N N N 
FSL S10-1745 Newport environment, farm Y N N N 
FSL S10-1748 Newport environment, farm Y N N N 
FSL S10-1752 Newport environment, farm Y N N N 
FSL S10-1755 Newport environment, farm Y N N N 
FSL S10-1813 Newport environment, farm Y N N N 
FSL S5-0270 Newport animal Y N N N 
FSL S5-0272 Newport animal Y N N N 
FSL A4-0549 Oranienburg animal Y Y Y Y 
FSL A4-0564 Oranienburg human Y Y Y Y 
FSL A4-0594 Oranienburg human Y Y Y Y 
FSL A4-0642 Oranienburg human Y Y Y Y 
FSL A4-0644 Oranienburg human Y Y Y Y 
FSL A4-0668 Oranienburg human Y Y Y Y 
FSL A4-0688 Oranienburg human Y Y Y Y 
FSL A4-0809 Oranienburg human Y Y Y Y 
FSL R6-0209 Oranienburg human, clinical Y Y Y Y 
FSL R6-0240 Oranienburg human Y Y Y Y 
FSL R6-0586 Oranienburg animal Y Y Y Y 
FSL R6-0587 Oranienburg animal, clinical Y Y Y Y 
FSL R6-0594 Oranienburg animal, clinical Y Y Y Y 
FSL R6-0595 Oranienburg animal, clinical Y Y Y Y 
FSL R6-0598 Oranienburg animal, clinical Y Y Y Y 
FSL R8-0169 Oranienburg environment, farm Y Y Y Y 
FSL R8-0170 Oranienburg environment, farm Y Y Y Y 
FSL R8-1257 oranienburg animal, clinical Y Y Y Y 
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FSL R8-1278 oranienburg animal, clinical Y Y Y Y 
FSL R8-1416 Oranienburg environment, farm Y Y Y Y 
FSL R8-1417 Oranienburg environment, farm Y Y Y Y 
FSL R8-1809 Oranienburg animal, clinical Y Y Y Y 
FSL R8-1963 Oranienburg animal, clinical Y Y Y Y 
FSL R8-2013 Oranienburg environment, farm Y Y Y Y 
FSL R8-2352 Oranienburg animal, clinical Y Y Y Y 
FSL R8-3270 Oranienburg animal, clinical Y Y Y Y 
FSL R8-3769 Oranienburg human, clinical Y Y Y Y 
FSL R8-3835 Oranienburg animal, clinical Y Y Y Y 
FSL R8-3884 Oranienburg human, clinical Y Y Y Y 
FSL R8-4067 Oranienburg human, clinical Y Y Y Y 
FSL R8-4427 Oranienburg human, clinical Y Y Y Y 
FSL R8-4439 Oranienburg human, clinical Y Y Y Y 
FSL R8-4443 Oranienburg human, clinical Y Y Y Y 
FSL R8-4532 Oranienburg human, clinical Y Y Y Y 
FSL R8-4662 Oranienburg human, clinical Y Y Y Y 
FSL R8-5000 Oranienburg human, clinical Y Y Y Y 
FSL R8-5030 Oranienburg human, clinical Y Y Y Y 
FSL R8-5060 Oranienburg human, clinical Y Y Y Y 
FSL R8-5072 Oranienburg human, clinical Y Y Y Y 
FSL R8-6094 Oranienburg human, clinical Y Y Y Y 
FSL R8-6542 Oranienburg animal, clinical Y Y Y Y 
FSL R8-7954 Oranienburg human, clinical Y Y Y Y 
FSL R8-8138 Oranienburg human, clinical Y Y Y Y 
FSL R8-8683 Oranienburg human, clinical Y Y Y Y 
FSL R8-9673 Oranienburg human, clinical Y Y Y Y 
FSL R9-0033 Oranienburg human, clinical Y Y Y Y 
FSL R9-0442 Oranienburg human, clinical Y Y Y Y 
FSL R9-1721 Oranienburg human, clinical Y Y Y Y 
FSL S5-0427 Oranienburg animal Y Y Y Y 
FSL S5-0642 Oranienburg human Y Y Y Y 
FSL A4-0634 Saintpaul human Y N N N 
FSL A4-0662 Saintpaul human Y N N N 
FSL A4-0687 Saintpaul human Y N N N 
FSL A4-0828 Saintpaul human Y N N N 
FSL M8-0499 Saintpaul food Y N N N 
FSL M8-0500 Saintpaul environmental Y N N N 
FSL M8-0501 Saintpaul food Y N N N 
FSL M8-0502 Saintpaul environmental Y N N N 
FSL M8-0503 Saintpaul environmental Y N N N 
FSL M8-0504 Saintpaul environmental Y N N N 
FSL M8-0505 Saintpaul food Y N N N 
FSL M8-0506 Saintpaul food Y N N N 
FSL M8-0507 Saintpaul environmental Y N N N 
FSL R6-0208 Saintpaul human, clinical Y N N N 
FSL R6-0219 Saintpaul human, clinical Y N N N 
FSL R6-0222 Saintpaul human, clinical Y N N N 
FSL R6-0399 Saintpaul human, clinical Y N N N 
FSL R6-0536 Saintpaul human Y N N N 
FSL R6-0990 Saintpaul human, clinical Y N N N 
FSL R8-1523 Saintpaul human, clinical Y N N N 
FSL R8-1531 Saintpaul human, clinical Y N N N 
FSL R8-1535 Saintpaul human, clinical Y N N N 
FSL R8-1585 Saintpaul human, clinical Y N N N 
FSL R8-2507 Saintpaul human, clinical Y N N N 
FSL R8-3582 Saintpaul human, clinical Y N N N 
FSL R8-3635 Saintpaul human, clinical Y N N N 
FSL R8-3641 Saintpaul human, clinical Y N N N 
FSL R8-3680 Saintpaul human, clinical Y N N N 
FSL R8-4063 Saintpaul human, clinical Y N N N 
FSL R8-4437 Saintpaul human, clinical Y N N N 
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FSL R8-4445 Saintpaul human, clinical Y N N N 
FSL R8-4484 Saintpaul human, clinical Y N N N 
FSL R8-4652 Saintpaul human, clinical Y N N N 
FSL R8-4660 Saintpaul human, clinical Y N N N 
FSL R8-4670 Saintpaul human, clinical Y N N N 
FSL R8-4809 Saintpaul human, clinical Y N N N 
FSL R8-4907 Saintpaul human, clinical Y N N N 
FSL R8-4985 Saintpaul human, clinical Y N N N 
FSL R8-4992 Saintpaul human, clinical Y N N N 
FSL R8-4996 Saintpaul human, clinical Y N N N 
FSL R8-5023 Saintpaul human, clinical Y N N N 
FSL R8-5029 Saintpaul human, clinical Y N N N 
FSL R8-5058 Saintpaul human, clinical Y N N N 
FSL R8-6469 Saintpaul human, clinical Y N N N 
FSL R8-6472 Saintpaul human, clinical Y N N N 
FSL R8-7964 Saintpaul human, clinical Y N N N 
FSL R8-7989 Saintpaul human, clinical Y N N N 
FSL R8-8692 Saintpaul human, clinical Y N N N 
FSL R8-8946 Saintpaul human, clinical Y N N N 
FSL M8-0519 Saintpaul food Y N N N 
FSL P3-1113 Thompson environment, farm Y N N N 
FSL R6-0200 Thompson human, clinical Y N N N 
FSL R6-0202 Thompson human, clinical Y N N N 
FSL R6-0216 Thompson human, clinical Y N N N 
FSL R6-0217 Thompson human, clinical Y N N N 
FSL R6-0223 Thompson human, clinical Y N N N 
FSL R6-0225 Thompson human, clinical Y N N N 
FSL R8-0014 Thompson human, clinical Y N N N 
FSL R8-0123 Thompson human, clinical Y N N N 
FSL R8-0131 Thompson human, clinical Y N N N 
FSL R8-0152 Thompson human, clinical Y N N N 
FSL R8-1835 thompson animal, clinical Y N N N 
FSL R8-1846 thompson animal, clinical Y N N N 
FSL R8-3268 thompson animal, clinical Y N N N 
FSL R8-3269 thompson animal, clinical Y N N N 
FSL R8-3845 Thompson animal, clinical Y N N N 
FSL R8-4006 Thompson animal, clinical Y N N N 
FSL R8-4047 Thompson animal, clinical Y N N N 
FSL R8-4101 Thompson animal, clinical Y N N N 
FSL R8-4314 Thompson animal, clinical Y N N N 
FSL R8-4693 Thompson animal, clinical Y N N N 
FSL R8-6492 Thompson animal, clinical Y N N N 
FSL R8-6505 Thompson animal, clinical Y N N N 
FSL R8-6506 Thompson animal, clinical Y N N N 
FSL R8-6523 Thompson animal, clinical Y N N N 
FSL R8-6524 Thompson animal, clinical Y N N N 
FSL R8-7252 Thompson animal, clinical Y N N N 
FSL R8-7253 Thompson animal, clinical Y N N N 
FSL R8-7254 Thompson animal, clinical Y N N N 
FSL R8-7261 Thompson animal, clinical Y N N N 
FSL R8-7735 Thompson animal, clinical Y N N N 
FSL R8-7736 Thompson animal, clinical Y N N N 
FSL R8-8237 Thompson animal, clinical Y N N N 
FSL R8-8637 Thompson animal, clinical Y N N N 
FSL R8-8919 Thompson animal, clinical Y N N N 
FSL R8-8925 Thompson animal, clinical Y N N N 
FSL R8-8930 Thompson animal, clinical Y N N N 
FSL R8-9066 Thompson animal, clinical Y N N N 
FSL R8-9125 Thompson animal, clinical Y N N N 
FSL R9-0521 Thompson animal, clinical Y N N N 
FSL S10-1014 Thompson environment, farm Y N N N 
FSL S10-1031 Thompson environment, farm Y N N N 
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FSL S10-1034 Thompson environment, farm Y N N N 
FSL S10-1548 Thompson environment, farm Y N N N 
FSL S10-1550 Thompson environment, farm Y N N N 
FSL S10-1552 Thompson environment, farm Y N N N 
FSL S10-1555 Thompson environment, farm Y N N N 
FSL S10-1568 Thompson environment, farm Y N N N 
FSL S10-1574 Thompson environment, farm Y N N N 
FSL A4-0730 Typhimurium animal Y N N N 
FSL A4-0731 Typhimurium animal Y N N N 
FSL A4-0732 Typhimurium animal Y N N N 
FSL A4-0733 Typhimurium animal Y N N N 
FSL A4-0734 Typhimurium animal Y N N N 
FSL A4-0765 Typhimurium animal Y N N N 
FSL A4-0766 Typhimurium animal Y N N N 
FSL A4-0767 Typhimurium animal Y N N N 
FSL P3-1552 Typhimurium environment, farm Y N N N 
FSL P3-1558 Typhimurium environment, farm Y N N N 
FSL R8-0148 Typhimurium human, clinical Y N N N 
FSL R8-0171 Typhimurium environment, farm Y N N N 
FSL R8-0172 Typhimurium environment, farm Y N N N 
FSL R8-0173 Typhimurium environment, farm Y N N N 
FSL R8-0174 Typhimurium environment, farm Y N N N 
FSL R8-0175 Typhimurium environment, farm Y N N N 
FSL R8-0281 Typhimurium human, clinical Y N N N 
FSL R8-0283 Typhimurium human, clinical Y N N N 
FSL R8-0287 Typhimurium human, clinical Y N N N 
FSL R8-0291 Typhimurium human, clinical Y N N N 
FSL R8-0812 Typhimurium environment, farm Y N N N 
FSL R8-0813 Typhimurium environment, farm Y N N N 
FSL R8-0819 Typhimurium environment, farm Y N N N 
FSL R8-0820 Typhimurium environment, farm Y N N N 
FSL R8-0920 Typhimurium environment, farm Y N N N 
FSL R8-1385 Typhimurium environment, farm Y N N N 
FSL R8-1386 Typhimurium environment, farm Y N N N 
FSL R8-1387 Typhimurium environment, farm Y N N N 
FSL R8-1952 Typhimurium animal, clinical Y N N N 
FSL R8-1953 Typhimurium animal, non-clinical Y N N N 
FSL R8-4097 Typhimurium animal, clinical Y N N N 
FSL R8-5263 Typhimurium animal, clinical Y N N N 
FSL R8-8947 Typhimurium human, clinical Y N N N 
FSL R9-1304 Typhimurium animal, clinical Y N N N 
FSL R9-1305 Typhimurium animal, clinical Y N N N 
FSL R9-1307 Typhimurium animal, clinical Y N N N 
FSL R9-1308 Typhimurium animal, clinical Y N N N 
FSL R9-1310 Typhimurium animal, clinical Y N N N 
FSL S10-1134 Typhimurium environment, farm Y N N N 
FSL S10-1269 Typhimurium environment, farm Y N N N 
FSL S10-1766 Typhimurium environment, farm Y N N N 
FSL S5-0397 Typhimurium human Y N N N 
FSL S5-0452 Typhimurium human Y N N N 
FSL S5-0462 Typhimurium human Y N N N 
FSL S5-0473 Typhimurium human Y N N N 
FSL S5-0476 Typhimurium human Y N N N 
FSL R8-8956 Typhimurium var. O:5- human, clinical Y N N N 
FSL R8-9657 Typhimurium var. O:5- human, clinical Y N N N 
FSL R8-9661 Typhimurium var. O:5- human, clinical Y N N N 
FSL R8-9669 Typhimurium var. O:5- human, clinical Y N N N 
FSL R8-4925 Montevideo human, clinical Y Y Y Y 
FSL R8-4926 Montevideo human, clinical Y Y Y Y 
FSL S5-0386 Thompson animal Y N N N 
FSL R8-4829 Oranienburg animal, clinical Y Y Y Y 
FSL S5-0415 Enteritidis human, clinical Y N N N 
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HeLa cells were grown in Eagle’s Minimum Essential Medium (EMEM; Gibco-
Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) fetal bovine serum (FBS; Gibco-
Invitrogen), and were incubated at 37°C with 5% CO2. For infection, HeLa cells were grown in 
6-well or 12-well plates (Corning, Corning, NY) to desired confluency (40-50% confluency for 
flow cytometry analyses, or 40-70% for immunofluorescence analyses). 
PCR screen for S-CDT genes pltA, pltB, and cdtB. Isolates were plated on BHI agar plates 
from frozen glycerol stocks, followed by overnight incubation at 37°C. Cell lysates were 
prepared by inoculating 100 μl of sterile water with bacterial cells, followed by heating at 95°C 
for 15 min in a thermocycler. Each isolate was screened for genes encoding the 3 components of 
S-CDT (pltA, pltB, and cdtB) using the primers and their respective annealing temperatures listed 
in Table 3.3. Screening was performed using 2 PCRs. The first PCR contained primers to 
amplify (i) a portion of the 16S rDNA (included as positive control), and (ii) an internal 
fragment of pltA. The second PCR was used to simultaneously amplify internal regions 
of pltB and cdtB. Thermocycling conditions included an initial denaturation at 94°C for 3 min, 
followed by 30 cycles of denaturation at 94°C for 30 s, annealing at either 48°C or 50°C (Table 
3.3) for 30 s, and extension at 72°C for 1 min; a final extension at 72°C for 7 min was also 
included. PCR products were visualized using agarose gel electrophoresis. In the event that PCR 
amplification did not yield amplicons for 16S rDNA, a new lysate was prepared and both PCRs 
were re-performed. 
Sequencing of full-length pltA, pltB, and cdtB for phylogenetic comparison. Full-length gene 
segments were amplified for 5 representative isolates (with the exception of serotype 
Mississippi, which only had 4 isolates that were S-CDT-positive) from each serotype or clade 
FSL S5-0536 Typhimurium human, clinical Y N N N 
FSL S5-0639 Newport human, clinical Y N N N 
a Three isolates (FSL A4-0591, FSL R6-0620, FSL S5-0510) had an amplicon for the PCR screen for cdtB, but did not yield a 
PCR product for the full gene. In addition, all three of these isolates did not yield an amplicon with  pltA and pltB primers. 
Hence these isolates were classified as S-CDT negative. 
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that was identified as S-CDT-positive. Primers were designed to anneal to regions upstream and 
downstream of pltA, pltB, and cdtB (see Table 3.3). 
TABLE 3.3. Primers used in this study 
Primer Name Primer Sequence (5' to 3') 
Annealing 
Temperature
a 
Expected Amplicon 
Size (bp) 
RM45cdtBintF_2  CTGCGCTAATATCAGTGACTAC  
48°C 639 
RM46cdtBtintR_2  CAACCCTTTGTGAATAAGGTGC  
RM47pltBintF_2  ACGATGATAGTCCCACAAGAGC  
48°C 243 
RM48pltBintR_2  CCTACTACTCAGACGAAGTTATC  
RM49pltAintF_2  ATCACGCCAGGATTAGACGTAG  
50°C 313 
RM50pltAintR_2  GCTATATTGCAACAACCTCAAGTG  
16s-PEU7  GCAAACAGGATTAGATACCC  
50°C 700 
16s-P3SH  CTACGGTTACCTTGTTACGACTT  
RM23PltAupstream  CCAGACCACTAATAAACGGTCTG  
60-50°C 801 
RM24PltAdownstream  TATCATCGTGCAGTGCGA  
RM25PltBupstream  GACTGGACTGTGATGTGGTG  
60-50°C 545 
RM26PltBdownstream  GTTGAGTCCACACGATACAC  
RM97cdtBupF CAACGTCATGAAACAATGGGTTATG 
57°C 935 
RM96cdtBdownR ATATTCTGCACCTTACGCTCAAAGTAC 
a
Annealing temperature used in PCR amplification; annealing temperatures reported as a range were performed 
using a range of temperatures as a part of a touchdown PCR 
 PCR amplification was performed using a touchdown method (for pltA and pltB) with initial 
denaturation at 94°C for 3 min, followed by 20 cycles of denaturation at 94°C for 30 s with 
annealing temperature decreasing by 0.5°C per cycle (from 60°C at cycle 1 to 50°C at cycle 20; 
Table 3.3) and extension at 72°C for 1.5 min; an additional 20 cycles of amplification were then 
performed using an annealing temperature of 50°C with a final extension at 72°C for 7 min. For 
cdtB, amplification was performed using the following thermocycling conditions; 94°C for 3 
min, followed by 30 cycles of denaturation at 94°C for 30 s, annealing at 50°C for 30 s, and 
elongation for 1 min at 72°C, followed by a final extension at 72°C for 5 min. PCR products 
were treated with 5 units exonuclease I (Affymetrix, Santa Clara, CA) and 5 units shrimp 
alkaline phosphatase (Affymetrix), followed by Sanger sequencing performed by the Cornell 
Biotechnical Resource Center (Cornell University, Ithaca, NY). Sequences were edited 
using Sequencher software (Gene Codes Corporation; Ann Arbor, MI).  Phylogenetic analyses 
were performed using Mega Software (Mega Version 6 Software). GenBank accession numbers 
for all S-CDT subunits sequenced are available in Table 3.4.  
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TABLE 3.4. Description of GenBank accession numbers for pltA, pltB, and cdtB sequences for 
Salmonella strains characterized in this study 
Sequence Description GenBank Accession ID 
FSL A4-0564_pltB KX810866 
FSL A4-0642_pltB KX810867 
FSL A4-0594_pltB KX810868 
FSL A4-0644_pltB KX810869 
FSL A4-0668_pltB KX810870 
FSL M8-0480_pltB KX810871 
FSL M8-0489_pltB KX810872 
FSL M8-0491_pltB KX810873 
FSL M8-0494_pltB KX810874 
FSL M8-0495_pltB KX810875 
FSL R8-1549_pltB KX810876 
FSL R8-2004_pltB KX810877 
FSL R8-2005_pltB KX810878 
FSL R8-2106_pltB KX810879 
FSL R8-2124_pltB KX810880 
FSL R8-2165_pltB KX810881 
FSL R8-2455_pltB KX810882 
FSL R8-2779_pltB KX810883 
FSL R8-2533_pltB KX810884 
FSL R8-7996_pltB KX810885 
FSL S5-0642_pltB KX810886 
FSL A4-0564_pltA KX810887 
FSL A4-0594_pltA KX810888 
FSL A4-0642_pltA KX810889 
FSL A4-0644_pltA KX810890 
FSL A4-0668_pltA KX810891 
FSL M8-0480_pltA KX810892 
FSL M8-0489_pltA KX810893 
FSL M8-0491_pltA KX810894 
FSL M8-0494_pltA KX810895 
FSL M8-0495_pltA KX810896 
FSL R8-2004_pltA KX810897 
FSL R8-2005_pltA KX810898 
FSL R8-2106_pltA KX810899 
FSL R8-2124_pltA KX810900 
FSL R8-2165_pltA KX810901 
FSL R8-2455_pltA KX810902 
FSL R8-2533_pltA KX810903 
FSL R8-1549_pltA KX810904 
FSL R8-2779_pltA KX810905 
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FSL R8-7996_pltA KX810906 
FSL A4-0564_cdtB KX810907 
FSL A4-0594_cdtB KX810908 
FSL A4-0642_cdtB KX810909 
FSL A4-0644_cdtB KX810910 
FSL A4-0668_cdtB KX810911 
FSL M8-0480_cdtB KX810912 
FSL M8-0489_cdtB KX810913 
FSL M8-0491_cdtB KX810914 
FSL M8-0494_cdtB KX810915 
FSL M8-0495_cdtB KX810916 
FSL R8-1549_cdtB KX810917 
FSL R8-2004_cdtB KX810918 
FSL R8-2005_cdtB KX810919 
FSL R8-2106_cdtB KX810920 
FSL R8-2124_cdtB KX810921 
FSL R8-2165_cdtB KX810922 
FSL R8-2455_cdtB KX810923 
 
7-Gene MLST. For selected isolates, multi locus sequence typing (MLST) was performed as 
described previously, using internal fragments of housekeeping genes 
aroC, dnaN, hemD, hisD, purE, sucA, and thrA (30). Sequences were edited and compared to 
the S. enterica MLST database, which allows for assignment of MLST sequence types (30). 
Salmonella infection of HeLa cells. Bacterial cultures were plated from frozen glycerol stocks 
onto BHI agar plates, followed by incubation at 37°C for 22-24 h. Subsequently, single colonies 
were used to inoculate 5 ml aliquots of LB (pH 8; 0.3 M NaCl) broth, followed by incubation 
under static conditions at 37°C for 14 + 1 h. These cultures were then sub-cultured 1:100 into 
fresh 5 ml aliquots of LB (pH 8; 0.3 M NaCl) broth, followed by incubation at 37°C under static 
conditions until bacteria reached early to mid-log phase (OD600 of 0.4 + 0.1). Treatments (i.e. 
level of inoculum and strain of NTS used) were randomly assigned to HeLa cells seeded in 6-
well or 12-well plates. HeLa cells were infected with bacterial cultures at multiplicities of 
infection (MOI) of approximately 5 and 10. After incubation of the infected cells for 
approximately 1 h at 37°C (with 5% CO2), HeLa cells were washed 3 times with phosphate 
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buffered saline (PBS), followed by incubation with EMEM supplemented with 100 μg/ml 
gentamicin (Gibco) for 1.25 h at 37°C to kill extracellular bacteria. Subsequently, HeLa cells 
were washed an additional 3 times with PBS, and were then maintained in EMEM containing 10 
μg/ml gentamicin (Gibco) to prevent recurrent infection and bacterial outgrowth during 
incubation.  
Flow Cytometry. After the selected incubation periods, HeLa cells were washed once with PBS, 
and were harvested using 0.5% Trypsin EDTA (Gibco). Cells were fixed in 70% ethanol at -
20°C for at least 3 h. Ethanol-fixed cells were permeabilized with PBS containing 0.1% Tween-
20 (PBS-T) and bovine serum albumin (1 g/100 ml) (Sigma-Aldrich, St. Louis, MO) at room 
temperature for 10 min. Cells were subsequently stained (10 min at room temperature) with a 
solution containing propidium iodide (PI; ThermoFisher Scientific, Waltham, MA) at a final 
concentration of 50 μg/ml and RNase A (Sigma-Aldrich) at a final concentration of 100 μg/ml. 
Stained cells were held at 4°C for no longer than 4 h, prior to DNA content analysis using the 
BD FACSARIA. Cells were gated to exclude doublets and multiplets, as described previously 
(31). 
Immunofluorescence Staining. HeLa cells grown on 12 mm coverslips (ThermoFisher 
Scientific) seeded in 12-well plates were infected with NTS strains at a MOI of approximately 5, 
as described above. At 48 hours post infection (hpi), cells were washed with PBS and then fixed 
with 4% paraformaldehyde in PBS at room temperature for 15-20 min. Slides were washed with 
PBS, followed by permeabilization with 0.5-1% Triton-X 100 in PBS at room temperature for 10 
min. Permeabilized cells were then blocked with 10% horse serum (Gibco) in PBS-T for 1 h at 
room temperature. Incubation with primary antibodies was performed for 1 h at room 
temperature using the following dilution factors in PBS-T: polyclonal goat anti-Salmonella 
antibody (KPL antibodies, Gaithersburg, MA; 1:500), mouse anti-γ-H2AX (EMD Millipore, 
Billerica, MA; 1:500), rabbit anti-53BP1 (Novus Biologicals, Littleton, CO; 1:500). Incubation 
with secondary antibodies diluted 1:200, except where noted, in PBS-T was performed for 1 h at 
room temperature; antibodies used were donkey anti-mouse conjugated to Alexa 405 (Abcam, 
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Cambridge, MA); donkey anti-goat conjugated to Alexa 488; donkey anti-rabbit conjugated to 
Alexa 555 (diluted 1:500); and donkey anti-mouse conjugated to Alexa 647 (all ThermoFisher 
Scientific). Nuclei were stained with either 4’,6-diamidino-2-phenylindole (DAPI) at a final 
concentration of 1 μg/ml, or PI at a final concentration of 40 μg/ml for 5 min at room 
temperature. Slides were subsequently mounted onto microscope slides with glycergel (Dako, 
Carpinteria, CA) and were imaged using a Zeiss 710 confocal microscope. Two Z-stacks 
(representing 2 independent fields of view) were collected and analyzed per slide.  Images were 
processed with FIJI software, and cells were counted using the cell counter plug-in (32). At least 
90 nuclei were analyzed per slide to identify cells that had more than four 53BP1 positive foci 
and were also positive for γH2AX; these cells were designated as 53BP1 and γH2AX positive 
cells (or “double positive cells”).  The observer was blinded to the treatment while collecting and 
analyzing images. 
Cell-free supernatant intoxication. Media supernatant was collected at 48 hpi from HeLa cells 
infected with different Salmonella strains, and was filtered through a 0.2 µm filter to remove 
bacterial cells. The resulting cell-free supernatant was co-incubated with fresh HeLa cell 
monolayers for 24 h. Following incubation, cells were fixed for flow cytometry, or for 
immunofluorescence microscopy, as described above. Cell-free supernatants were also tested 
after heat treatment (70°C or 95°C for 10 min). 
Statistical Analysis. All statistical analyses were performed using R software (version 3.0.2; R-
project, Vienna, Austria). Linear mixed effects models were used to assess significant 
associations between S-CDT status (presence or absence of S-CDT-encoding genes, or WT vs. 
ΔcdtB isogenic mutants) and either (i) proportions of cell populations in G2/M, or (ii) 
proportions of cells with an activated DDR as determined using immunofluorescence staining for 
53BP1 and γH2AX foci. MOI and S-CDT status were included as fixed effects. To account for 
potential variability due to (i) the passage number of the HeLa cells, and (ii) the Salmonella 
strain, these variables were included in models as random effects. An interaction term was 
included for S-CDT status and the MOI, when appropriate. Data were transformed by taking the 
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log10, natural log, square root, or performing a rank transformation, when appropriate to obtain a 
normal distribution of the residuals. Data shown in Figs represent untransformed data. The 
lsmeans (least square means) package was used to perform pairwise comparisons among 
treatments, and P-values were adjusted using the Tukey method to account for multiple 
comparisons. The 90% confidence interval for the binomial proportion of human Mississippi 
isolates positive for S-CDT was estimated using the Wilson score interval. 
Data Availability. All sequence data is available in NCBI GenBank (see Table 3.4 for accession 
numbers), and in the publicly available online database www.foodmicrobetracker.com.  
 
RESULTS 
S-CDT is conserved among isolates of NTS serotypes Javiana, Montevideo, and 
Oranienburg, while for serotype Mississippi isolates genes encoding S-CDT are clade-
associated. A PCR screen used to detect internal gene fragments for pltA, pltB, and cdtB showed 
that, among the 21 NTS serotypes, all S. enterica serotypes Javiana, Montevideo, and 
Oranienburg isolates screened (n = 50 for each serotype) encoded all 3 toxin components. For 
serotype Mississippi, only 4 of the 8 isolates tested were S-CDT-positive (see Table 3.5).  
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TABLE 3.5 Distribution of S-CDT-encoding genes among 21 nontyphoidal Salmonella enterica 
serotypes most commonly isolated from human cases in the US in 2011 
 
Serotype Serogroup 
Number of reported laboratory 
confirmed human clinical cases in 2011
a 
Proportion of S-CDT-
positive isolates
b
 
Enteritidis D1 7,553 0%  (0/50) 
Typhimurium
c
 B 6,131 0%  (0/50) 
Newport C2-C3 5,211 0%  (0/50) 
Javiana D1 2,937 100%  (50/50) 
I 4,[5],12:i:- B 1,339 0%  (0/50) 
Montevideo C1 1,196 100%  (50/50) 
Heidelberg B 1,103 0%  (0/50) 
Muenchen C2-C3 984 0%  (0/48) 
Infantis C1 910 0%  (0/50) 
Braenderup C1 739 0%  (0/50) 
Oranienburg C1 721 100%  (50/50) 
Saintpaul B 709 0%  (0/50) 
Mississippi G 549 50%  (4/8) 
Thompson C1 536 0%  (0/50) 
Agona B 505 0%  (0/50) 
Bareilly C1 429 0%  (0/22) 
Berta D1 321 0%  (0/20) 
Anatum E1 282 0%  (0/50) 
Hartford C1 241 0%  (0/18) 
I 13,23:b:- G 218 0%  (0/1) 
Hadar C2-C3 205 0%  (0/47) 
a Reported laboratory confirmed human clinical cases in 2011 according to CDC National Salmonella Surveillance report 2011 
bPresence of all S-CDT components (pltA, pltB, and cdtB) as determined by PCR amplification; proportion of S-CDT-positive 
strains tested per serotype 
cSerotype Typhimurium includes Typhimurium variant O:5- 
 
 
Subsequent 7-gene MLST characterization of the 8 serotype Mississippi isolates indicated that 
this serotype is polyphyletic and that these isolates represented 2 distinct clades (Fig. 2.1). S-
CDT-encoding genes were present in all 4 isolates with MLST sequence type (ST) 425 (see Fig. 
2.1) (30), while the 4 isolates in the other clade (representing ST 448 and a new ST) were 
negative for the S-CDT genes. Two other Salmonella Mississippi STs (i.e. ST 356 and 764), 
obtained from the MLST database, also clustered into the S-CDT-negative clade (30). 
Interestingly, the S-CDT-negative Mississippi clade clustered with S. Typhi (S-CDT-positive), 
suggesting that this clade may have lost the S-CDT genes (Fig. 3.1).  
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FIGURE 3.1 Genes encoding S-CDT are clade restricted for serotype Mississippi. Maximum-likelihood 
tree showing phylogenetic clades based on concatenated 7-gene MLST sequences for serotype Mississippi, 
closely related serotypes Adelaide, Paratyphi A, and Typhi (22), and S-CDT positive serotypes Javiana, 
Oranienburg, and Montevideo, which are included for comparison. MLST data for the Mississippi isolates 
designated as STnew, ST356, ST425, ST448, and ST764 were obtained here; all other sequence data were 
extracted from the MLST database (30). Branch lengths represent a substitution rate of 2 nucleotides per 
1000. Numbers at nodes represent bootstrap values based on 1000 repetitions. Blue represents S-CDT-
negative MLST sequence types and serotypes as determined in this study, and by den Bakker et al. (22); red 
represents S-CDT-positive MLST sequence types and serotypes. S-CDT status for serotype Mississippi 
ST764 and ST356 are unknown, and these STs are thus shown in black lettering. 
 
Based on CDC data on the frequency of different NTS serotypes among human clinical 
cases in the US, the 3 serotypes Javiana, Montevideo, and Oranienburg (where all isolates were 
S-CDT-positive) represent 4,854 of the 32,819 reported cases of nontyphoidal salmonellosis 
caused by the 21 NTS serotypes screened (listed in Table 3.5). Serotype Mississippi on the other 
hand accounted for 549 reported cases; with 4/8 Mississippi isolates testing as S-CDT positive, 
we can estimate that the binomial proportion of human Mississippi isolates positive for S-CDT is 
0.5 with a 90% confidence interval of 0.25 to 0.75. Based on this, infections with S-CDT-
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encoding Mississippi strains account for approximately 275 cases per year (90% C.I.: 137 - 412). 
Overall, S-CDT-positive isolates among these 21 human clinical NTS associated serotypes were 
estimated to cause approximately 5,129 reported human cases in the US.  As Scallan et al. (17) 
previously suggested that only 1 out of each 29.3 cases of nontyphoidal salmonellosis is reported 
(90% CI 21.8 - 38.4), we estimated that approximately 150,280 cases (90% C.I.: 111,812 – 
196,954) of salmonellosis in the US are caused by S-CDT-positive isolates representing 
serotypes Javiana, Montevideo, Oranienburg, and Mississippi.  
 pltA, pltB, and cdtB are highly conserved among NTS serotypes encoding S-CDT. To 
characterize the sequence conservation of pltA, pltB, and cdtB (encoding S-CDT subunits PltA, 
PltB, and CdtB, respectively) we sequenced PCR amplicons for each of these genes for 5 
representative isolates from each of the S-CDT-positive serotypes, except for serotype 
Mississippi where all 4 S-CDT-positive isolates were characterized. Overall, the predicted 
peptide products of pltA, pltB, and cdtB were highly conserved across serotypes (including S. 
Typhi strain CT-18) with 98.3%, 94.9%, and 99.3% of amino acids (aa) conserved, respectively. 
DNA sequences for pltA, pltB, and cdtB were also highly conserved, with 98.1%, 96.1%, and 
99.4% of nt identical among all isolates, respectively.  
The CdtB subunit was the most conserved among the toxin-encoding subunits. Among 
the isolates analyzed, we found 2 CdtB sequence types. All serotype Javiana, Montevideo, and 
Oranienburg isolates had the same CdtB aa sequences (see Table 3.6), which were identical to 
Typhi strain CT-18 (designated CdtB sequence type 1). CdtB sequence type 2 included all S-
CDT-positive serotype Mississippi isolates, which had aa 
substitutions at residues 217 (Thr vs. Ala in CT-18) and 223 (Ala vs. Glu in CT-18). The 
cysteine residue (Cys269) essential for anchoring CdtB and PltA (12) was conserved among the 
predicted CdtB peptide sequences for all S-CDT-positive NTS isolates analyzed. 
 
 
74 
 
TABLE 3.6 Amino acid differences in S-CDT subunits between Typhi and nontyphoidal serotypes. 
a
AA = amino acid residue in subunit 
b
three letter abbreviation for amino acid residue in S. enterica serotype Typhi strain CT-18; codon encoding the 
amino acid residue is shown in parenthesis. The specific SNP causing the amino acid change is shown in bold font. 
c
three letter abbreviation for amino acid residue in nontyphoidal serotypes listed in right-most column; codon 
encoding the amino acid residue is shown in parenthesis. The specific SNP causing the amino acid change is shown 
in bold font. 
 
d
Salmonella Oranienburg strain FSL A4-0642 showed the same amino acid substitution in PltB as the 5 Javiana 
isolates tested 
e
In addition to the aa differences listed here, isolate FSL R8-1549 (serotype Mississippi) had a SNP resulting in an 
amino acid change from glycine to serine at position 211; this genotype was not detected in any other isolates   
 
The key aa residues for PltA, the ribosyl transferase subunit, were also conserved. Both 
the PltA aa residue implicated in binding to the CdtB subunit (Cys214), as well as the catalytic 
residue (Glu133) were conserved among all isolates. A total of 4 amino acid substitutions were 
identified, compared to Typhi CT-18 (see Table 3.6). Serotype-specific amino acid substitutions 
included (i) a His215 residue in Typhi strain CT-18 (compared to Gln215 for all other serotypes), 
and (ii) a Val227 residue in all Javiana isolates (compared to a Met227 for all other isolates) (see 
Table 3.6).  
The PltB subunit was the most variable of the toxin subunits, with 7 variable aa residues 
(see Table 3.6). While for 3 variable sites (residues 3, 4, and 29), the PltB sequence for S. Typhi 
CT-18 differed from all other isolates, other residues showed different aa substitution patterns. 
For example, all serotype Javiana and 1 serotype Oranienburg isolate showed an Ile65 (in place 
Subunit 
AA 
Residue
a 
AA (nt codon) 
in CT-18
b 
AA (nt codon) in 
Serotype
c Serotypes with Substitution
 
CdtB 217 Ser (GCC)  Thr (ACC) Mississippi 
223 Glu (GAA) Ala (GCA) Mississippi 
     
PltB
d 
3 Met (ATG) Ile (ATA) Javiana, Montevideo, Mississippi, Oranienburg 
4 Ser (AGT) Asn (AAT) Javiana, Montevideo, Mississippi, Oranienburg 
6 Tyr (TAT) Phe (TTT) Javiana, Montevideo, Mississippi, Oranienburg 
29 Asn (AAT) Lys (AAA) Javiana, Montevideo, Oranienburg 
50 Ser (AGT) Gly (GGT) Javiana, Oranienburg 
65 Thr (ACA) Ile (ATA) Javiana, 1 of the 5 Oranienburg isolates 
116 Thr (ACC) Ala (GCC) 4 of the 5 Oranienburg isolates
 
     
PltA
e 
 
6 Phe (TTC) Leu (CTC) Javiana, Oranienburg 
169 Ala (GCC) Ser (TCC) Javiana, Montevideo, Oranienburg 
215 His (CAT) Gln (CAA) Javiana, Montevideo, Mississippi, Oranienburg 
227 Met (ATG) Val (GTG) Javiana 
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of Thr65 in all serotype Montevideo isolates, the 4 remaining serotype Oranienburg isolates, and 
strain Typhi CT-18). For 1 Oranienburg isolate, the complete PltB aa sequence was identical to 
the Javiana isolates. We confirmed that this was not due to misidentification of this isolate as the 
7-gene MLST sequence for this isolate matched STs of other serotype Oranienburg isolates. All 
key residues involved in binding to sugar moieties (Tyr33, Ser35, and Lys59) were conserved 
across all serotypes (12).  
Infection with S-CDT-positive serotypes results in G2/M cell cycle arrest, while infection 
with S-CDT-negative serotypes does not. To determine if the presence of S-CDT-encoding 
genes altered the outcome of infection at the cellular level we infected HeLa cells with S. 
enterica isolates representing S-CDT-positive and S-CDT-negative serotypes. Overall, we found 
that HeLa cell populations infected with isolates representing S-CDT-positive serotypes (i.e. 
Javiana, Montevideo, Mississippi, and Oranienburg) showed a significantly higher proportion of 
cells in the G2/M phase (Fig. 3.2A and 3.2B), compared to HeLa cells infected with S-CDT-
negative serotypes (i.e., Enteritidis, Newport, and Typhimurium), both at MOI 5 (p = 0.016) and 
at MOI 10 (p = 0.011). For example, for an MOI of 10, the proportion of HeLa cells in the G2/M 
phase ranged from 25.9% to 89.7% for the different S-CDT-positive isolates, and from 13.8% to 
21.1% for the S-CDT-negative isolates (see Fig. 3.2A). For HeLa cells infected with S-CDT-
negative serotypes, the proportion of cells in the G2/M phase, did not significantly differ from 
the proportion of uninfected cells in the G2/M phase, regardless of MOI (MOI 5 p = 0.999; MOI 
10 p = 0.998). We also found a significant effect (p < 0.0001) of the isolate used for infection, on 
the proportion of HeLa cells in G2/M phase. Post-hoc Tukey’s specifically showed significant 
differences in the magnitude of G2/M arrest caused by the different S-CDT-positive isolates 
tested (Fig. 3.2); HeLa cells infected with either serotype Mississippi or Oranienburg both 
showed a significantly lower (p < 0.05) proportion of HeLa cells in the G2/M phase, as 
compared to HeLa cells infected with either Javiana or Montevideo. Importantly, even for 
infections with Mississippi and Oranienburg isolates, the proportion of HeLa cells in the G2/M 
phase was still significantly (p < 0.05) higher as compared to any of the infections involving S-
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CDT-negative isolates. Overall, our results indicate that infection with S-CDT-encoding 
serotypes is associated with a significant increase in the proportion of cell populations arrested in 
the G2/M phase, indicative of DNA damage. 
FIGURE 3.2 Infection with NTS serotypes encoding S-CDT results in a significantly higher proportion of HeLa 
cells arrested in G2/M. HeLa cells were infected with isolates representing S-CDT-positive serotypes (Mississippi, 
Montevideo, Javiana, and Oranienburg) and S-CDT-negative serotypes (Enteritidis, Typhimurium, and Newport), at 
multiplicities of infection (MOI) of approximately 5 and 10. At 48 hpi, cells were fixed and stained with PI. DNA 
content was analyzed by flow cytometry, and cells were gated to exclude multiplets. Least square means from a 
linear mixed effects model were used to determine significant differences in proportions of HeLa cells in the G2/M 
phase for cells infected with the 2 MOIs. Results represent 4 independent experiments. (A) Bar chart showing 
average proportions of cell populations in G2/M phase among HeLa cells infected with S-CDT-negative (blue bars) 
or S-CDT-positive serotypes (red bars) at 2 MOIs (5 and 10, shown on X-axis); data shown are the averages for the 
4 S-CDT-positive and the 3 S-CDT-negative strains. Green bars represent values for uninfected control cells (4 
independent replicates). Bars that do not share identical letters represent statistically significantly different 
proportions of cells in G2/M phase (p < 0.05). (B) Bar chart showing G2/M arrest resulting from infection with the 
individual Salmonella strains used in this study (see Table 1). Light blue and red bars represent infection at MOI of 
5, and dark blue and dark red bars represent infection at MOI of 10. Statistical models are based on log-transformed 
data; non-transformed data are shown. Error bars represent standard deviations. 
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S-CDT-encoding serotypes activate the DNA damage response while S-CDT-negative, or S-
CDT-null serotypes do not. CdtB, the active component of S-CDT has nuclease activity in 
vitro, and activates the host cell’s DDR (3, 12, 16). To determine if infection with NTS serotypes 
encoding S-CDT resulted in an activated DDR among infected HeLa cell populations, we used 
immunofluorescence staining to detect 53BP1 foci, and then confirmed this by also staining for 
phosphorylated Serine 139 on H2AX (yielding γH2AX) (33, 34). HeLa cell populations infected 
with S-CDT-encoding Salmonella had a significantly higher proportion of cell populations with 
both 53BP1 and γH2AX foci (“double positive cells”; Fig. 3.3A and 3.3B), compared to either 
HeLa cells infected with S-CDT-negative isolates (p < 0.001) or uninfected controls (p = 0.003).  
 
FIGURE 3.3 Infection with S-CDT-encoding serotypes is associated with activation of the DNA damage response. 
HeLa cells grown on glass coverslips were infected with Salmonella strains at a multiplicity of infection of 
approximately 5. Cells were fixed at 48 hpi and were stained with antibodies recognizing 53BP1, γH2AX, and 
Salmonella cells. DAPI was included as a nucleic acid stain. (A) Representative images for strain FSL S5-0642 
(serotype Oranienburg; S-CDT-positive) and FSL S5-0415 (serotype Enteritidis; S-CDT-negative); data for other 
strains are shown in Fig. S1. Scale bars represent 25 μm. (B) A mixed effects linear model was used to determine 
whether the proportion of HeLa cells that were positive for 53BP1 and γH2AX foci at 48 hpi, differed between S-
CDT-positive and negative serotypes and uninfected controls. Data represent 2 technical replicates from 2 
independent experiments for each serotype. The S-CDT-negative bar represents the average of all data for HeLa 
cells infected with serotypes Typhimurium, Newport, and Enteritidis; the S-CDT-positive bar represents the average 
for all data for HeLa cells infected with serotypes Javiana, Montevideo, Mississippi, and Oranienburg.  *** 
represents p < 0.001; ** represents p < 0.01. While the data were transformed for statistical analyses, non-
transformed data are shown. Bars represent standard deviations. 
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This effect was consistent for all isolates tested (Fig 3.4). Specifically, 27.1% to 91.6% of HeLa 
cells infected with S-CDT-positive isolates representing serotypes Javiana, Montevideo, 
Mississippi, and Oranienburg showed both 53BP1 and γH2AX foci (“double positive cells”), 
compared to 0.0% to 9.3% of HeLa cells infected with isolates representing S-CDT-negative 
serotypes. For HeLa cells infected with isolates representing S-CDT-negative serotypes, the 
proportion of double-positive cells (i.e. cells with both 53BP1 and γH2AX foci) also did not 
differ from uninfected controls (p = 0.992). As 53BP1 and γH2AX foci have been shown 
previously to localize to sites of DNA damage, these results also support the hypothesis that 
HeLa cells infected with S-CDT-positive serotypes sustain more DNA damage than HeLa cells 
infected with S-CDT-negative serotypes (35). Therefore, these results suggest that infection with 
isolates representing different S-CDT-encoding NTS serotypes results in DNA damage which 
activates the host cell DDR, while infection with isolates representing S-CDT-negative serotypes 
does not.  
 To confirm that the observed activation of the host cell DDR was due to CdtB, we 
infected HeLa cells with ΔcdtB isogenic mutants of serotype Javiana and Montevideo isolates. 
Deletion of cdtB abolished the ability of these strains to activate the host cell DDR, as the 
proportion of ΔcdtB infected HeLa cells that were double positive for 53BP1 and γH2AX foci 
was not significantly different from uninfected controls (p = 0.805).  HeLa cell populations 
infected with WT isolates of Javiana and Montevideo also had significantly (p = 0.004) higher 
proportions of cells with an activated DDR (i.e., with 53BP1 and γH2AX foci) as compared to 
HeLa cell populations infected with the ΔcdtB isogenic mutants (Fig. 3.5A and 3.5B); 
immunofluorescence images indicated similar levels of intracellular Salmonella in HeLa cells 
infected with WT parent strains and their respective ΔcdtB isogenic mutants, suggesting that 
cdtB did not influence rates of invasion or intracellular survival within HeLa cells. Taken 
together, these results suggest that CdtB is essential for the activation of the DDR response 
among cells infected with S-CDT-positive NTS serotypes. 
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FIGURE 3.4 Infection with S-CDT-positive serotypes activates the host DNA damage response while infection 
with S-CDT-negative serotypes does not.  HeLa cells were infected with S-CDT-positive, S-CDT-negative, and 
ΔcdtB isogenic mutants, at a multiplicity of infection of approximately 5. Immunofluorescence staining was 
performed to detect 53BP1 and γH2AX foci at 48 hpi. Representative images are included for all serotypes. Scale 
bars represent 25 μm. 
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cdtB is required for the G2/M cell cycle arrest associated with infection with S-CDT-
positive serotypes. To confirm that the G2/M arrest was due to CdtB we compared the cell cycle 
progression of populations of HeLa cells infected with the WT Javiana and Montevideo strains 
and their ΔcdtB isogenic mutants. HeLa cells infected with the WT Javiana and Montevideo 
strains had a significantly higher proportion of cells in the G2/M phase at both MOI 5 (p < 
0.001) and MOI 10 (p < 0.001), compared to cell populations infected with ΔcdtB isogenic 
mutants (Fig. 3.5C). There was no statistically significant effect of MOI (5 or 10) on the 
proportion of HeLa cells that arrested in G2/M after infection with S-CDT-positive serotypes (p 
= 0.831), indicating that MOI did not have a significant effect on the observed G2/M cell cycle 
arrest, even though immunofluorescence imaging showed that only a small proportion of HeLa 
cells were infected with Salmonella (see Fig 3.5; at an MOI of approximately 5, only a median of 
10% of HeLa cells were infected). Importantly, for either an MOI of 5 (p = 0.167) or an MOI of 
10 (p = 0.149), the proportion of HeLa cells in the G2/M phase, following infection with ΔcdtB 
Salmonella isolates, was not significantly different from the proportion of uninfected controls in 
the G2/M phase. Deletion of cdtB thus abolished the ability of the S-CDT-positive serotypes 
Javiana and Montevideo to arrest HeLa cells in the G2/M phase (Fig. 3.5C), demonstrating that 
CdtB is required for the G2/M cell cycle arrest associated with infection involving S-CDT-
positive serotypes.  
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FIGURE 3.5 cdtB is essential for activation of the host DNA damage response and G2/M cell cycle arrest. HeLa 
cells infected with wild-type and ΔcdtB isogenic mutants of serotypes Javiana and Montevideo were analyzed for 
the presence of 53BP1 and γH2AX foci, at 48 hpi. (A) Representative images showing 53BP1 and γH2AX foci, 
among HeLa cells infected with wild-type Javiana and a ΔcdtB isogenic mutant. Scale bars represent 25 μm. (B) 
Quantification of the proportion of HeLa cells with both 53BP1 and γH2AX foci; data represent 2 technical 
replicates from 2 independent experiments for each of the 4 strains (Javiana and Montevideo parent strains and their 
respective isogenic mutants); error bars represent standard deviations. **signifies p-value < 0.01; * signifies p-value 
< 0.05 (C) Proportion of HeLa cell populations in the G2/M phase determined by DNA content analysis using flow 
cytometry. HeLa cells were infected at 2 multiplicities of infection with either wild-type or ΔcdtB isogenic mutants 
of serotypes Javiana and Montevideo. Cells were fixed at 48 hpi, and DNA content was measured using PI staining. 
Data represent the averages for both serotypes from 4 independent experiments for each strain. Bars that do not 
share identical letters represent statistically different values (p < 0.05). Error bars represent standard deviations. 
 
 
S-CDT-mediated intoxication can occur via autocrine or paracrine pathways. 
Immunofluorescence staining clearly showed that cells which were not infected with Salmonella, 
but were located near Salmonella infected HeLa cells, had an activated DDR (see Figs 3.3, 3.4, 
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and 3.5). To determine if the activation of the DDR and G2/M arrest could occur via intoxication 
arising from paracrine pathways, we co-incubated uninfected HeLa cell populations with cell-
free supernatants collected from previous infections with S-CDT-positive serotypes and their 
respective ΔcdtB isogenic mutants. HeLa cell populations incubated with cell-free supernatants 
from infections with WT isolates encoding S-CDT had a significantly higher proportion of cells 
in the G2/M phase compared to HeLa cells incubated with cell-free supernatants from ΔcdtB-
infected HeLa cells, after incubation at 5% (p = 0.034) and 20% (p = 0.014) total volume (Fig 
3.6A).  
In contrast, the proportion of HeLa cells in the G2/M phase did not differ significantly between 
untreated cells, and cells co-incubated with either 5% or 20% v/v cell-free supernatant from a 
previous infection with ΔcdtB isogenic mutants (p = 0.450, and p = 0.979, for 5% and 20% v/v 
treatments, respectively). 
 We also found that HeLa cells co-incubated with filter-sterilized cell-free supernatant 
from past infections with S-CDT-positive WT strains showed a significantly higher proportion of 
cells with 53BP1 and γH2AX foci as compared to untreated control cells; this was observed at 
both concentrations of 5% v/v (p = 0.047), and 20% v/v (p = 0.004) (Figs 3.6B and 3.6C).  
Furthermore, HeLa cells treated with cell-free supernatant from WT infections, had a 
significantly higher proportion of cells having both 53BP1 and γH2AX foci, compared to cells 
treated with cell-free supernatant from ΔcdtB infections (p = 0.015, and p = 0.003 for 5% v/v and 
20% v/v, respectively). HeLa cells co-incubated with cell-free supernatant from infections with 
ΔcdtB isolates also did not differ significantly from untreated control cells with regard to the 
proportion of cells with 53BP1 and γH2AX foci (p = 0.958 for 5% v/v, p = 0.555 for 20% v/v).  
  
83 
 
 
 
FIGURE 3.6 S-CDT-mediated activation of the DNA damage response and G2/M cell cycle arrest can occur via 
paracrine pathways. HeLa cells were co-incubated with cell-free supernatants from previous infections with S-CDT-
positive wild-type strains FSL S5-0395 (serotype Javiana) and FSL R8-4841 (serotype Montevideo), and their 
respective isogenic ΔcdtB mutants; supernatants were added at final concentrations of 5% and 20% v/v. (A) At 24 h 
post intoxication, cells were stained with PI to determine DNA content, and quantify the proportion of cells in the 
G2/M phase. Results represent 2 independent experiments for each of the 4 strains. Bars that do not share identical 
letters represent statistically different values (p < 0.05). (B) HeLa cells grown on coverslips were co-incubated with 
cell-free supernatants from previous infections. Immunofluorescence staining was performed to detect cells with 
53BP1 and γH2AX foci, at 24 h post intoxication. Bar charts represent data from 2 independent experiments. Bars 
that do not share identical letters represent statistically different values (p < 0.05). (C) Representative images are 
shown for supernatants from infections with FSL R8-4841 (WT strain of serotype Montevideo) and FSL B2-0364 
(ΔcdtB mutant of serotype Montevideo). Data for FSL S5-0395 (Javiana WT) and FSL B2-0360 (ΔcdtB mutant of 
serotype Javiana) are shown in Fig. S1. Scale bars represent 25 μm. 
 
Heat inactivation of supernatants collected from infection with S-CDT positive isolates abolished 
the ability of the toxin-containing supernatant to induce 53BP1 and γH2AX foci (see Fig 3.7), 
suggesting that a heat-labile toxin is responsible for activation of the DDR. This is consistent 
with previous studies which have shown that heating CDT-containing supernatant from E. coli 
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and Campylobacter spp. at 70°C for 1 h abolished the cytotoxic effect of this toxin in tissue 
culture (36, 37).  
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FIGURE  3.7 Heat treatment of supernatants from previous infections inactivates S-CDT-mediated activation of the 
DNA damage response. Supernatant was collected, at 48 hours post infection, from HeLa cells that were initially 
infected (or uninfected, in the case of the ‘uninfected control’) with Salmonella; the Salmonella Enteritidis WT 
strain is S-CDT-negative, while the Salmonella Javiana WT strain is S-CDT-positive. Supernatants were filtered 
with a 0.2 μm filter and were subsequently heat treated at 95°C for 10 min. These supernatants were then added 
(final volume 10% v/v) to HeLa cell cultures, and were incubated for 24 h prior to fixation with 4% PFA. 
Immunofluorescence staining was performed to detect 53BP1 (green) and γH2AX (red) foci. Nuclei were stained 
with DAPI. Scale bars represent 25 μm. 
Previous studies had suggested a strict requirement for internalization of Salmonella cells, 
in order for S-CDT production to occur (2, 16). Similarly, we found that co-incubation of HeLa 
cells with either LB broth or EMEM tissue culture media used to culture S-CDT positive 
Salmonella, failed to induce activation of the host DDR, and failed to induce a G2/M arrest (Fig 
3.8). This result suggests that the S-CDT production only occurs by intracellular Salmonella; 
hence the paracrine-route of  S-CDT-induced intoxication requires initial intracellular infection 
of at least some host cells to allow for production of S-CDT needed for the paracrine 
intoxication. Overall, these results suggest that intoxication with S-CDT may occur via autocrine 
or paracrine pathways, implicating that the eukaryotic cells do not need to be infected with S-
CDT-positive NTS in order to sustain DNA damage.  
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FIGURE 3.8 S-CDT-mediated intoxication does not occur when Salmonella are grown in LB broth or in EMEM. 
(A) Salmonella cells were cultured in 0.3 M NaCl LB broth pH 8 at 37°C under stationary conditions until mid-log 
phase; the LB broth was filtered with a 0.2 μm filter to remove bacterial cells, and the resulting filtered broth (at a 
final concentration of 10% v/v) was added to HeLa cells grown on glass coverslips in 24-well plates. After 24 h, 
HeLa cells were fixed with 4% PFA, and immunofluorescence staining was performed to detect γH2AX (red) and 
53BP1 foci (green). DAPI is included as a nucleic acid stain. Uninoculated LB was included as a negative control, 
and 2 μM etoposide was included as a positive control. Scale bars represent 25μm. (B) HeLa cells grown in 6-well 
plates were co-incubated with sterile-filtered LB broth or EMEM media inoculated with S-CDT-positive Salmonella 
(wild type S. Javiana FSL S5-0395) or S-CDT null (ΔcdtB S. Javiana FSL B2-0360) at a final concentration of 10% 
v/v. After 24 h, cells were harvested and subjected to flow cytometry to determine cell cycle phase based on DNA 
content (i.e. G1, S, or G2/M cell cycle phases).  
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DISCUSSION 
Nontyphoidal Salmonella (NTS) serotypes represent one of the most common causes of 
foodborne illness worldwide, and therefore have a tremendous economic and public health 
impact. While most NTS infections cause mild gastrointestinal symptoms, systemic infections 
are not uncommon and may be associated with specific serotypes, such as serotypes Dublin or 
Choleraesuis (19). In addition, long-term sequelae of NTS infections (e.g., reactive arthritis and 
post-infectious irritable bowel syndrome) have been reported (38). While recent studies of S-
CDT production by S. Typhi have suggested that this virulence factor plays an important role in 
establishing a chronic infection, and in the development of typhoid fever (8, 12), extensive 
genomic and phenotypic analyses have largely failed to definitively identify specific virulence 
factors that may be responsible for virulence differences among NTS serotypes, suggesting that 
multiple virulence factors likely contribute to the severity of an infection (20, 39). The recent 
identification of genes encoding S-CDT in the genomes of some NTS serotypes, however has 
provided a specific set of genes that may impart unique virulence characteristics to a subset of 
NTS serotypes. As the specific contributions of S-CDT to pathogenicity of NTS serotypes have 
remained largely uncharacterized, we conducted a series of experiments to assess the distribution 
and conservation of S-CDT-encoding genes among NTS serotypes and to determine the 
contributions of these genes to Salmonella pathogenicity, using a cell culture model.   
In this study, we established that among 21 NTS serotypes causing the majority of human 
clinical cases of salmonellosis in the US, serotypes Javiana, Montevideo, Oranienburg, as well as 
some serotype Mississippi isolates, encode S-CDT. Interestingly, we found that serotype 
Mississippi is polyphyletic, and that S-CDT-encoding genes are only present for isolates in 1 of 
the 2 clades. We estimated that infections with S-CDT-positives isolates representing these 
serotypes accounts for approximately 150,280 cases (90% C.I.: 111,812 – 196,954) of foodborne 
salmonellosis in the US in 2011, suggesting that a relatively large population of individuals are 
exposed to this toxin (17). In general, the results of our PCR screen agree with previous reports 
on the distribution of S-CDT-encoding genes among NTS serotypes (20, 22-24). For example, 
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using a much smaller set of isolates (1 – 2 isolates) per serotype, den Bakker et al. also reported 
that serotypes Javiana, Montevideo, Oranienburg encode cdtB (22). While our study focused on 
characterizing S-CDT presence among the most common NTS serotypes causing human 
salmonellosis in the US, other studies indicated that in addition to serotypes Javiana, 
Montevideo, Oranienburg, and Mississippi, at least 37 other, rarer, NTS serotypes also encode S-
CDT, suggesting further human exposure to S-CDT-positive NTS strains (22, 25). While some 
evidence supports that S-CDT-positive NTS represent a specific NTS clade, there is at least 
some evidence that S-CDT is not exclusively associated with a specific clade (22). For example, 
a recent study by den Bakker et al. identified that Salmonella serotypes encoding S-CDT were 
primarily found in Clade B (e.g., serotypes Javiana, Schwarzengrund, Montevideo), while a 
small sub-clade (including serotypes Paratyphi A and Typhi) of Clade A also represented strains 
that encode S-CDT (22). While future additional studies on the presence of S-CDT among 
additional NTS serotypes will be valuable, the data presented here on S-CDT presence among a 
large number of isolates representing serotypes commonly associated with human disease 
provides important information that allows for an initial assessment of the population in the US 
which is exposed to S-CDT through infections involving NTS serotypes. 
Not surprisingly, alignments of predicted amino acid sequences suggested that CdtB, 
PltA, and PltB are highly conserved across serotypes, with the active subunit (CdtB) having the 
fewest amino acid substitutions. It is interesting to note that several SNPs in the coding 
sequences of PltB and PltA involved transitions to codons which are less frequently used (i.e. 
“rare”) by Salmonella, potentially leading to a reduction in the overall quantities of these 
proteins in some strains (40). Importantly, our data suggest that the S-CDT produced by NTS 
serotypes, based on overall nucleotide similarity to coding sequences of S-CDT genes encoded 
by S. Typhi, likely induces DNA damage in eukaryotic cells in a similar manner to the S-CDT 
produced by S. Typhi. 
To date, few studies have specifically examined the contributions of S-CDT production 
by NTS serotypes to infection and pathogenesis (23-25). While limited prior studies have shown 
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that some S-CDT-positive serotypes (e.g., Javiana) induce a G2/M arrest (23, 25), our results not 
only confirmed that infection with S-CDT-positive NTS serotypes causes a cell cycle arrest that 
is not observed in cells infected with S-CDT-negative serotypes, but also show that this cell 
cycle arrest is associated with activation of the host DDR. In addition, we show that serotypes 
Oranienburg and Mississippi also induce DNA damage in infected eukaryotic cells, further 
confirming that an active S-CDT is produced by these NTS serotypes, and that the DNA 
damaging effects are not restricted to serotype Typhi. Our data show that infection with wild-
type strains of S-CDT-positive NTS serotypes significantly impacts the cellular outcome of 
infection, suggesting that S-CDT is an important pathogenicity factor in strains that encode S-
CDT.  
An important difference between S-CDT and the CDTs produced by other Gram-negative 
pathogens is the additional ADP-ribosyl transferase activity of the PltA subunit in S-CDT (2, 3). 
Here we confirmed that the DNA damaging effects are due to the activity of the CdtB subunit, as 
deletion of cdtB abolished the ability of S-CDT-positive serotypes to cause DNA damage (as 
shown by the G2/M cell cycle arrest and the 53BP1 and γH2AX foci). This is in agreement with 
previous studies in serotype Typhi, which also showed that cdtB deletion abolishes G2/M cell 
cycle arrest (2, 16). We therefore conclude that the S-CDT produced by NTS acts in the same 
manner as the S-CDT produced by serotype Typhi.  
Immunofluorescence staining of HeLa cells infected with S-CDT-positive NTS isolates 
showed that the DNA damage sustained from S-CDT-mediated intoxication is not restricted to 
infected cells, but impacts nearby cells as well. Previous studies with S. Typhi have similarly 
shown that intoxication with S-CDT may occur via autocrine or paracrine pathways, as 
intoxication of Henle cells in the presence of a toxin-neutralizing antibody abolished the cell 
cycle arrest of cells co-incubated with cell-free supernatant containing S-CDT from previous 
infections (2). In support of this, a previous study also showed that exogenous addition of 
purified S-CDT was sufficient to cause a G2/M phase arrest, suggesting that S-CDT is necessary 
and sufficient for the cytotoxic activity observed in S-CDT-encoding serotypes of Salmonella 
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(12). Furthermore, Guidi et al. (2013) showed that S-CDT is transported anterograde along host 
microtubules of infected cells in outer membrane vesicles and secreted from infected cells into 
the surrounding media (41). Consequently, it is likely that all cells, whether or not they are 
infected with Salmonella, sustain S-CDT-mediated DNA damage via the same mechanism, as all 
cells appear to take up S-CDT from the extracellular environment. This is important because 
during an infection, relatively few S. enterica cells successfully invade host cells (42). Together, 
these results suggest that dissemination of S-CDT into the surrounding tissues has the potential 
to impact a greater number of host cells, which may contribute to the overall outcome of 
infection. 
It has been established previously that Salmonella may induce host cell death via multiple 
mechanisms, including apoptosis and pyroptosis, depending on the host cell type (e.g., immune 
versus epithelial cells) (43-45). The majority of these analyses have been conducted using 
serotype Typhimurium, which is now known to be S-CDT negative. Therefore, S-CDT-mediated 
intoxication represents an important new mechanism by which NTS may induce cell death. 
While HeLa cells represent a standard cell line used for studies of DNA damage, future studies 
examining the cellular outcome of infection with S-CDT positive NTS serotypes in non-
cancerous (i.e. non-transformed) cell lines will be important to assess whether eukaryotic cells 
are able to repair the DNA damage induced by S-CDT positive NTS serotypes.  
Our data indicate that S-CDT significantly impacts the outcome of infection with NTS 
serotypes at the cellular level. It will be important to further assess the role of S-CDT in vivo to 
determine the implications of S-CDT-mediated DNA damage at the host level, and to also 
ascertain what, if any, long-term sequelae may result from the DNA damage sustained during an 
infection with S-CDT producing NTS. An analysis by Rodriguez-Rivera et al. (2015) reported 
that nontyphoidal serotypes which had a higher proportion of infections resulting in invasive 
disease (as reported by Jones et al. (2010) were significantly more likely to encode S-CDT, 
therefore suggesting that S-CDT contributes to the severity of human clinical cases as well (19, 
25). AbuOun et al. (2005) found that sera from humans who had previously been exposed to C. 
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jejuni (which encodes a CDT) neutralized the activity of the toxin in vitro, suggesting that 
individuals seroconvert following exposure to CDTs (46). Further studies will be beneficial in 
determining if S-CDT exposure also causes antibody production, and potentially neutralization, 
of S-CDT produced by NTS.  
  Overall, the data provided here contribute important new information that strongly 
suggest that a subset of NTS strains (i.e., those encoding S-CDT) are likely to cause unique 
consequences of infection at both the cellular and host level. Hence, there is an urgent need to 
determine the potential public health impacts of S-CDT-producing NTS serotypes. Ultimately, 
this work may lead to differential assessment of the food safety hazards posed by foods 
contaminated with S-CDT-positive and negative NTS strains. 
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CHAPTER 4 
TWO IS BETTER THAN ONE: NONTYPHOIDAL SALMONELLA SEROTYPE JAVIANA 
ENCODES MULTIPLE BINDING SUBUNITS OF THE SALMONELLA CYTOLETHAL 
DISTENDING TOXIN FOR ENHANCED ACTIVITY IN VITRO 
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ABSTRACT 
The ‘typhoid toxin’ (also known as the Salmonella cytolethal distending toxin [S-CDT]) 
produced by Salmonella enterica subsp. enterica serotype Typhi (S. Typhi) acts a nuclease in 
vitro, and is hypothesized to play a crucial role in the development of typhoid fever. Recently, it 
was found that >40 nontyphoidal serotypes also encoded S-CDT. S-CDT is encoded on two 
operons, and includes genes encoding toxin subunits (pltA, pltB, cdtB), as well as two genes, 
ttsA, encoding a putative phage muramidase, and STY1887, which has an unknown function. The 
requirement of each gene for S-CDT-mediated cytotoxicity in vitro had not yet been 
characterized for nontyphoidal serotypes. To this end, we constructed S. Javiana strains 
harboring deletions in each gene in the S-CDT islet. Infection of the normal human intestinal 
epithelial cells (HIEC-6) revealed that pltA and cdtB are essential for S-CDT-mediated DNA 
damage, similar to what had been shown for S. Typhi. While STY1887 was also dispensable for 
S-CDT activity in vitro, we found that, in contrast to what had been shown for S. Typhi, pltB and 
ttsA are also dispensable as infections with these strains did not result in a significant activation 
of the DNA damage response (DDR) in HIEC-6 cells. Simultaneous deletion of both pltB, and its 
homolog artB, abolished activity, suggesting that S. Javiana encodes two variants of the binding 
subunit, which could be important for differences in targeting host cells. Overall, these results 
suggest that production of active S-CDT has different genetic requirements in typhoidal and 
nontyphoidal serotypes.  
IMPORTANCE 
Nontyphoidal Salmonella is the second leading bacterial cause of foodborne illness 
world-wide. The recent discovery of the ‘typhoid toxin’ in select nontyphoidal serotypes 
represents an important gap in our understanding of nontyphoidal salmonellosis. Here, we show 
that genes encoding the active subunit, CdtB, and the ADP-ribosylation subunit, PltA, are 
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essential for S-CDT-mediated activation of the DNA damage response in normal human 
epithelial cells. However, the binding subunit was not essential, as infection with these strains 
resulted in an altered cell cycle progression, and had DDR foci indicative of DNA damage, 
similar to infection with wild-type bacteria. These data provide important information regarding 
the function of the typhoid toxin in NTS. Furthermore, our results show that ArtB may substitute 
for PltB in vitro, which may enhance production of the complete holotoxin, as both binding 
subunits are required for maximum S-CDT-mediated cytotoxicity.    
INTRODUCTION 
Infections by nontyphoidal Salmonella (NTS) serotypes account for an estimated 93.8 
million illnesses, and 155,000 deaths per year (1), making it the second leading cause of bacterial 
foodborne disease worldwide (2). The discovery of a cytolethal distending toxin (CDT) in S. 
enterica subsp. enterica serotype Typhi, the causative agent of typhoid fever, led to the toxin 
being named the ‘typhoid toxin’ (3, 4). However, genomic screens have shown that at least 40 
NTS serotypes encode genes for the ‘typhoid toxin’ as well (5-7), and further in vitro 
characterizations have shown that these toxin positive serotypes produce an active toxin (6, 8, 9).  
The CDT encoded by Salmonella differs from the CDT produced by other Gram-negative 
pathogens. In all other Gram-negative pathogens, CDT is encoded by 3 genes; cdtA and cdtC 
encode subunits CdtA and CdtC which play a role in toxin binding and trafficking within 
eukaryotic cells (10, 11), while cdtB encodes the active subunit CdtB, which is predicted to act 
as a nuclease (12). While Salmonella encodes cdtB, it does not encode cdtA or cdtC (5, 13). 
Instead, the CDT produced by Salmonella uses subunits PltA and PltB, which are homologous to 
the S1 and S2 subunits of the pertussis toxin, for binding and trafficking (4). For these reasons, 
we will refer to the special variant of CDT as S-CDT (for Salmonella CDT).  
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In vitro, infection with S-CDT positive strains of toxin positive serotypes (e.g., Typhi, 
Javiana, Montevideo, Mississippi, and Schwarzengrund) results in a G2/M cell cycle arrest (3, 6, 
9, 13), and activation of the DNA damage response (DDR) as determined by 
immunofluorescence staining for DDR proteins γH2AX and 53BP1 (8). In vivo, administration 
of purified S-CDT partially re-capitulated symptoms of typhoid fever in a mouse model (4). 
Similarly, infection with S-CDT-carrying strains of S. Typhimurium (a naturally S-CDT toxin 
negative serotype (8)) prolonged carriage of toxin positive strains, suggesting that the toxin alters 
the host-pathogen interaction in vivo, enabling S-CDT-positive Salmonella to persist for longer 
periods of time in the host (14).  
S. enterica subsp. enterica serotype Javiana is the 4
th
 most commonly isolated NTS 
serotype causing infections in the U.S. (15), and is the most common S-CDT-positive serotype. 
The majority of studies characterizing S-CDT activity have been performed using serotype 
Typhi, which has several important genotypic and phenotypic differences from NTS serotypes 
(16-18). While the roles of the other two accessory genes in the S-CDT islet, STY1887 and ttsA, 
have been characterized in Typhi (19), their role in the secretion and production of S-CDT in 
NTS serotypes, has not been established. Therefore, characterization of S-CDT in NTS serotypes 
represents a knowledge gap in our understanding of the role of S-CDT in NTS infections.  
Previous characterizations in vitro, which were critical for asserting the activity of S-
CDT, were conducted using cancer cell lines, and therefore limited analyses to determining 
whether or not DNA damage had occurred. Use of a non-transformed cell line is therefore 
necessary to understand how infection with S-CDT-positive Salmonella impacts the cellular 
outcome of infection.  
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 To determine the role of all genes in the S-CDT islet on S-CDT activity in NTS serotype 
S. Javiana, we infected normal human intestinal epithelial cells with strains of S. Javiana 
harboring gene deletions in different genes in the S-CDT islet. We found that infection of normal 
cells also results in a G2/M cell cycle arrest, and activation of the DDR. Genes cdtB and pltA, are 
essential for toxin activity in vitro, while pltB, STY1887, and ttsA are not. Moreover, we show 
that S. Javiana encodes multiple subunits, pltB and artB, which can be used interchangeably in 
vitro, for enhanced activity of S-CDT.  
RESULTS 
Infection with S-CDT-positive S. Javiana induces a DDR in normal epithelial cells. We 
previously established in a HeLa cell model, that infection with S-CDT positive strains of NTS 
activated the DDR and induced a G2/M arrest, while infection with either S-CDT negative 
serotypes or ΔcdtB mutants did not (8). To determine if non-cancerous cells were also 
susceptible to S-CDT intoxication, we infected normal human intestinal epithelial cells (HIEC-6 
cells) with wild-type and ΔcdtB strains of S. Javiana. Infection with wild-type S. Javiana resulted 
in 44% of cells with 53BP1 and γ-H2AX foci, compared to just 6% in either uninfected cells, or 
in cell populations infected with the ΔcdtB strain (P = 0.001; Fig. 4.1A and 4.1B). Similarly, 
HIEC-6 cell populations infected with wild-type S. Javiana also had significantly higher 
proportions of cells in the G2/M phase (P = 0.005) compared to uninfected controls (Fig. 4.1C). 
Cell populations infected with wild-type S. Javiana had 26% of cells in the G2/M phase, 
compared to 12% of cells in G2/M among uninfected controls. Similar to uninfected controls, 
infection with ΔcdtB S. Javiana resulted in cell populations having 11% of cells in G2/M, 
suggesting that the interference in cell cycle progression is dependent on the Salmonella 
encoding cdtB.   
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FIGURE 4.1 Infection with wild-type S. Javiana activates the DDR and induces a G2/M phase arrest. Normal 
human intestinal epithelial cells (HIEC-6 cells) were infected with 2 x 10
6
 or 4 x 10
6 
S. Javiana cells for 
immunofluorescence or flow cytometry analyses, respectively. As a positive control, cells were treated with the 
topoisomerase poison Etoposide (at a final concentration of 2 µM) for 24 h. At 48 hpi, cells were collected and 
stained for DDR foci γH2AX and 53BP1, or were stained with propidium iodide for flow cytometry analyses. A) 
Representative images of cells infected with wild-type S. Javiana and ΔcdtB strains, and positive (treated with 2 µM 
etoposide) and negative (untreated) controls. B) Quantification of proportions of cells with >four 53BP1 foci, which 
co-localized with γH2AX foci. Treatments which do not share letters have significantly different (p < 0.05) 
proportions of cells with 53BP1 foci that also co-localized with γH2AX foci. C) Cells were stained with PI to 
determine DNA content, and the proportion of cell populations in each cell cycle phase. Treatments that do not share 
letters within each cell cycle phase group (i.e., G1, S, G2/M) are significantly different (p < 0.05).  
101 
 
 
pltA and cdtB, but not pltB, ttsA, or STY1887 are required for S-CDT activity in vitro. S-
CDT is encoded in two operons (Fig 4.2B.). In addition to genes encoding S-CDT (pltB, pltA, 
and cdtB), the islet also contains a putative bacteriophage muramidase, ttsA, which is 
hypothesized to play a role in toxin secretion (19), and STY1887 which has an unknown function. 
To determine which genes were essential for S-CDT-mediated intoxication of HIEC-6 cells, we 
constructed strains with deletions in individiual genes in the S-CDT islet.  
Infection with strains harboring deletions in cdtB and pltA did not induce DDR foci when 
these mutants were used to infect HIEC-6 cells (Fig. 4.2A and 4.2C); HIEC-6 cells infected with 
ΔcdtB or ΔpltA strains had an average of 5.4% and 7.6% of cells that were double positive for 
DDR foci 53BP1 and γH2AX; infection with these strains did not differ significanlty from 
uninfected controls (infection with ΔcdtB vs. control P = 1.000 and ΔpltA vs. control P = 0.818,). 
Deletion of ttsA resulted in slightly lower levels of HIEC-6 cells with DDR foci, compared to 
wild-type S. Javiana (e.g., 31.6% of cells, versus 43.9%), but this was not significantly different 
(P = 1.000). ttsA is essential for S-CDT-mediated intoxication for S. Typhi, in contrast to S. 
Javiana.  
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FIGURE 4.2 pltB, ttsA, and STY1887 are not required for S-CDT-mediated intoxication of HIEC-6 cells. Normal 
human intestinal epithelial cells (HIEC-6 cells) were infected with 2 x 10
6
 CFU of S. Javiana strains harboring 
deletions in various genes in the S-CDT islet. Immunofluorescence staining was performed for DDR foci γH2AX 
and 53BP1 as described above. A) Organization of the S-CDT islet in S. Javiana. Genes shown in blue represent 
genes encoding S-CDT subunits; genes shown in white are contained within the islet, but do not encode protein 
products that become part of the S-CDT holotoxin. B) Quantification of proportions of cells with >four 53BP1 foci, 
which co-localized with γH2AX foci. Treatments which do not share letters have significantly different (p < 0.05) 
proportions of cells with 53BP1 foci that also co-localized with γH2AX foci. C) Representative images of cells 
infected with wild-type S. Javiana and S-CDT single gene deletion strains. Data for wild-type and ΔcdtB strains are 
included for ease of comparison, but are also represented in Fig. 1.   
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To determine if this discrepancy could be due to highly divergent sequences of ttsA in S. 
Typhi (strains CT-18 and Ty2) compared to ttsA encoded by S-CDT-positive nontyphoidal 
serotypes, we aligned the sequences of ttsA from typhoidal (e.g., Typhi strains CT-18 and Ty2, 
and Paratyphi A strain ATCC 11511) and nontyphoidal strains (e.g., Javiana, Montevideo, and 
Schwarzengrund). ttsA is highly conserved (Fig 4.3), with just 2 out of 180 amino acids different 
among the serotypes included, suggesting that either these 2 amino acid residues are essential for 
activity, or that ttsA is not required for S-CDT export in NTS serotypes. 
 
 
 
FIGURE 4.3 Amino acid alignment of TtsA from typhoidal and nontyphoidal serotypes. Amino 
acid sequence was predicted from artB equences extracted from whole genome sequence data. A 
maximum likelihood tree constructed based on translated sequence data for artB, encoding using 
WAG method with gamma distributed sites and 1000 bootstrap repetitions. Bar represents 0.001 
substitutions per site.   
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 Strains harboring deletions in STY1887 or pltB resulted in DDR foci in an average of 
44.1% and 55.7% of HIEC-6 cells, respectively, and did not differ significantly from proportions 
of HIEC-6 cells with DDR foci among cells infected with wild-type S. Javiana (STY1887 vs 
wild-type = 1.000 , ΔpltB vs. wild-type P = 0.779), suggesting that these genes are not essential 
for S-CDT-mediated intoxication.  
S. Javiana encodes a pltB homolog, artB, which can substitute for PltB in vitro. Because 
deletion of pltB, encoding the binding subunit of S-CDT, did not have a significant effect on S-
CDT-induced intoxication of infected HIEC-6 cells, we hypothesized that artB, encoding a 
homologous protein ArtB (20), could potentially substitute for PltB in vitro. S. Javiana encodes a 
truncated version of artA and a full-length copy of artB (Fig. 4.4A). To determine the importance 
of artA and artB in S-CDT intoxication, we constructed strains with deletions in (i) the entire 
artAB operon, or (ii) just artB (Fig. 4.4A). HIEC-6 cells infected with either ΔartAB or ΔartB 
had an average of 25.4% and 21.0% of cells with DDR foci (Fig. 4.4B), which did not differ 
from HIEC-6 cell populations infected with either wild-type or ΔpltB strains (P > 0.2 for all 
pairwise comparisons of wild-type, ΔpltB, ΔartB, ΔartAB). However, deletion of both pltB and 
artB, abolished S-CDT’s ability to induce DDR foci in HIEC-6 cells (Fig. 4.4B and 4.4C). 
Compared to HIEC-6 cells infected with ΔpltB which had an average of 55.7% of cells with 
DDR foci, infection with ΔpltB ΔartB resulted in an average of 3.9% of cells with DDR foci (P< 
0.001; Fig. 4.4B and 4.4C). Similarly, infection with  ΔpltB ΔartAB resulted in a significantly 
lower level of HIEC-6 cells with evidence of S-CDT intoxication (5.2% of cells with DDR foci, 
P <0.0001 compared to wild-type). 
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FIGURE 4.4  Strains require artB or pltB for S-CDT-mediated intoxication. Normal human intestinal 
epithelial cells (HIEC-6 cells) were infected with 2 x 10
6
 S. Javiana strains harboring either single gene 
deletions in artB, artAB, or double deletions in pltB and either artB or artAB. At 48 hpi, cells were stained 
for DDR foci γH2AX and 53BP1. A) Schematic of the gene deletions for ΔartB and ΔartAB strains. B) 
Quantification of proportions of cells with >four 53BP1 foci, which co-localized with γH2AX foci. 
Treatments which do not share letters have significantly different (p < 0.05) proportions of cells with 
53BP1 foci that also co-localized with γH2AX foci. C) Representative immunofluorescence images of 
HIEC-6 cells infected with S. Javiana strains. Green represents Salmonella cells, yellow foci represent 
53BP1 foci, and γH2AX foci are shown in red.  
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To determine if ArtB could substitute for PltB as the binding subunit, we compared the amino 
acid sequences of ArtB with PltB, and mapped the 5 amino acid residues which are predicted to 
interact with host receptors for toxin binding to host cell surfaces (21). The Ser35 residue which 
is essential for binding to host cells (21) is present in ArtB from S. Javiana (Fig 4.5A). Similarly, 
the other amino acid residues are either perfectly aligned, or are offset by just 1 amino acid 
residue, suggesting that ArtB has the 5 key binding amino acid residues (Fig 4.5 A). 
Furthermore, the predicted 3D structures of the PltB and ArtB subunits from S. Javiana were 
structurally similar (Fig. 4.5 B), supporting the hypothesis that ArtB, could serve as a monomer 
for the pentameric binding subunit of the holotoxin.   
 
 
  
FIGURE 4.5 Key amino acid residues necessary for binding to sugar moieties are conserved in ArtB. A) 
Clustal-w alignments of translated amino acid sequences of PltB and ArtB from S. Javiana strain CFSAN0001992. 
Letters highlighted in green represent key residues that are conserved, letters highlighted in red represent residues 
that differ between PltB and ArtB, but are next to letters in orange which show amino acid residues that interact with 
host glycans (21);  “*” represents amino acid residues common to all three sequences (26).B) Predicted 3D structure 
of PltB and ArtB based off of translated amino acid sequences of pltB and artB extracted from S. Javiana strain 
CFSAN0001992, generated using SWISS-MODEL online software (27).  
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artB by is encoded by other S-CDT positive Salmonella serotypes. ArtB (for ADP-
ribosylation toxin subunit B) was first described for S. enterica subsp. enterica serotype 
Typhimurium (20), a S-CDT-negative serotype (8). To determine if artB was conserved among 
S-CDT-positive and negative nontyphoidal serotypes, we aligned the predicted amino acid 
sequence of ArtB from S. Typhimurium with that of predicted ArtB amino acid sequences from 
other S-CDT positive serotypes. Predicted amino acid sequences of ArtB from S-CDT-positive 
serotypes Minnesota, Javiana, Rubislaw, Montevideo, and Schwarzengrund were highly similar, 
with just 2 out of 141 amino acids different (98.6% identical). Similarly, predicted amino acid 
sequences for ArtB from Typhi CT-18 and Paratyphi ATCC 11511 strain had just 1 amino acid 
different (99.3% identical). The predicted ArtB amino acid sequence from S. Typhimurium DT 
104 was the most variable (73.9% identical to ArtB from NTS serotypes in the data set, 73.2% 
identical to ArtB from typhoidal and paratyphoidal strains included, which agrees with what has 
been reported previously (6).  
Because PltB was previously reported to be homologous to the B1 subunit of the 
subtilase cytotoxin produced (abbreviated Sub B1) by some strains of E. coli (4), we also aligned 
the predicted amino acid sequences of ArtB, PltB, and Sub B1. PltB and Sub B1 subunits were 
more conserved (48.2% identical), compared to ArtB aligned with Sub B1 (36.8% identical), and 
PltB aligned with ArtB (34.0% identical).  
DISCUSSION 
 The ‘typhoid toxin’, characterized as an important virlunece factor for serotype Typhi, 
was recently found to be produced by nontyphoidal serotypes such as S. Javiana. The toxin’s role 
in nontyphoidal salmonellosis remains unclear. In this study, we determined which genes in the 
S-CDT islet are essential for S-CDT activity in vitro, for nontyphoidal serotype S. Javiana. We 
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also show that S. Javiana encodes multiple homologs of the binding subunit of S-CDT, and that 
deletion of both genes is necessary to abolish S-CDT-mediated intoxication.  
 To date, very few studies have been performed which characterize the role of genes in the 
S-CDT islet, and most have been performed using serotype Typhi. Multiple studies have 
confirmed that cdtB, encoding the active subunit of the toxin, is essential for the G2/M arrest and 
activation of the host’s DDR, in both typhoidal and nontyphoidal serotypes (4, 6, 8, 9, 13, 22). 
Similarly, other studies have shown that pltA, encoding the ADP-ribosylating subunit which 
serves as a molecular anchor that mediates the interaction of CdtB with the binding subunit PltB 
(4), is also essential for S-CDT-mediated intoxication (3, 9). Deletion of pltB, encoding the 
binding subunit PltB, in S. Typhi is sufficient to abolish its ability to induce a G2/M cell cycle 
arrest (3); this does not appear to be true for S. Javiana though, as the ΔpltB S. Javiana strains 
used both in this study, and reported by Mezal et al.(9), retained their activity in vitro, suggesting 
that PltB is necessary for S-CDT intoxication by S. Typhi, but not S. Javiana. Deletion of 
accessory genes STY1887 and ttsA, did not have a significant impact on the activity of S-CDT in 
vitro in this study. In contrast, in S. Typhi, ttsA was characterized as an N-acetyl-β-ᴅ-
muramidase, and was shown to be essential for export of the toxin out of the host cell, but 
deletion of STY1887 did not have any effect (19). Although a different cell type was used in that 
study (Henle cells vs. HIEC-6 cells in this study) it is unlikely that this alone may account for the 
observed differences, as both cell lines are of human origin. Together, these results suggest that 
the S-CDT produced by nontyphoidal serotypes such as S. Javiana, may utilize different 
mechanisms for S-CDT excretion, binding, and trafficking, compared to the S-CDT produced by 
S. Typhi.  
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 Deletion of artB alone resulted in a significant decrease in cytotoxic activity (Fig 4.4) 
compared to wild-type. Because deletion of both pltB and artB was required to achieve 
proportions of HIEC-6 cells with activated DDR responses that were similar to uninfected 
control cells, it is likely that for S. Javiana, both ArtB and PltB can be incorporated into the S-
CDT holotoxin. The conservation of key amino acid residues in ArtB, which have been shown to 
bind to host glycoproteins for PltB (4, 21), suggests that ArtB could potentially bind to host cells. 
Deletion of pltA, encoding PltA which serves as the physical anchor between CdtB and the PltB 
pentamer (4), abolished activity in vitro, this suggests that the binding pentamer is essential for 
S-CDT, further supporting the hypothesis that in the absence of pltB, artB could serve as a 
substitute. Alternatively, due to the significant decrease in cytotoxicity observed among HIEC-6 
cells infected with ΔartB strains, it could be that S. Javiana uses both ArtB and PltB monomers 
for the monomer. Interestingly, S. Typhi strains CT-18 and Ty2 both encode artB, and 
alignments with artB from nontyphoidal serotypes show that these are highly conserved. It is 
unknown whether the Typhi strain used by Spano et al. (3) also encodes artB, which would 
account for why in that strain pltB is essential for S-CDT activity.  
 Alternatively, ArtB could facilitate binding to alternative molecular targets, either 
providing flexibility with binding to known cells, or expanding the variety of cell types that may 
be bound by the toxin. Deng et al. suggested that S-CDT binds to Neu5Ac-terminal glycans 
which are unique to humans due to a loss of function in the enzyme catalyzing the conversion of 
Neu5Ac to Neu5Gc, therefore supporting the hypothesis that the typhoid toxin is a host-adapted 
toxin produced by the host-restricted serotype (21). Future studies examining the potential for 
ArtB to substitute for PltB, or potentially, for the binding subunit to be comprised of both PltB 
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and ArtB monomers, will be essential to determining how ArtB contributes to S-CDT-mediated 
intoxication in vitro.  
 Overall, this study provides the first report of S-CDT islet and accessory genes, and their 
role in S-CDT-mediated intoxication in a normal epithelial cell model of infection. These results 
support that the S-CDT produced by nontyphoidal serotypes, may use multiple genes encoding 
homologs of the binding subunit. Furthermore, there are key differences in the requirement of 
genes pltB and ttsA for S-CDT-mediated intoxication for S. Typhi and the nontyphoidal serotype 
S. Javiana, suggesting that these serotypes differ mechanistically in the production, trafficking, or 
activity, of S-CDT in vitro.  
MATERIALS AND METHODS 
Bacterial strains, human cell lines, and culturing conditions. Salmonella strains (see Table 
4.1) were stored at -80°C in 15% v/v glycerol. Salmonella were grown on brain heart infusion 
(BHI; Becton Dickinson, Sparks, MD) agar plates, which were incubated at 37°C. For infections, 
single colonies of Salmonella isolates grown on BHI agar plates were inoculated into 5-ml 
aliquots of LB (pH 8; 0.3 M NaCl), followed by incubation under static conditions at 37°C for 12 
- 14 h. These cultures were subsequently sub-cultured 1:100 into fresh aliquots of LB (pH 8; 0.3 
M NaCl), followed by incubation at 37°C under static conditions, until mid-log (OD600 = 0.4 – 
0.5).  
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TABLE 4.1 Strains used in this study. 
Strain ID Genotype 
FSL S5-0395 Wild-type 
FSL M8-0532 S5-0395 ΔpltA 
FSL M8-0533 S5-0395 ΔpltB 
FSL M8-0540 S5-0395 ΔcdtB 
FSL M8-0578 S5-0395 ΔSTY1887 
FSL M8-0577 S5-0395 ΔttsA 
FSL M8-0582 S5-0395 ΔartB 
FSL M8-0583 S5-0395 ΔartAB 
FSL M8-0588 S5-0395 ΔphoN::kanR 
FSL M8-0587 S5-0395 ΔcdtB ΔphoN::kanR 
FSL M8-0585 S5-0395 ΔpltB ΔartB::kanR 
 
Human intestinal epithelial cells (HIEC-6 cells; ATCC) were grown in Opti-MEM media 
supplemented with recombinant epidermal growth factor (10 ng/mL; Gibco-Invitrogen, 
Carlsbad, CA) supplemented with 10% (v/v) fetal bovine serum (FBS; Gibco-Invitrogen), and 
were incubated at 37°C with 5% CO2. Cells were tested every 3 months for Mycoplasma 
infection using the VenorGEM Mycoplasma detection kit (Sigma-Aldrich). For infections, 
HIEC-6 cells were grown in 6-well or 24-well plates (Corning, Corning, NY). Cells were seeded 
into 6-well (2 x 10
5
 cells per well) or 24-well plates (1 x 10
5
 cells) 48 + 4 hours before infection. 
Construction of Gene Deletions. Bacterial strains are shown in Table 2. All deletions were 
performed using the λ Red Recombinase system to create in-frame deletions (23). Briefly, FSL 
S5-0395 (S. Javiana wild-type) containing the pKD46 plasmid (described in (23)) was grown 
shaking at 30°C in LB broth containing 100 μg/mL ampicillin and 0.01% L-Arabinose (Sigma), 
to an optical density at 600 nm (OD600) of  0.5 -  0.7. Cells were transformed with kanamycin 
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resistance cassettes containing flanking regions homologous to chromosomal sites homologous 
to the gene targeted for deletion, using electroporation followed by a 2 h recovery in SOC media 
(NEB) at 37°C. PCR amplification of kanamycin resistance cassettes were generated with high-
fidelity polymerase Q5 (NEB; Ipswich, MA) was used to amplify kanamycin cassettes from 
pKD46, using primers listed in Table 4.2. Subsequently, cells were plated on LB supplemented 
with 50 μg/mL kanamycin and were incubated at 37°C for 18 – 24 h. Successful chromosomal 
integration of the kanamycin resistance cassette was confirmed by colony PCR. For removal of 
the kanamycin resistance cassette, cells were grown to mid-log phase (OD600 ~0.5- 0.7) and were 
electroporated with pCP20, followed by incubation at 30°C for 2 h; colonies were selected by 
plating on LB agar supplemented with 100 μg/mL ampicillin for 20 – 24 h. For strains requiring 
multiple deletions, crosses with phage P22 were conducted.  In-frame deletions were confirmed 
by Sanger sequencing of PCR products amplifying upstream and downstream of the region 
deleted. 
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TABLE 4.2 Primers used in this study 
 
 
 
  
Primer Name Purpose Primer sequence (5' to 3') 
RM91cdtBKanup Deletion of cdtB 
AACACATATATCATTCAGATAAAAAAGTAATAATCGGG
AGAGTAGATATCGTGTAGGCTGGAGCTGCTTC 
RM92cdtBKandown Deletion of cdtB 
TATTCTGCACCTTACGCTCAAAGTACATGTCGTCAACG
CTATTTACTCACATATGAATATCCTCCTTAG 
RM97cdtBup_F Confirm deletion of cdtB CAACGTCATGAAACAATGGGTTATG 
RM96cdtBdown_R Confirm deletion of cdtB ATATTCTGCACCTTACGCTCAAAGTAC 
RM174PcdtBGFP_EcoRI_F Complementation of cdtB TAAGCAGAATTCTAAGTCACCTGTTTTGTGTTGAG 
RM199_artBupstreamF Confirm deletion of artB CTTCCGCCGTCTGTTGCTTA 
RM200_artBdownstreamR Confirm deletion of artB GGTGACAGTATCTGCGGCATTGTT 
RM209_STY1887kanF Deletion of STY1887 
AATTATGAGTTGTTTTACCAGTCCAGCAATTATGGTGT
AGGCTGGAGCTGCTTC 
RM210_STY1887kanR Deletion of STY1887 
TTAATTATGTTGTATGGTATGAGAATGATAGTATTTCAT
ATGAATATCCTCCTTAG 
RM211_STY1887F Confirm deletion of STY1887 GTACTTTGAGCGTAAGGTGCA 
RM212_STY1887R Confirm deletion of STY1887 TGGCGGTTTGTGATGATAGCATA 
RM213_ttsAkanF Deletion of ttsA 
TTACAACCTTACCCGTTCCTTTATCCATCCGTGTAGGCT
GGAGCTGCTTC 
RM214_ttsAkanR Deletion of ttsA 
ATCTTTGCAGCTATCCTTAGTAGAGAAGGTGGTTACCA
TATGAATATCCTCCTTAG 
RM215_ttsAF Confirm deletion of ttsA GTGGCTTTCACCAGTTCTCT 
RM216_ttsAR Confirm deletion of ttsA GATGCAAGACCTGTAATAGAACTT 
RM221_artABkanF Deletion of artAB 
ATGCAGTTACAAAGTGAGTATGTATCTGTAGTGTAGGC
TGGAGCTGCTTC 
RM222_cdtBcomp_AatII_R Complementation of cdtB GACGTCCATGTCGTCAACGCTATTTACTCA 
RM223_artBintF Screen for artB GCTCTTGCGTCATTATCCAGTGTT 
RM224_artBintR Screen for artB CACTTTACACATGGCATTGACACTAA 
RM225_artB2kanF Deletion of artB 
AGTAATGTTCAGATTAAAAACCTGTCTTATGGTGTGTA
GGCTGGAGCTGCTTC 
RM226_artB2kanR Deletion of artB 
CCTGTTCTTTAGAGCGTTTAATACCCAGCAACATCATAT
GAATATCCTCCTTAG 
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Salmonella infection of HIEC-6 cells. Treatments (i.e. strain used for infection, negative or 
positive control treatments) were randomly assigned to HIEC-6 cells seeded in 6-well or 24-well 
plates. HIEC-6 cells were infected with approximately 2 x 10
6
 cfu or 4 x 10
6
 cfu Salmonella, for 
HIEC-6 cells seeded in 24-well and 6-well plates, respectively. After incubation of the infected 
cells for 1 h at 37°C (with 5% CO2), HIEC-6 cells were washed 3 times with phosphate buffered 
saline (PBS), followed by incubation with media supplemented with 100 μg/ml gentamicin 
(Gibco) for 1 h at 37°C to kill extracellular bacteria. Subsequently, HIEC-6 cells were washed an 
additional 3 times with PBS, and were then maintained in media containing 10 μg/ml gentamicin 
(Gibco) to prevent recurrent infection and bacterial outgrowth during incubation.  
Flow Cytometry. Cell cycle analyses were performed on populations of HIEC-6 cells that were 
infected with Salmonella strains as described above, in order to determine the role of infection 
with S-CDT-positive strains on cell cycle progression. Briefly, HIEC-6 cells were washed once 
with PBS, and were harvested using 0.25% Trypsin EDTA (Gibco). Cells were fixed in ice-cold 
70% ethanol, and were stored at -20°C. Ethanol-fixed cells were permeabilized with PBS 
containing 0.1% Tween-20 (PBS-T) and bovine serum albumin (1 g/100 ml) (Sigma-Aldrich, St. 
Louis, MO) at room temperature for 10 min. Cells were subsequently stained (10 min at room 
temperature) with a solution containing propidium iodide (PI; ThermoFisher Scientific, 
Waltham, MA) at a final concentration of 50 μg/ml and RNase A (Sigma-Aldrich) at a final 
concentration of 100 μg/ml. Stained cells were held at 4°C for no longer than 4 h, prior to DNA 
content analysis using the BD FACSARIA. Cells were gated to exclude doublets and multiplets, 
as described previously (24). 
Immunofluorescence Staining. Immunofluorescence staining for γ-H2AX and 53BP1 foci was 
performed at 48 + 2 h post infection (hpi) as described previously (8). Briefly, HIEC-6 cells 
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grown on 12 mm coverslips (ThermoFisher Scientific) were washed with PBS and were then 
fixed with 4% formaldehyde in PBS at room temperature for 10 - 15 min. Fixed cells were 
permeabilized with 0.1% Triton-X 100 in PBS at room temperature for 10 min. Permeabilized 
cells were blocked with 10% v/v normal donkey serum (Sigma) in PBS containing 0.1% Tween-
20 (PBS-T; Sigma) for 1 h at room temperature. Incubation with primary and secondary 
antibodies was performed for 1 h at room temperature using the following dilution factors in 
PBS-T: polyclonal goat anti-Salmonella antibody (KPL antibodies, Gaithersburg, MA; 1:500), 
mouse anti-γ-H2AX (EMD Millipore, Billerica, MA; 1:500), rabbit anti-53BP1 (Novus 
Biologicals, Littleton, CO; 1:500). Incubation with secondary antibodies diluted 1:200, except 
where noted, in PBS-T was performed for 1 h at room temperature; donkey anti-goat conjugated 
to Alexa 488; donkey anti-rabbit conjugated to Alexa 555 (diluted 1:500); and donkey anti-
mouse conjugated to Alexa 647 (all ThermoFisher Scientific). Nuclei were stained with 4’,6-
diamidino-2-phenylindole (DAPI) at a final concentration of 1 μg/ml for 5 min at room 
temperature. Slides were mounted onto microscope slides with glycergel (Dako, Carpinteria, 
CA) and were imaged using a Zeiss 710 confocal microscope. Images were processed with FIJI 
software, and cells were counted using the cell counter plug-in (25). At least 50 nuclei were 
analyzed per slide to identify cells that had more than four 53BP1 positive foci and were also 
positive for γH2AX; these cells were designated as 53BP1 and γH2AX positive cells (or “double 
positive cells”).  The observer was blinded to the treatment while collecting and analyzing 
images. 
Statistical Analysis. All statistical analyses were performed using R software (version 3.0.2; R-
project, Vienna, Austria). Linear mixed effects models were developed to determine significant 
associations between strains (i.e. genotypes) and either (i) proportions of cell populations in 
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G2/M, or (ii) proportions of cells with an activated DDR as determined using 
immunofluorescence staining for 53BP1 and γH2AX foci. Strain was included as a fixed effect, 
while date of experiment was included in models as a random effect. Data were transformed by 
taking the square root or performing a rank transformation when appropriate to obtain a normal 
distribution of the residuals. Figs were constructed using the untransformed data. The lsmeans 
(least square means) package was used to perform pairwise comparisons among treatments, and 
P-values were adjusted using the Tukey method to correct for multiple comparisons.  
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
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CONCLUSIONS 
Not all Salmonella serotypes cause the same disease. The discovery of the typhoid toxin 
in serotype Typhi represented an important advancement in the understanding of the biology of 
typhoid fever, demonstrating that the toxin plays a role in the resulting disease. Furthermore, 
characterization of this same toxin in nontyphoidal serotypes has shown that S-CDT plays an 
important role in pathogenesis at the cellular level.   
Nontyphoidal serotypes produce a S-CDT that acts in a similar manner to the typhoid 
toxin produced by serotype Typhi. Importantly, the research presented here highlights that, 
among the 21 nontyphoidal serotypes causing the majority of clinical cases of salmonellosis in 
the US, 4 of these serotypes carry genes encoding S-CDT. Altogether, this accounts for an 
estimated 150,280 cases (90% C.I.: 111,812 – 196,954) of salmonellosis in the US each year 
which are caused by these S-CDT-positive serotypes. In vitro, infection of eukaryotic cells with 
S-CDT-positive serotypes results in activation of the DNA damage response, and a cell cycle 
arrest, both supporting the conclusion that infection with these serotypes results in DNA damage. 
Because these effects were also observed for uninfected cells in close proximity to infected cells, 
S-CDT is capable of acting via autocrine and paracrine pathways, therefore suggesting that 
exposure to S-CDT in the course of an infection with S-CDT-positive serotypes is widespread, as 
the cells do not have to be infected in order to exhibit signs of S-CDT intoxication.  
Introduction of a new cellular model of S-CDT-mediated intoxication. One of the key 
limitations of previous studies characterizing the effect of S-CDT in vitro, was the use of cancer 
cell lines. While cancerous cell lines were beneficial for first establishing the activity of S-CDT, 
these cell lines often have defects in either DNA damage checkpoints or in DNA damage repair 
pathways, which therefore limits their use in determining the cellular outcome of the DNA 
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damage. To this end, one of the primary goals of this research was to establish that the S-CDT-
mediated intoxication also occurs in non-cancerous cell lines. This represents an important next 
step in determining the fate of cells that sustain DNA damage following exposure to S-CDT.  
Expanding the repertoire of S-CDT-associated genes and their importance in vitro. As the 
holotoxin is only comprised of the protein products of cdtB, pltB, and pltA, very few studies had 
been undertaken to investigate the role of ttsA and STY1887 in S-CDT-mediated virulence (1). 
This research provides evidence that the S-CDT encoded by nontyphoidal serotype S. Javiana 
may have alternative requirements for trafficking and export, as deletion of ttsA did not abolish 
S-CDT activity, as was reported for serotype Typhi (1).  
Despite the discovery of the PltB and PltA homologs ArtB and ArtA in serotype 
Typhimurium, their role in S-CDT-intoxication of nontyphoidal serotypes was unknown. The 
research described here provides the first evidence that ArtB influences S-CDT-induced 
intoxication in vitro. Future work involving proteomic methods to characterize the physical 
interactions between ArtB and S-CDT, as well as any potential differences in cell receptors 
bound by PltB versus ArtB will be beneficial in determining the true impact or requirement of 
nontyphoidal serotypes encoding multiple binding subunits for S-CDT. 
FUTURE DIRECTIONS 
This research provides an important framework for future investigations regarding the 
regulation of S-CDT, as well as its contributions to acute disease severity and any associated 
long-term sequelae. Given the large number of infections with S-CDT-positive serotypes, it will 
be important to better understand how S-CDT impacts the severity and outcome of infection. 
Furthermore, the transcriptional and translational regulation of S-CDT is poorly understood. 
Future investigations aimed at expanding our understanding of i) the transcriptional and 
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translational regulation of S-CDT, (ii) the role of S-CDT in the acute onset of disease, and 
contributions to disease severity, and (iii) the long-term effects of S-CDT exposure, will be 
beneficial for understanding the true influence of S-CDT in salmonellosis (Fig 5.1).  
FIGURE 5.1. Possible future directions for S-CDT characterizations in nontyphoidal Salmonella 
serotypes. Abbreviations: Salmonella Cytolethal Distending Toxin (S-CDT); gastrointestinal 
tract (GI); single strand break (SSB); double strand break (DSB); non-homologous end joining 
(NHEJ); homologous recombination (HR). 
 
Transcriptional and translational regulation of S-CDT for predicting anatomical regions 
most likely to be exposed to S-CDT. Transcriptional regulation of S-CDT has only been briefly 
characterized for serotype Typhi (1, 2). Due to the marked genomic differences between S. Typhi 
and other serotypes (3, 4), it is necessary to identify regulatory factors governing expression and 
translation of S-CDT for NTS serotypes. For serotype Typhi, transcription of pltA, pltB, and cdtB 
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(encoding the S-CDT toxin subunits PltA, PltB, and CdtB, respectively), only occurs when S. 
Typhi cells are located within the salmonella containing vacuole (SCV), approximately 5 hours 
post infection (5). This mirrors expression of salmonella pathogenicity island 2 (SPI-2) encoded 
genes (6), which are expressed when Salmonella cells are located within the SCV. It is likely that 
the same intracellular requirement is also true for S-CDT production for nontyphoidal serotypes 
as well, as co-incubation with supernatants of stationary phase cultures of S. Javiana fail to 
invoke a G2/M arrest and to activate the DNA damage response (DDR) in HeLa cells. Because 
relatively few Salmonella cells successfully invade host cells (7), this would limit the production 
and dissemination of the toxin. However, export of S-CDT outside of infected cells, would 
increase dissemination of the toxin, thereby increasing the potential exposure. 
Immunofluorescence staining clearly shows that DNA damage is not restricted to infected cells, 
and that intoxication with S-CDT may occur by paracrine pathways, as uninfected HeLa cells 
among populations of cells infected with S. Javiana also show an activated DDR. It is still 
unclear which environmental cues serve as the molecular signals governing transcription and 
translation of S-CDT subunits and associated proteins (i.e. TtsA and STY1887). Understanding 
the regulatory elements controlling expression of S-CDT would inform the anatomical regions 
which would be exposed to S-CDT during the course of an infection, and would guide in vivo 
analyses for examining S-CDT-mediated DNA damage. 
S-CDT’s contributions to acute salmonellosis. Analysis of rates of invasive disease among 
NTS serotypes suggests that infections with S-CDT-encoding serotypes are significantly more 
likely to result in invasive disease (8). For S. Typhi, S-CDT has been established as an important 
virulence factor, not only contributing to acute symptoms of typhoid fever (9), but also to 
immune suppression which enables prolonged infection and invasive disease in a mouse model 
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of infection (10). Due to the established link between S-CDT and the development of invasive 
disease and prolonged duration of infections with S. Typhi, it is likely that S-CDT plays an 
important role for NTS infections as well.  
 CDT production by other Gram-negative pathogens has been shown to be necessary for 
establishment of chronic infections with Helicobacter hepaticus (11) and the development of 
gastroenteritis for Campylobacter jejuni (12). Therefore, in vivo studies represent a necessary 
next step in characterizing the activity of, and implications of, S-CDT exposure accompanying 
infections with NTS serotypes.  
Contributions to long-term sequelae- the outcome of DNA damage. S-CDT acts as a nuclease 
in vitro, causing a G2/M cell cycle arrest and activation of the DDR (13-15). The ultimate 
outcome of the DNA damage sustained (i.e. successful repair of damaged DNA, apoptosis, 
senescence, etc.), remains unknown. Analyses with E. coli CDT demonstrated that single strand 
breaks (SSB) are converted to double strand breaks (DSB) during the G2 cell cycle phase (16). 
The extent of DNA damage, including whether S-CDT induces SSB or DSB, or both, as well as 
the mechanisms by which this DNA are repaired, are currently unknown. DNA damage repair 
mediated by non-homologous end joining (NHEJ) is error prone, and occurs by excising 
nucleotides in order to join blunt ends (17). However, during S/G2 phases, when a suitable 
template is available, DNA damage repair can occur using homology directed repair, which is 
essentially error free (17). Characterizing how the DNA damage induced by S-CDT is repaired 
will be important for assessing the potential for carcinogenic transformation following S-CDT 
induced cytotoxicity. For Salmonella, it is still not clear if the DNA damage preferentially occurs 
in G2/M phases, or if the damage occurs throughout the cell cycle, but the damage is not being 
repaired. Since the cell cycle influences the repair pathway (18, 19), it is necessary to assert 
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when the damage is occurring, as this will provide important information about the potential for 
carcinogenic transformation.  
 Cancer-derived cell lines which have been used to characterize activation of the DDR 
following exposure to S-CDT, often have faulty DNA repair mechanisms, and therefore do not 
recapitulate normal DNA repair processes (reviewed in (20)). Therefore, use of untransformed 
cell lines to study the overall outcome of S-CDT induced DNA damage, represents an important 
step in assessing the implications of S-CDT DNA damage.  
FOOD SAFETY REGULATORY IMPLICATIONS OF S-CDT PRODUCTION BY 
NONTYPHOIDAL SEROTYPES 
Toxin-based classification of foodborne pathogens facilitates clinical treatment decisions 
and epidemiological investigations. Select foodborne pathogens are differentiated based on the 
presence of certain virulence factors for both epidemiological and clinical reasons. For example, 
shiga toxin producing E. coli (STEC) are characterized based on the presence of stx1 and stx2 
genes encoding shiga toxins 1 and 2, respectively (21), as antibiotic treatment of STEC 
infections is associated with a significantly higher incidence of hemolytic uremic syndrome and 
is therefore discouraged (22). S-CDT status could influence treatment regimens, and could also 
serve as an epidemiological tool for comparing similar strains implicated with a common food 
vehicle, as is done with the stx genes in E. coli (21).  
Foodborne pathogens as adulterants. According to 64 CFR 2803, foods containing select 
STEC serotypes are considered adulterated (23). While nontyphoidal Salmonella serotypes are 
not currently classified as adulterants, the potential genotoxic effect of S-CDT in the context of 
foodborne salmonellosis may merit future investigation and discussion regarding the status of S-
CDT-producing nontyphoidal serotypes as adulterants.  
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 Overall, S-CDT is best likened as a proverbial ‘Pandora’s Box’ – efforts to characterize 
and understand its’ regulation, structure-function, activity, and impact on hosts at both a cellular 
and organismal level, are still in their infancy, with each new discovery leading to a very exciting 
contribution to the S-CDT story.  
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